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Cancer, cardiovascular diseases and tuberculosis (TB) are major therapeutic challenges, 
for which various drug strategies have been developed, including the use of inorganic 
agents such as metallo-drugs and NO• (nitric oxide)/ HNO (nitroxyl). Within this 
prospect, the thesis objective addresses the design, synthesis, physical-chemical studies 
and biological evaluation of metal-based drugs capable of releasing NO• and/or HNO 
with pharmacological effects. Two types of organic platforms are thus envisaged as 
ligands in FeII/III complexes devised as potential sources of NO•/HNO: the spectator 
cyclam ligand (1,4,8,11-tetraazacyclotetradecane) and three reactive azine hydroxamic 
acid ligands (ArC(O)NHOH).  
The first chapter deals with the chemical reactivity of a trans-[Fe(cyclam)(NO)Cl]Cl2 
complex, which is shown to decompose by releasing NO• under physiological pH and 
temperature conditions, the process being significantly accelerated upon light irradiation 
at 365 nm. In contrast, in vitro experiments in the presence of glutathione revealed that 
the same complex produces HNO. Angiogenesis studies showed that the complex is 
able to significantly inhibit the hypoxia-inducible factor (HIF-1α) induced by hypoxia 
or addition of a NO• donor (Spermine NONOate) in breast cancer cells: this result is 
consistent with a release of HNO by the nitrosyl complex. On the other hand, 
vasodilation assays using precontracted rat aortic rings revealed that the complex 
exhibits a relaxation IC50 of 910 nM, vs 24 nM for the reference drug, nitroprusside.  
The next chapters deal with the oxidation-promoted release of HNO from aromatic 
hydroxamic acids. Chapter 2 focuses on the oxidation mechanism of isonicotinoic, 
nicotinoic and pyrazinoic hydroxamic acids, mediated by potassium ferricyanide 
(K3[FeIII(CN)6]) in physiological pH conditions. It is shown that oxidative activation of 
aryl hydroxamic acids, mediated by FeIII, involves the production of the N,O-
di(di)azinoylhydroxylamine intermediate with concomitant release of HNO, instead of 
the putative acyl nitroso species. The free hydroxamic acids were also evaluated for 
different biological activities and used as controls to be compared with iron complexes 
described in chapter 3. These pentacyanoferrate(II) complexes, 
Na3FeII(CN)5(ArCONHOH), initially devised as potential hybrid of isoniazid (INH, 
first-line anti-TB prodrug, for which the isonicotinoyl radical is the active metabolite) 
and delamanid (third-line anti-TB, for which HNO is the active metabolite), were 
synthesized and characterized by spectroscopic techniques, cyclic voltammetry, and 





complexes with H2O2 was shown to result in the release of HNO and corresponding 
azinoic acids, through a likely intramolecular electron transfer. In contrast to what was 
observed from the INH complex (Na3[FeII(CN)5(INH)]), no azinoyl radical species was 
evidenced to be produced from the corresponding hydroxamic acid complexes. Instead, 
the corresponding carboxylic acids were found to be formed, in particular pyrazinoic 
acid which is the active metabolite of pyrazinamide, another antitubercular pro-drug: 
this result would be relevant for the treatment of pyrazinamide-resistant tuberculosis, as 
the activation could thus occur without assistance of the pyrazinamidase enzyme of 
Mycobacterium tuberculosis (Mtb). 
The free hydroxamic acids and corresponding complexes did not show any antibiotic 
action against an actively growing/non-resistant Mtb strain. However, the complexes 
showed a strong dose-dependent and reversible vasodilation activity, close to that of 
nitroprusside (64-250 nM vs 13 nM). The free hydroxamic acids were found ca. 19- to 
76-fold less active than the corresponding complexes. On the basis of in vivo 
experiments, Na4[FeII(CN)5(PyCONHO-)] also showed a promising cardiovascular 
activity profile for the development of a new antihypertensive agent.  
 
Key words: antiangiogenesis, cyclam, hydroxamic acids, iron complexes, nitric oxide, 




Le cancer, les maladies cardiovasculaires et la tuberculose (TB) sont des défis de santé 
majeurs pour lesquels diverses stratégies médicamenteuses ont été développées, y 
compris l'utilisation d'agents inorganiques tels que des complexes métalliques et l'oxyde 
nitrique (NO•) ou le nitroxyle (HNO). L'objectif de la thèse porte sur la conception, la 
synthèse, les études physico-chimiques et l'évaluation biologique de molécules à base 
de métaux capables de libérer NO• et/ou HNO avec des effets pharmacologiques. Deux 
types de plates-formes organiques sont envisagés comme ligands des complexes de fer, 
conçus comme sources potentielles de NO•/HNO : le ligand spectateur cyclam 
(1,4,8,11-tétraazacyclotétradécane) et les ligands réactifs du type azine acide 
hydroxamique (ArC(O)NHOH). 
Le premier chapitre traite de la réactivité du complexe trans-[Fe(cyclam)(NO)Cl]Cl2, 





irradiation lumineuse à 365 nm. En revanche, des expériences in vitro en présence de 
glutathion ont révélé que le même complexe produit HNO. Des études d'angiogenèse 
ont montré que le complexe est capable d'inhiber le "facteur inductible par hypoxie" 
(HIF-1α) induit par hypoxie ou ajout d'un donneur de NO• (Spermine NONOate) dans 
les cellules cancéreuses du sein, résultat cohérent avec une libération de HNO. Des tests 
de vasodilatation, des anneaux aortiques de rat précontractés, ont révélé que le 
complexe présente une CI50 de relaxation de 910 nM, contre 24 nM pour le médicament 
de référence nitroprussiate. 
Les chapitres suivants traitent de la libération de HNO par oxydation d'acides 
hydroxamiques aromatiques. Le chapitre 2 se concentre sur le mécanisme d'oxydation 
des acides hydroxamiques isonicotinoïque, nicotinoïque et pyrazinoïque par le 
ferricyanure de potassium à pH physiologique. Il est montré que l'activation oxydante 
des acides hydroxamiques par des ions FeIII implique la production de l'intermédiaire 
N,O-di(di)azinoylhydroxylamine avec libération concomitante de HNO, au lieu de 
l'espèce hypothétique acyl nitroso. Les acides hydroxamiques ont été évalués pour 
différentes activités biologiques et utilisés comme témoins pour être comparés aux 
complexes de fer décrits au chapitre 3. Les complexes de type 
Na3FeII(CN)5(ArCONHOH), initialement conçus comme modèles de médicaments 
hybride d'isoniazide (INH, anti-TB, dont le radical isonicotinoyle est le métabolite actif) 
et du délamanide (anti-TB, dont HNO est le métabolite actif), ont été synthétisés et 
caractérisés par des techniques spectroscopiques, voltammétrie cyclique, et calculs 
DFT. En utilisant la spectroscopie RPE et RMN 1H, l'oxydation de ces complexes de 
FeII avec H2O2 s'est avérée entraîner la libération de HNO et des acides azinoïques 
correspondants, via un probable transfert d'électrons intramoléculaire. Contrairement à 
ce qui a été observé pour le complexe Na3[FeII(CN)5(INH)], aucun radical azinoyle n'a 
été produit à partir des complexes d'acide hydroxamiques. Les acides carboxyliques 
correspondants ont par contre été observés, en particulier l'acide pyrazinoïque, 
métabolite actif du pyrazinamide, un autre promédicament anti-TB: ce résultat est a 
priori pertinent pour le traitement de la TB résistante au pyrazinamide, car l'activation 
pourrait ainsi se produire sans l'aide de l'enzyme pyrazinamidase de Mycobacterium 
tuberculosis (Mtb). 
Les acides hydroxamiques libres ou complexés n'ont montré aucune action antibiotique 
contre une souche de Mtb non résistante en croissance active. Cependant, les complexes 





celle du nitroprussiate (64-250 nM vs 13 nM). Les acides hydroxamiques libres ont été 
19 à 76 fois moins actifs que les complexes correspondants. Sur la base d'expériences in 
vivo, Na4[FeII(CN)5(PyCONHO-)] a aussi montré un profil d'activité cardiovasculaire 
prometteur pour le développement d'un nouveau médicament antihypertenseur. 
 
Mots clés : acides hydroxamiques, antiangiogenèse, complexes de fer, cyclam, 









NO•: nitric oxide 
WHO: World Health Organization 
FDA: Food and Drug Administration 
HIFs: hypoxia-inducible factors 
CVDs: cardiovascular diseases 
TB: Tuberculosis 
Mtb: Mycobacterium tuberculosis 
INH: isoniazid 
PZA: pyrazinamide 
MDR-TB: multidrug-resistant tuberculosis 
SNP: sodium nitroprusside 
sGC: soluble guanylate cyclase 
IQG607: Na3[Fe(CN)5(INH)] 
NOS: nitric oxide synthases 
GSH: glutathione 
GTN: glyceryl trinitrate 
IPA/NO: sodium 1-(isopropylamino)diazen-1ium-1,2-diolate 
Cyclam: 1,4,8,11-tetraazacyclotetradecane 
IC: inhibitory concentration 
cPTIO: 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide potassium 
salt 
EPR: electron paramagnetic resonance 
DFT: density functional theory 
TD-DFT: time-dependent DFT 
LLCT: ligand-to-ligand charge transfer 
ILCT: intraligand charge transfer 












Cancer, cardiovascular disorders, and tuberculosis are diseases that significantly 
affect the world population. Among the therapeutic strategies used to treat these 
diseases, administration of medicines is one of the most important, allowing the control 
of health problems, and improving the quality of patients’ life. Such strategy has been 
increasingly adopted however, spite of the benefits brought by the use of medicines, in 
many cases, mainly in situations of prolonged use as for cardiovascular therapy, several 
side effects are observed. For cancer, the discovery for miraculous molecules allowing 
the cure of the disease is still anxiously waited. Moreover, the emergence of infectious 
diseases promoted by pathogenic strains resistant to conventional antibiotics (e.g., 
Mycobacterium tuberculosis towards isoniazid and rifampicin) is also a worldwide 
health problem urgently needing for new agents that could exhibit better efficacy and 
lesser side-effects. 
While chemical organic drugs are largely employed to treat these affections and 
others, inorganic compounds have been much less developed. However, a few inorganic 
drugs containing metal atoms can also play a crucial role in therapeutic (e.g., LiCO3, 
cisplatin, sodium nitroprusside, etc.) and diagnostic (e.g., Magnevist® and Cardiolite®, 
etc.) arsenals. Among the inorganic compounds involving metals, metallo-drug is a 
class of molecules that exhibits a series of chemical characteristics (e.g., charge 
variation and metal-ligand interaction) and properties (e.g., redox activity and Lewis 
acid properties) that make it excellent scaffold for the development of new medicinal 
chemistry strategies. Additionally, another family of inorganic compounds that draw 
our attention is the nitric oxide (NO•) and nitroxyl (HNO) molecules, which are both 
widely studied due to their relevant biological properties. As these molecules are very 
unstable and cannot be planned as direct drugs, pro-drugs able to release these reactive 
species in vivo are also of our interest. All these advances prompted us to propose new 
anticancer, antihypertensive and antituberculosis drug-development strategies based on 
the release of NO•/HNO mediated by transition-metal. In this context, this thesis focuses 
on the design, synthesis, physico-chemical and biological studies of new metal 
complexes able to release NO•/HNO in physiological conditions as a way to assist in the 
treatment of cancer, hypertension disorders, and tuberculosis. 
The overview presented in the introduction is devoted in the first part to 





the significant biological aspects of NO• and HNO, their pharmacological importance in 
the context of cancer, cardiovascular disease and tuberculosis, and finally, to report their 
organic and inorganic donors. The results obtained under this thesis are presented in the 
form of scientific papers. The first part of this thesis (Chapter 1) describes the study of 
the reactivity of the FeII complex, trans-[Fe(cyclam)(NO)Cl]Cl2, with regard to the 
release of NO• through a photochemical process and the release of HNO via the 
activation of the complex by biological reducing agents. The vasodilation properties of 
this nitrosyl complex were also examined. 
The second part of this thesis is divided in two chapters (chapters 2 and 3). In the 
chapter 2, a mechanistic study of the oxidative activation of three (di)azine hydroxamic 
acids (isonicotino-, nicotino-, and pyrazino- hydroxamic acids) was described. These 
results led us to propose a new mechanism for the activation of these (di)azine 
hydroxamic acids in aqueous medium. These compounds were also evaluated for 
different biological activities and they were used as control molecules to be compared to 
the metal-drugs prepared in the chapter 3. In the third chapter, three new 
pentacyanoferrate(II) complexes derived from the aromatic hydroxamic acids 
mentioned above, originally conceived as a potential hybrid of isoniazid (front-line 
antitubercular, for which radical isonicotinoyl is the active metabolite) and delamanid 
(third-line anti-TB, for which HNO is the active metabolite), were synthesized, 
characterized and their ability to release dual active metabolites (NO•/HNO and aroyl 
radical) in the presence of H2O2, as well as their biological effects as antitubercular and 




Le cancer, les troubles cardiovasculaires et la tuberculose sont des maladies qui 
affectent de manière significative la santé de la population mondiale. Parmi les 
stratégies thérapeutiques utilisées pour traiter ces maladies, l’administration de 
médicaments est l’une des plus importantes, permettant de pallier les problèmes de 
santé, et d’améliorer la qualité de vie des patients. Cette stratégie est de plus en plus 
adoptée, néanmoins dans de nombreux cas et principalement dans les situations 
d’utilisation prolongée, comme pour les maladies cardiovasculaires, plusieurs effets 





permettant la guérison de la maladie est encore attendue avec impatience. En outre, 
l’émergence de maladies infectieuses favorisées par des souches pathogènes résistantes 
aux antibiotiques conventionnels (par exemple Mycobacterium tuberculosis face à 
l’isoniazide et rifampicine) est également un problème de santé mondiale nécessitant 
urgemment la découverte de nouveaux agents qui pourraient présenter une meilleure 
efficacité et moins d’effets secondaires. 
Alors que les médicaments chimiques organiques sont en grande partie utilisés 
pour traiter ces maux et d’autres, les composés inorganiques ont été beaucoup moins 
développés. Cependant, quelques médicaments inorganiques contenant des atomes 
métalliques peuvent également jouer un rôle crucial dans les arsenaux thérapeutiques (p. 
ex. : LiCO3, cisplatine, nitroprussiate de sodium, etc.) et diagnostiques (p. ex. : 
Magnevist® et Cardiolite®, etc.). Parmi les composés inorganiques à base de métaux, 
ceux appelés “drogues métalliques” appartiennent à une classe de molécules qui 
présente une série de caractéristiques chimiques (par exemple : variation de charge et 
interaction métal-ligand) et de propriétés (par exemple : activité redox et propriétés de 
l'acide de Lewis) qui font d'elle un excellent échafaudage pour le développement de 
nouvelles stratégies de chimie médicinale. En outre, une autre famille de composés 
inorganiques qui attire notre attention est l’oxyde nitrique (NO•) et nitroxyle (HNO), qui 
sont tous les deux largement étudiés en raison de leurs propriétés biologiques 
pertinentes. Comme ces molécules sont très instables et ne peuvent pas être 
administrées comme des médicaments, des pro-médicaments capables de libérer ces 
espèces réactives in vivo sont également de notre intérêt. Toutes ces avancées nous ont 
incités à proposer une nouvelle stratégie de développement de médicaments 
anticancéreux, antihypertenseurs et antituberculeux basée sur la libération de NO•/HNO 
induite par la modification de l’état d’oxydation du métal de transition. Dans ce 
contexte, cette thèse vise la conception, la synthèse, les études physico-chimiques et 
biologiques de nouveaux complexes métalliques capables de libérer NO•/HNO dans des 
conditions physiologiques de pH comme un moyen d’assister au traitement du cancer, 
des troubles de hypertension, et de la tuberculose. 
L’aperçu présenté dans l’introduction consiste, dans un première temps, à faire 
ressortir la place des complexes métalliques en thérapeutique et dans un deuxième 
temps, à signaler les aspects biologiques significatifs des molécules NO• et HNO, leur 
importance pharmacologique dans le contexte du cancer, des maladies cardiovasculaires 





Les résultats obtenus dans le cadre de cette thèse sont présentés sous forme 
d’articles scientifiques. La première partie de cette thèse (chapitre 1) décrit l’étude de la 
réactivité du complexe de FeII, trans-[Fe(cyclam)(NO)Cl]Cl2, en ce qui concerne la 
libération de NO• par un processus photochimique et la libération de HNO via 
l’activation du complexe par des agents biologiques réducteurs. Les propriétés de 
vasodilatation de ce complexe de nitrosyle ont également été examinées. 
La deuxième partie de cette thèse est divisée en deux chapitres (chapitres 2 et 3). 
Dans le chapitre 2, une étude du mécanisme de l’activation oxydative de trois (di)azine 
acides hydroxamiques (acide hydroxamique isonicotinique, acide hydroxamique 
nicotinique et acide hydroxamique pyrazinique) a été décrite. Ces résultats nous ont 
amenés à proposer un nouveau mécanisme pour l’activation des acides hydroxamiques. 
Ces composés ont également été évalués vis-à-vis de différentes activités biologiques et 
ils ont été utilisés comme des molécules témoins pour être comparés aux complexes 
métalliques préparés dans le chapitre 3. Dans le troisième chapitre, trois nouveaux 
complexes pentacyanoferrate(II) dérivés des acides hydroxamiques mentionnés ci-
dessus, originalement conçus comme hybride potentiel de l’isoniazide (antituberculaire 
de première ligne, pour lequel le radical isonicotinoyle est le métabolite actif) et du 
délamanide (anti-TB de troisième ligne, pour lequel HNO est le métabolite actif), ont 
été synthétisés, caractérisés et leur capacité à libérer deux métabolites actifs (NO•/HNO 
et le radical aroyle) en présence de H2O2, ainsi que leurs effets biologiques (propriétés 
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1. Metallo-drugs in medicine - Brief historical account  
 
Metallo-drugs constitute a class of pharmaceutical substances that contains a 
metal as an active ingredient. Several substances in this class have been used in 
therapeutic and diagnostic medicine throughout history [1]. In terms of modern 
chemotherapy, the first metallo-drug used was salvarsan (Figure 1), an arsenic(III)-
based antimicrobial agent developed by the German physician Paul Ehrlich in 1910. It 
was used in the treatment of syphilis, before being replaced by penicillin after World 
War II [1,2]. Several other treatments based on metallo-drugs have emerged, such as 
gold compounds (e.g., gold cyanide (K[Au(CN)2]) and sodium aurothiomalate) for the 
treatment of tuberculosis during the years of 1925-1935 (described as the “Gold 
Decade”) [3]. Despite the ineffectiveness of such complex ions in the treatment of 
tuberculosis in animals, the same compounds proved to be effective in the treatment of 
rheumatoid arthritis, culminating with the oral use of the drug auranofin (Figure 1) in 
1985 [4], for the treatment of this pathology. 
 








Another milestone of modern medicine involves the metal-complex cis-
diamminedichloroplatinum(II) (cisplatin or platinol) (Figure 1), first synthesized in 
1845 by the Italian chemist Michele Peyrone [5]. However, it was the chemists Barnett 
Rosenberg and Loretta VanCamp who, in 1965, while studying the effect of electric 
current on Escherichia coli, reported biological actions of cisplatin. Rosenberg's work 
culminated with the discovery of cisplatin as one of the most well-known antitumor 
agent of all times, leading to development of a series of analogues, which have been 
used in ca. 50% of all cancer treatments [5,6]. 
 
Relevant properties of metal complexes within the therapeutic context 
Metal complexes provide highly versatile platforms for drug design. In addition 
to the variations in the metal nature and oxidation state, metal ions adopt diverse 
geometries and coordination numbers, allowing the adjustment of chemical reactivity in 
terms of kinetics (bond exchange rates) and thermodynamics (metal-ligand bond 
strengths, redox potential, etc.) [7]. Not only the metal, but also the ligands are 
anticipated to play important roles in the biological activity, such as recognition of the 
outer sphere by a target, or biological action resulting from the release of the ligand [7]. 
According to a brief summary cited by Haas and Franz [8], the properties that make a 
platform of metallic complexes useful and versatile in biology are: 
i. Charge Variation – “Metal ions are positively charged in aqueous solution, but 
that charge can be manipulated depending on the coordination environment so 
that a metal complexed by ligands can be cationic, anionic, or neutral.” 
ii. Metal-Ligand Interaction – “Metal ions bind to ligands via interactions that are 
often strong and selective. The ligands impart their own functionality and can 
tune properties of the overall complex that are unique from those of the 
individual ligand or metal. The thermodynamic and kinetic properties of 
metal−ligand interactions influence ligand exchange reactions.” 
iii. Structure and Bonding – “Metal−ligand complexes span a range of coordination 
geometries that give them unique shapes compared with organic molecules. The 
bond lengths, bond angles, and number of coordination sites can vary depending 
on the metal and its oxidation state.” 
iv. Lewis Acid Properties – “Metal ions with high electron affinity can significantly 






v. Partially Filled d-shell – “For the transition metals, the variable number of 
electrons in the d-shell orbitals (or f-shell for lanthanides) imparts interesting 
electronic and magnetic properties to transition metal complexes.” 
vi. Redox Activity – “Coupled with the variability of electrons in the d-shell is the 
ability for many transition metals to undergo one-electron oxidation and 
reduction reactions.” 
Despite these advantages, the current diversity of metal complexes with medical 
therapeutic application is still limited. However, metallo-drugs are more widely 
represented in the category of diagnostic compounds (gadolinium, technetium, indium 
compounds among others) [1,9-11]. As part of this thesis, the next section will focus on 
therapeutic metal complexes with cardiovascular, cancer and tuberculosis interests. 
 
Anticancer metallo-drugs 
Cisplatin, cis-(NH3)2PtCl2, was the first metal-based drug used clinically against 
cancer (Figures 1 and 2) [1]. Currently, it is believed that its mode of cytotoxic action is 
mainly due to its ability to interact with DNA by forming stable adducts. Replacement 
of anionic Cl– ligands by neutral H2O ligands, mediated by the variation in chloride 
concentration inside of the cells, has been identified as the main route of activation. The 
globally cationic hydrolyzed complex [(NH3)2PtCl2-x(H3O)x]x+, is a potent electrophile 
agent able to react with any nucleophile, including sulfhydryl groups on proteins and 
nitrogen donor atoms on nucleic acids. Cisplatin therapy including combination with 
other drugs has been considered as a standard protocol against many types of cancer 
[12]. Nevertheless, new platinum drugs were investigated due to serious side effects of 
cisplatin, in addition to the aim of prolonging the use inducing drug resistance. Other 
platinum(II)-containing anticancer drugs such as carboplatin, approved in 1989 by the 
Food and Drug Administration (FDA), and oxaliplatin, approved in 2002 by FDA, have 







Figure 2. Anticancer platinum metallo-drugs clinically used or in current clinical trials. 
 
New PtII complexes, nedaplatin, lobaplatin, and heptaplatin (Figure 2), were 
prepared and clinically used in Japan, China, and South Korea, respectively [13]. Beside 
this, low spin 5d6 PtIV octahedral complexes have also been explored as potential 
anticancer agents, such as satraplatin (JM216) (Figure 2), the first orally administered 
platinum analogue, which is currently in advanced Phase III clinical trials [14]. 
Like platinum (Pt), substances containing arsenic (As) are also examples of 
approved drugs and in clinical studies for the treatment of cancer (Figure 3). Arsenic 
trioxide (trisenox) was approved by the FDA in 2000 particularly for the treatment of 
promyelocytic leukemia, but its toxicity, as well as the substantially reduced antitumor 
effects, limit its use in the treatment of other non-APL (Acute Promyelocytic Leukemia) 
cancers [15]. Liu and co-workers [16], recently indicated that the main target of 
trisenox, responsible for its cytotoxic action, is the promyelocytic leukemia protein 
(PML). Therefore, new therapeutic agents based on As have been developed, such as S-
dimethylarsino-glutathione (Darinaparsin®, ZIO-101) (Figure 3), a new chemotherapy 
agent in Phases I/II of clinical trial, which has shown more potent anticancer properties 
against various types of solid tumors and hematologic malignancies, both in vitro and in 
vivo [15]. Its molecular mechanism of action remains unclear; recently, however, Sun 
and collaborators [15] showed that darinaparsin (Figure 3), when interacts with 







Figure 3. Arsenic anticancer metallo-drugs: trisenox (clinically used) and darinaparsin 
(in clinical trials). 
 
Problems related to platinum metallo-drugs in the treatment of cancer have also 
stimulated the search for anticancer drugs containing ruthenium. Ruthenium complexes 
have emerged as a promising alternative to platinum-based chemotherapy. 
Imidazolium(imidazole)(dimethylsulfoxide)tetrachlororuthenate(III) (NAMI-A) (Figure 
4) was the first ruthenium complex to achieve clinical investigations in humans. It was 
synthesized for the first time by Mestroni and collaborators in Italy [17]. In preclinical 
studies, NAMI-A showed promising antimetastatic activity. It was well successful in 
Phase I clinical trial, but in studies of Phase II it showed limited efficacy, resulting in a 
halt in clinical development. Indazolium trans-tetrachlorobis(1H-
indazole)ruthenate(III)] (KP1019) (Figure 4) was another ruthenium derivative that 
entered in Phase I clinical trial, however its low solubility limited its progress in the 
later stages. Nevertheless, its sodium salt derivative, KP1339 (Figure 4), has advanced 
in clinical tests [18]. Finally, [Ru(II)(4,4′-dimethyl-2,2′-bipyridine(dmb))2(2-
(2′,2′′:5′′,2′′′-terthiophene)-imidazo[4,5-f][1,10]phe-nanthroline)]Cl2 (TLD1433) (Figure 
4) is the first metal-based photosensitizer, not containing a tetrapyrrolic fragment, to 
enter in clinical trials for non-muscle invasive bladder cancer treatment via 







Figure 4. Structures of ruthenium compounds in clinical trials. 
 
 Gallium (Ga) and molybdenum (Mo) compounds (Figure 5) are also included in 
the list of chemotherapeutic agents in clinical testing phases. Some examples are: 
gallium nitrate (Ga(NO3)3) (Figure 5), that displayed antineoplastic activity against non-
Hodgkin's lymphoma and bladder cancers in Phase I/II clinical trials [20], and two 
hexacoordinate complexes: gallium(III) tris(maltolate) (Figure 5), which is in Phases 
I/II of clinical tests in patients with prostatic neoplasms, multiple myeloma, bladder 
neoplasms and lymphoma, (ClinicalTrials.gov Identifier: NCT00050687) [21] and 
tris(8-quinolato)gallium(III) (KP46) (Figure 5) successfully tested in a Phase I clinical 
trial against kidney cancer [22]. It is believed that the antiproliferative activity of these 
two complexes is related to the inhibition of ribonucleotide reductase, the iron-
dependent enzyme essential for DNA synthesis, triggering apoptosis [7]. Bis-Choline 
tetrathiomolybdate (ATN-224) (Figure 5), is a molybdenum(VI) metallo-drug 
derivative, currently in Phases I/II of clinical tests, with patients affected by various 
forms of cancer (melanoma, breast, colon, kidney, and relapsed prostate cancer). These 
studies indicate that the possible chemotherapeutic action of ATN-224 may be related to 








Figure 5. Chemotherapeutic agents based on gallium(III) and molybdenum(VI) metals 
assayed in clinical trials. 
 
Cardiovascular metallo-drugs 
The number of metallo-drugs used for the treatment of cardiovascular disorders 
in clinical trials is much lower than the number of complexes developed for the 
treatment of cancer. Currently, the only metallic drug used for cardiovascular 
therapeutic purposes is sodium nitroprusside (SNP, Na2[Fe(CN)5NO]) (Figure 6), an 
FeII complex used in cardiac surgery, hypertensive crises, heart failure, vascular 
surgery, pediatric surgery, and other acute applications [24]. SNP is the first metal 
complex used in cardiovascular therapy, discovered by Playfair in 1849. The 
effectiveness of this metallo-drug, as a hypertensive agent, was only established in 1955 
[24,25]. The pharmacological action of SNP is based on its ability to release NO•. 
However, the rapid release of NO•, and the emergence of the cyanide toxicity, has been 
suggested as the main causes of the side effects observed for this prodrug [24]. Several 
other metal complexes have been developed and tested as less toxic and more efficient 
agents than SNP, however none of the representatives have yet participated in clinical 







Figure 6. Cardiovascular metallo-drugs in clinical use (SNP) and clinical trials Phases 
I/II (Oxacom® and M40403 (clinical phases suspended)). 
 
Oxacom®, the dinitrosyl iron complex (DNIC) (Figure 6), is a promising 
candidate for the development of a cardiovascular metallo-drug as it has proven to be an 
effective hypotensive drug, with no adverse effects reported so far. It is currently in 
Phase I/II clinical trials [26]. The endogenous effects of Oxacom® are related to its 
ability to delivery NO•, with sGC (soluble guanylate cyclase) as its main target, similar 
to SNP. The process of sGC activation via NO• and the consequent vasorelaxation 
activity will be detailed in the section 2.3.2 paragraph 6. M40403, the SOD mimicking 
manganese(II) (pentaaza)macrocycle (Figure 6), is another example of a hypotensive 
metallo-drug in clinical trials (Phase I/II clinical trials currently suspended). It is 
indicated that its action is related to its ability to mimic the activity of superoxide 
dismutase, eliminating superoxide radicals and exerting beneficial effects on models of 
intestinal ischemia-reperfusion, and on acute inflammation [27]. 
 
Antituberculosis metallo-drugs 
During the years of 1925 − 1935, also known as the “Gold Decade”, gold 
cyanide, sodium aurothiomalate, and sodium aurothiosulfate AuI compounds were used 
for the treatment of pulmonary tuberculosis. Although auranofin is in clinical trials 
(Phase II) as a possible agent in host directed therapy for tuberculosis in combination 
with rifabutin [28], the majority of gold-based metallo-drugs available today are 
classified as antirheumatic drugs [1,29]. At the date of this thesis, there is no metallo-
drug clinically approved for use in tuberculosis. Although there are a significant number 
of metal complexes with a potential antitubercular activity proven [30,31], few or none 
are in pre-clinical or clinical phases of study and, in most cases, their mechanisms of 






Figure 7, their respective minimum inhibitory concentration (MIC) values against Mtb 
H37Rv cells are also presented [30-36]. 
 
 
Figure 7. Promising metal-complex antitubercular compounds and their minimum 
inhibitory concentration (MIC) against Mtb H37Rv cells. 
 
Nonetheless, Sousa e co-workers [31], synthesized an isoniazid metal complex 
with pentacyanoferrate(II) moiety, called IQG607 (Na3[Fe(CN)5(INH)], INH = 
isoniazid) (Figure 7). This compound showed significantly promising inhibitory activity 
against Mtb H37Rv cells (MIC = 0.43 μM), in addition to the in vitro inhibition of the 
enoyl-ACP reductase enzyme (InhA), even without using catalase-peroxidase KatG 
enzyme [31]. The mechanistic studies carried out by Sousa [37] and collaborators 
indicated that the action of this complex may be related to its ability to be oxidized by 






active isonicotinoyl radical form (INH active species), responsible, after reaction with 
NADH, for inhibition of an InhA of Mtb. Inhibition of this enzyme involves interruption 
of mycolic acid bio-synthesis, an essential constituent of the bacterial cell wall. Unlike 
INH, IQG607 could be a potential anti-TB metallo-drug targeting InhA without 
depending on catalase-peroxidase KatG enzyme. Although this mechanistic route may 
not occur in vivo [38], IQG607 has exhibited exciting toxicological and 
pharmacological profiles, indicating also a potential to reduce the lengthy treatment 
once in combination with other first-line drugs [39]. These promising biological 
activities of IQG607 have stimulated the advances in pre-clinical studies [39-43]. 
 
2. Nitric oxide (NO•) and nitroxyl (HNO) in medicine and their donors as 
therapeutic platforms 
 
2.1. Nitric oxide (NO•) 
The role of nitric oxide (NO•) in biology was elucidated in the early 1980s, when 
researchers understood that NO• was the endothelium-derived relaxing factor (EDRF), 
which is involved in the stimulation of the soluble guanylate cyclase protein (sGC) via 
interaction with the heme group [44,45]. These discoveries led Robert F. Furchgott, 
Louis J. Ignarro and Ferid Murad to be awarded the Nobel Prize in Medicine or 
Physiology in 1998. 
2.1.1. Biological production of nitric oxide 
This small molecule is produced endogenously via the oxidation of L-arginine to 
L-citrulline, catalyzed by three types of isoenzymes called nitric oxide synthases (NOS) 
(Figure 8A and B) [46,47]. The main isoforms are known as: neuronal (nNOS or NOS1) 
[48], inducible (iNOS or NOS2) [49], and endothelial enzymes (eNOS or NOS3) 
[47,50], but there are others [51]. Most of the known effects of NO• are directly related 
to the stimulation of sGC (Figure 8C) [45,52]. This stimulus occurs through the NO• 
bond to the heme-iron unity of the beta subunit of sGC causing conformational changes 
that accelerate the conversion of guanosine-5'-triphosphate (GTP) into cyclic guanosine-
3′,5′-monophosphate (cGMP) and pyrophosphate (PPi) [53,54]. The important 
secondary messenger cGMP is responsible to trigger a series of downstream processes 







Figure 8. Endogenous production of nitric oxide. Panel A shows the two-step formation 
of NO• from arginine to citrulline, through the intermediate N-omega-hydroxy-L-
arginine formation. This reaction is catalyzed by nitric oxide synthase (NOS) with 
participation of O2, NADPH and the cofactor tetrahydrobiopterin (H4B) (Panel B). 
Panel C shows NO• diffusion from its production site (e.g., endothelial cells) into 
another cell reaching soluble guanylate cyclase (sGC), whose enzymatic activity is 
strongly stimulated with conversion of GTP to cGMP. 
 
A one-electron reduced form of nitric oxide, called nitroxyl (HNO) [60], has 
also brought considerable attention due to some distinct biological and/or 
pharmacological properties. This molecule exhibits protective effects against 
reperfusion damage for the treatment of myocardial infarction [61], ability to improve 
myocardial contractility in the treatment of heart failure [62], aldehyde dehydrogenase 
inhibitory activity in the treatment of alcoholism [63], and tumor growth inhibitory 
property and antiangiogenic effect in cancer treatment [64,65]. 
2.2. Nitroxyl (HNO)  
 Nitroxyl (HNO), a small molecule whose pKa is ca. 11.4 [66,67], was first 
mentioned by the Italian scientist Angelo Angeli, who obtained experimental evidence 
for the release of HNO and nitrate from sodium trioxodinitrate salt (N2Na2O3) [68,69]. 
The currently known Angeli's salt (AS) was placed in evidence as the first HNO donor 






roles of NO• [68]. Endogenous HNO production in human is still speculative, requiring 
further studies, which have motivated the scientific community [66,70-74]. One of the 
main issues contributing to this scenario is the fast reactivity of HNO, which 
decomposes reacting with itself to generate N2O (k = (8 ± 3) x 106 M-1 s-1) [75], with 




Scheme 1. HNO decomposition reactions followed by their respective constants 
[75,76]. 
 
 During the last decades, several pathways for HNO endogenous production have 
been proposed [74,77]. The first one is associated to the absence of the cofactor 
tetrahydrobiopterin (H4B) during endogenous production of NO• as a way to generate 
HNO [78]. This cofactor works in different ways during the synthesis of NO•, such as 
by stabilizing a dimeric structure of NOS (nitric oxide synthases) [79-81], accelerating 
the decomposition of the complex dioxygen-ferrous heme (NOS-FeII(O2)) [78,82], and 
increasing the rate of consumption of NADPH (Figure 8B) [83,84]. In addition, this 
cofactor is essential for the biosynthesis of NO• rather than for that of HNO [51,85]. So, 
it is possible that under these conditions of low concentrations or in absence of H4B, the 
production of HNO is favored. Based on that, mechanistic studies suggested NOS-
FeII(O2•-) would react with N-omega-hydroxy-L-arginine (NOHA), converting this 
hydroxamic intermediate into L-citrulline, water, ferric enzyme NOS-FeIII and HNO 
[51,78]. Other possible pathways for HNO biosynthesis are the decomposition of 
nitrosothiols [86,87], through nitrosothiol enzymatic reduction [88-90], and oxidation of 
hydroxylamine (NH2OH) by hemeproteins [74,77], which will be discussed below. 
2.2.1. HNO endogenous synthesis by NOS 
While there is a consensus on the mechanism of NO• biosynthesis, HNO 
endogenous production is still poorly understood. This is likely due to the high 
instability of HNO and the lack of effective detection methods [72,91]. Nonetheless, 






of the first proposals was based on the conventional NO• biosynthesis pathways in 
conditions of low H4B concentration [51,78,80,82-84]. In the endogenous NO• 
synthesis, the absence of H4B increases the probability of HNO release rather than NO•. 
According to Stuehr and co-workers [78], the NOHA intermediate can be produced by 
NOS and L-arginine in the absence of H4B, requiring only the participation of the 
NADPH cofactor. This can lead to the formation of a nitroso intermediate, which can 
ensue with production of HNO. This nitroso intermediate can react with the heme group 
to produce NOS-FeII(NO), which might release HNO without any oxidative species. 
Scheme 2 shows the proposed mechanism of HNO production from L-
arginine/NOS/NADPH system without H4B cofactor. 
 
 
Scheme 2. The biological synthesis of NO• and likely production of HNO by NOS, 






2.2.2. HNO endogenous production mediated by nitrosothiols decomposition 
Another possible endogenous route for the production of HNO arises from the 
decomposition of nitrosothiols (RSNO), which is considered the most physiologically 
relevant pathway [86,87,92]. RSNO are products of the reaction between nitric oxide 
and thiols (RSH). Thiols are biomolecules that play important biological roles and can 
be found in abundance as large (cysteine rich proteins) or small molecules [93,94]. The 
homocysteine (Hcy), cysteine (Cys), cysteinylglycine (CysGly), and glutathione (GSH) 
are examples of thiols performing vital functions in physiological processes. These 
molecules can be found in cells in different concentration ranges (from 5-15 µM for 
Hcy to 0.5-10 mM for GSH) [95-97]. RSNO is produced by the reaction of NO• with 
thiols under aerobic conditions, where nitrogen oxides play a critical role (Scheme 3) 
[98]. 
 
Scheme 3. Nitrosothiol (RSNO) production under aerobic conditions, reference [98]. 
 
Some authors also reported the production of RSNO through a reaction of the 
nitrosonium cation (NO+) with thiolate anion (RS-) [99-101]. However, free NO+ is 
stable only at low pH (~ 2.0) [102], while thiolate formation, dependent on the nature of 
the molecule and pH medium, is more abundant at pH > 7 [103-107]. Due to these 
properties, this route is likely less relevant in biology. 
2.2.3. HNO production by enzymatic reduction 
Enzymatic reduction of NO• mediated by superoxide dismutase (SOD) or 
xanthine oxidase (XO) under anaerobic conditions has been described as a potential 
route for HNO production. SOD can directly reduce NO• to HNO in the absence of O2 
through a reversible process [88,89]. In another reductive process, XO catalyzes an 
expected irreversible process where hypoxanthine is used as an electron donor to reduce 
NO• to HNO, in the absence of oxygen [90]. However, these routes of production of 
HNO are still under debate, particularly considering the methodology employed for 
HNO detection, which is susceptible to bring significant mistakes [108,109]. 
Another protein earlier claimed to produce HNO was the cytochrome c via a 






doubts were raised due to the probe used during those studies. Later, the same team has 
concluded HNO was indeed not produced discarding this route as a biological option 
[111]. 
2.2.4. HNO production by hydroxylamine oxidation 
Another possible pathway for the biosynthesis of HNO is the oxidation of 
hydroxylamine (NH2OH) to HNO mediated by heme proteins using H2O2 [74,112-114]. 
Wink and coworkers found that heme proteins containing proximal histidine ligand 
(e.g., horseradish peroxidase, lactoperoxidase, myeloperoxidase, myoglobin, and 
hemoglobin) could catalyze the conversion of NH2OH to HNO, in the presence of 
hydrogen peroxide (H2O2) [112]. Recently, Álvarez and coworkers confirmed this 
hypothesis, reporting that myoglobin catalyzes HNO production via peroxidation of 
NH2OH [74]. 
Hydroxylamine is a cellular metabolic product commonly found in physiological 
environments [113,115,116], its oxidation into HNO is caused by the intermediate heme 
FeIV•=O formed by the reaction of heme FeIII with H2O2 found in the cellular medium 
[117,118]. This reaction involves the heme FeIV•=O, which oxidizes NH2OH that 




Scheme 4. HNO synthesis via oxidation of hydroxylamine (NH2OH) mediated by heme 
proteins and H2O2 [112,117-120]. 
 
2.3. The pharmacological importance of NO• and HNO in cancer, 
cardiovascular and tuberculosis diseases 
We have already mentioned that NO• and HNO play key roles in various 
physiological processes [121-123]. In the context of this thesis, only the implication of 






summary of each pathology will be addressed below mainly in order to explain how 
HNO can be considered as pertinent therapeutic agent. 
2.3.1. Cancer 
Cancer (neoplasia or malignant tumor) is the name for a set of diseases that have 
in common the uncontrollable cell growth [124]. Cells that grow out of control, also 
called cancer cells or tumor cells, are the result of genetic mutations that lead to growth, 
unrestricted cell division, and resistance to apoptosis [125]. As cancer cells increase, the 
process of cellular angiogenesis is stimulated, which in turn induces blood vessels 
formation as a way of obtaining nutrients and oxygen [126,127]. In the course of these 
processes, eventually, tumor cells can invade adjacent tissues spreading to other parts of 
the body, this process is called metastasis [128]. 
i. Global panorama 
The International Classification of Diseases lists more than 600 types of cancer. 
According to the World Health Organization (WHO), cancer is one of the main causes 
of death in the world, having registered 9.6 million deaths in 2018, with an estimated 
29.4 million cases in 2040 [124]. In 2018, the most diagnosed cancer type was lung 
(11.6% of all cases), followed by female breast (11.6%) and colorectal cancer (10.2%) 
[124]. From a geographical point of view, the incidence of cancer is influenced by sex 
and type of cancer. In 2018 the highest rates of lung cancer in men were reported in 
Micronesia/Polynesia (52.2 cases per 100,000 inhabitants), while in women it was in 
Northern America (30.7 cases per 100,000 inhabitants), while the highest rates of breast 
and prostate cancers occurred in Australia/New Zealand (breast = 106.8 cases per 
100,000 inhabitants, and prostate = 96.6 per 100,000 inhabitants) [129]. 
ii. Prevention and treatment 
Cancer is within non-communicable diseases (NCDs, or chronic diseases), 
configuring as non-transmissible, presenting long treatment, and can result from a 
combination of genetic, physiological, socioenvironmental, economic and behavioral 
factors [130,131]. The main factors that can influence the onset of cancer are: smoking 
(the agent that most contributes to cancer mortality), infections (e.g., Helicobacter 
pylori - stomach cancer, human papillomavirus (HPV) - cervical cancer, hepatitis B and 






exposures (e.g., workers exposed to chemicals), pollution, food contaminants, medical 
drugs, ultraviolet and ionizing radiation, immunosuppressive drugs, and genetic 
susceptibility [124,132,133]. 
 Cancer is generally the most complex disease in terms of treatment among 
NCDs. Treatment can occur through surgery (procedure in which a surgeon removes 
cancer from your body), immunotherapy (treatment that helps your immune system 
fight cancer), hormone therapy (treatment that blocks the body's natural production of 
hormones), radiotherapy (treatment that uses high doses of radiation to kill cancer cells 
and shrink tumors), chemotherapy (use of drugs to kill cancer cells) and targeted 
therapy (treatment that targets proteins that control how cancer cells grow, divide, and 
spread) [124,134-139]. Targeted therapy can work via different mechanisms: i) helping 
the immune system to destroy can cells [140], ii) starving cancer cell from hormones 
that they need to growth [141], iii) helping cancer cells to go through dying process 
[142], iv) delivering cell-killing substances to cancer cell [143], and v) stopping signals 
that favor blood vessels formation, blocking the neo-angiogenesis of the tumor [127]. 
This last approach is a known way how NO•/HNO exert their anticancer action. 
Cancer treatment can occur through one or more combined treatment 
modalities/techniques. The combination of chemotherapy and targeted therapy, for 
example antiangiogenic drugs, have increased the progression-free survival (PFS, time 
period during and after treatment, in which a patient lives with the disease, but it does 
not get worse) of patients with metastatic cancer (pancreatic, colorectal, and breast), 
compared to treatment using chemotherapy alone [126,127,144,145]. These results 
helped to validate the concept of antiangiogenic agents in the treatment of cancer. 
Several antiangiogenic molecules have been approved by the Food and Drug 
Administration (FDA) for use as anticancer agents in combination with chemotherapy 
[127]. Figure 9 illustrates some examples of approved antiangiogenic drugs with their 







Figure 9. FDA approved antiangiogenic drugs and their targets in parentheses. 
 
NO• can have beneficial and harmful roles on cancer disease tightly dependent 
on its biological levels. At low concentrations (100-300 nM), NO• can promote cancer 
growth through cell stimulation and enhancement of angiogenesis and metastasis. On 
the other hand, at high concentrations of NO• (>400 nM), it can disrupt cancer cell 
growth via apoptosis induction, tumor sensitization to chemo-, radio-, or immuno-
therapy treatments, and may also function by reversing resistance to chemotherapy and 
by inhibiting the angiogenic and metastatic cascades [146,147].  
Angiogenesis is a normal and complex process controlled by certain 
biomolecules produced in the body, and consists of the growth of new blood vessels 
from existing ones [148]. These new blood vessels will serve to take up the oxygen 
necessary to the growth of the cancer cell [126]. 
In cancer cells, the production of pro-angiogenic factors is induced in hypoxia 
conditions (caused by abnormal accelerated metabolism), which leads to the rapid and 
chaotic formation of blood vessels. Adaptation to different levels of oxygen in the cell 
(normal and cancer cells) is mediated by a family of transcriptional regulators, called 
hypoxia-inducible factors (HIFs) [127]. HIFs are heterodimers consisting of an oxygen-
independent β-subunit (HIF-β) and an oxygen-dependent α-subunit (HIF-α), which has 






Under normoxia, transcriptional activity of HIF is specifically suppressed 
through the degradation of the HIF-1α subunits, via a hydroxylation process mediated 
by an asparaginyl hydroxylase factor. Low oxygen conditions induce the stabilization of 
HIF-1α, promoting the upregulation of several pro-angiogenic genes including VEGF 
(vascular endothelial growth factor), FGF (fibroblast growth factor), and PDGF (platelet 
derived growth factor) [127,149]. The latters are responsible for inducing the formation 
of endothelial cells composing the blood vessels [148]. Thus, these different pro-
angiogenic factors have been considered as promising targets for anticancer therapy 
[126,127,145]. 
NO• and HNO have played a key role in the regulation of HIF-1α in tumor cells. 
While NO• has been indicated as a stabilizing agent for HIF-1α in normoxic conditions, 
HNO has been shown to act in the opposite way, blocking HIF-1α stabilization, induced 
by both hypoxia and NO• in normal air conditions, and hence inducing antiangiogenesis 
and cell death by apoptosis [65,150-152]. These properties open doors for the use of 
HNO donor agents as new and promising anticancer platforms. In the section 2.5, 
several HNO donor agents with potential antiangiogenesis and anticancer action are 
reported. One of such examples is object of this thesis and is described in chapter 1. 
2.3.2. Cardiovascular diseases 
Cardiovascular diseases (CVDs), or heart disease, are a group of disorders of the 
heart and blood vessels (cardiovascular system), including coronary heart disease, 
cerebrovascular disease, angina pectoris, myocardial infarction (heart attack), rheumatic 
heart disease, hypertensive heart disease, stroke, heart failure, cardiomyopathy, cardiac 
arrhythmias, among others [153-155]. 
i. Global panorama 
According to WHO, CVDs are the number 1 cause of death globally, with about 
17.9 million deaths per year (31% of all deaths worldwide) [153]. Roth and co-workers 
reported that in 2015 the countries with the highest CVD rates were those in Western 
and Eastern sub-Saharan Africa with 9,475 and 8,444 cases per 100,000 inhabitants, 
respectively [156]. 
ii. Prevention and treatment 
CVDs also belong to NCDs, therefore they are not transmissible, they tend to 
have a long duration, and the resulting factors for these diseases can be genetic, 






the development of CVDs: tobacco use, physical inactivity, unhealthy diet (rich in salt, 
fat, and calories), harmful use of alcohol, high blood pressure (hypertension), high 
blood sugar (diabetes), high blood lipids (e.g., cholesterol), overweight and obesity, 
poverty and low educational status, advancing age, male gender, genetic disposition and 
psychological factors (e.g., stress, depression) [154]. Currently, it is also known that 
Coronavirus Disease 2019 (COVID-19) pneumonia has significantly influenced the 
increase in clinical complications in patients with CVDs [157-160]. 
The choice for healthier lifestyle habits, good social habits avoiding stress, 
panic, among others, has proved to be an extremely strong ally in the prevention and 
treatment of CDVs [161]. Many heart problems are also amenable to treatment via 
surgical procedure and medication [154,162,163]. Cardiovascular drugs have been the 
most prescribed drugs in the world. The purpose of these medications is to prevent and 
treat morbid conditions that affect the cardiovascular system [163].  
Generally, the use of cardiovascular drugs is directed towards disease-related 
pathophysiological mechanisms, that is, cardiovascular drugs include compounds that 
directly regulate the function of the heart and blood vessels, through interaction with 
certain biological targets, resulting in a therapeutic response [164]. For example, in 
cases of hypertension, the treatment can occur by different types of drugs with different 
actions [155,165,166]: diuretics, β-blockers, calcium (Ca2+) channel blockers, ACE 
(angiotensin converting enzyme) inhibitors, α-adrenergic receptor, and direct 
vasodilators. Some examples of classic antihypertensive drugs used in cardiovascular 
treatment are listed in Figure 10, their classification within the group of 







Figure 10. Some examples of cardiovascular drugs, followed in the parentheses by their 
pharmacological class. 
 
Vasodilation is one of the main therapeutic strategies to obtain an 
antihypertensive effect. In this thesis, we are particularly interested on the 
antihypertensive effects of NO•/HNO. From a mechanistic point of view, after the 
production of NO• in the body, either endogenously or through donor drugs, NO• readily 
diffuses through cell membranes, until it reaches its main target, soluble guanylate 
cyclase (sGC) protein (Figure 11) [54]. sGC is a heterodimeric protein made up of two 
subunits α and β. The β subunit has the prosthetic group (heme), which has a strong 
affinity for NO•. When NO• binds to FeII-heme of sGC, it disrupts the bond between FeII 
and the histidine residue (105) of the protein, a phenomenon also called trans-labilizing 
effect of NO•. As a result of the previous step, a significant conformational change in 
sGC is initiated in order to activate the catalytic site of the enzyme. This activation 
promotes an increase in Mg2+ dependent catalytic activity, resulting in the conversion of 
GTP into PPi and cGMP [54]. The latter regulates the effect of several biological 
systems such as cGMP-dependent protein kinases, ion channels, and 
phosphodiesterases, responsible for mediating several physiological processes including 






mechanisms for HNO mediated vasodilation have been proposed, including NO•-like 




Figure 11. Activation mechanism of soluble guanylate cyclase by NO•, reference [170]. 
 
2.3.3. Tuberculosis 
 Tuberculosis (TB) is an infectious disease caused by the Mycobacterium 
tuberculosis (Mtb) bacillus. It mainly affects the lungs (pulmonary TB) but can also 
affect other organs (extrapulmonary TB) [171]. 
i. Global panorama 
WHO indicates TB as one of the main infectious diseases present in the world. 
In 2018, it was estimated that 10 million people were contaminated by TB, and 1.5 
million had died from it [171]. More than one third of the current world’s population 
(1.7 billion) has latent tuberculosis, which means that these people are 
asymptomatically infected with Mtb [172]. From a geographical perspective, 
tuberculosis is widespread worldwide, however, in 2018, the majority of the cases, 
estimated by WHO, were concentrated in South-East Asia Region (44%), African 
Region (24%) and Western Pacific Region (18%), with the most affected countries 
being India (2,690 cases per 100,000 inhabitants), Indonesia (845 cases per 100,000 







ii. Transmission of disease 
In general, transmission occurs when an infected person coughs, sneezes or 
speaks, releasing pathogens into the air through micro-droplets of mucus, so a simple 
inhalation is enough to become infected [173]. In cases of primary infection, 
tuberculosis is usually cured spontaneously by the action of the host's immune system 
[174]. The bacilli ingested by macrophages multiply and trigger a chemotactic reaction, 
in which other macrophages and other defensive cells are attracted to the infected area. 
This agglomerate of cells, forms a granuloma (or tuber), in which Mtb develops poorly 
due to lack of oxygen and can therefore remain inactive. The disease remains in the 
latent phase and the lesions calcify. However, although tuberculosis bacilli are 
phagocyted by immune cells (e.g., macrophages, neutrophils, dendritic cells), they do 
have virulence factors that allow them to survive within these phagocytic cells [175].  
In 90% of cases of primary infection, the tubercular bacillus remains inactive. In 
this case, the infection is latent (latent TB infection (LTBI)), and asymptomatic, in 
addition, the host is not at risk of contagion [175,176]. Nevertheless, in conditions of 
low immunity (HIV-1 serostatus, diabetes, undernutrition, immunosuppressive) [171], 
Mtb tubers can be reactivated causing local inflammation and impairing the functioning 
of the lungs. Eventually a deficient immune response results in necrosis and rupture of 
granulomas, dispersing more infectious bacilli in the airways [177,178]. This 
pathological condition is called pulmonary tuberculosis (pulmonary TB). If adequate 
treatment does not occur, the spread of tuberculosis bacilli throughout the host's body 
can lead to extrapulmonary tuberculosis (extrapulmonary TB), in addition to eventual 
death [179]. 
iii. Treatment 
 The cell wall of Mycobacterium is the main characteristic of this genus. It is rich 
in fatty acids and lipids, making this microorganism one of the most pathogenic species 
to humans. Mtb has an extremely complex and impermeable mycobacterial wall, this 
protection consists of peptidoglycan, arabinogalactan, mycolic acids, and external lipids 
[180]. This protective structure contributes significantly to high virulence and resistance 
to classic antibiotic treatments [181]. 
The treatment of TB consists of the use of vaccine and antibiotics. In the case of 
treatment through vaccination, Bacillus Calmette – Guérin (BCG) is the only one 
specifically used to prevent severe forms of tuberculosis (TB meningitis and miliary 






first-, second- and third-line drugs. The treatment modalities depend on the bacteria's 
sensitivity to the antibiotics used. Details are presented below. 
iv. First-line antitubercular drugs 
 Treatment regimen for all new cases of all forms of pulmonary and 
extrapulmonary tuberculosis (except meningoencephalitis), as well as for all cases of 
relapse and return after default, consists of 6 months. In the first 2 months, there is a 
daily intake of the four first-line drugs rifampicin, isoniazid (INH), pyrazinamide (PZA) 
and ethambutol (Figure 12), followed by another 4 months, using only rifampicin and 
INH, in order to ensure the complete extermination of Mtb from the host body [183]. 
 
 
Figure 12. First-line antitubercular drugs. 
v. Second-line antitubercular drugs 
The emergence of treatment-resistant bacteria using first-line antitubercular 
drugs has resulted in the employment of other medicines called second-line 
antitubercular drugs. The main second-line antitubercular drugs are: p-aminosalicylic 
acid, thioamides (ethionamide and prothionamide), cycloserine derivatives (cycloserine 
and terizidone), aminoglycosides (amikacin e streptomycin) and fluoroquinolones 
(levofloxacin and moxifloxacin) (Figure 13). Nevertheless, these compounds are 
generally less potent, more toxic, and more expensive. In addition, drug-resistant TB 
treatment is long, ranging from 9-12 months (shorter regimen) and 18-20 months 







Figure 13. Some examples of antitubercular second-line drugs. 
vi. Third-line antitubercular drugs 
Although the development of second-line drugs provides a cure for many 
multidrug-resistant tuberculosis (MDR-TB) patients, in some cases, the treatment is not 
effective beyond the high toxicity of these drugs [185]. As a way to overcome these 
treatment failures, new drugs with MDR-TB action, called antitubercular third-line 
drugs, have been developed. Three examples of third-line antitubercular drugs are 
bedaquiline, delamanid, and pretomanid. These drugs were the last antitubercular 
molecules approved for clinical use, bedaquiline in 2012 (by FDA), delamanid in 2014 
(by European Medicines Agency (EMA)), and pretomanid in 2019 (by FDA) (Figure 
14) [185,186]. WHO recently included bedaquiline and delamanid in the group of 
medicines recommended for use in longer MDR-TB regimens [187]. 
 
 
Figure 14. Structures of bedaquiline, delamanid, and pretomanid. 
 
Within the context of this thesis, delamanid stands out because it is reported as a 
HNO donor prodrug with anti-TB action. Despite delamanid is known to inhibit 






molecular level remains uncertain [188]. It has been shown that to exert its anti-TB 
activity, an intracellular bioreductive activation via mycobacterial nitroreductase 
enzyme (Ddn) is required, consequently producing HNO/NO• as potential active 
metabolites (scheme 5) [189]. In fact, it has been proposed that HNO and NO• have 
anti-TB action, however the way, in which these molecules act against Mtb is still not 
well elucidated [190,191]. 
 
 
Scheme 5. Proposed mechanism for the activation reaction of delamanid by the Ddn 
enzyme, reference [188]. 
  
The pharmacological properties of NO•/HNO, discussed above, offer new 
medical perspectives for the use of NO•/HNO as a promising new anticancer, 
antihypertensive and anti-TB agent. As NO•/HNO are molecules highly unstable with 
no ideal chemical and pharmacokinetic properties to justify its use alone, the 
development of a new chemical family, able to act as pro-dugs and deliver NO•/HNO in 
vivo, is an exciting research topic, in which several researchers are working on it. In the 
next paragraph, an overview of NO• and HNO donors will be discussed. 
2.4. Nitric oxide (NO•) donors 
Nitric oxide must reach certain biological levels to establish its effects, which 
can vary from signaling regulation of blood pressure to cellular apoptosis of cancer 
cells. This illustrates well how critical are the strategies to delivery this molecule in a 






Aiming at different targets, several strategies have been used in the design NO• donors, 
particularly taking advantages of specific stimulus promoted by the body (e.g., pH, and 
enzymatic reaction) or even externally (e.g., light). Throughout the text, we will discuss 
the chemistry and biological properties of some NO• donors. 
2.4.1. Organic Nitrates 
Organic nitrite molecules are the oldest class of NO• donors [193]. Structurally 
they are nitric acid esters, generally represented by the formula RONO2. The glyceryl 
trinitrate (GTN), pentaerythrityl tetranitrate (PETN), and isosorbide dinitrate (ISDN), 
are examples of molecules that integrate this group (Figure 15). GTN is one of the most 
commonly known nitric acid esters, originally used in the industry of explosives, then 
recognized as a drug in the treatment and prevention of angina pectoris pain [194]. 
Curiously, the famous Alfred Nobel who made a fortune developing explosive 
formulations including GTN, was indeed treated with this same compound due to his 
angina pectoris medical problem. Today, GTN is also used in hypertensive crises [195] 
and erectile dysfunction [196]. Several other organic nitrates have been used in the 
treatment of cardiovascular diseases [197], angina pectoris, pre-eclampsia, pulmonary 
hypertension, and chronic heart failure in combination with hydralazine [198-200]. 
 
 
Figure 15. Classic organic nitrates. 
 
However, due to the side effects of some organic nitrates [197,201-207], the 
scientific community moved to explored its use in hybrid compounds of known drugs, 
expecting to generate dual pharmacological activities. The nicorandil (antianginal drug) 
[208], 2-acetoxy-benzoate-2-(2-nitroxymethyl)-phenyl ester (NCX4016, colorectal 
cancer prevention in clinical trials Phase I) [209], HCT 3012 (analgesic and anti-
inflammatory drug in clinical trials Phase III) [210], and NCX 701 (analgesic and anti-
inflammatory drug in clinical trials Phase I) [210], are examples of hybrid molecules 






analgesic, anticancer, and anti-inflammatory. Figure 16 illustrates various nitrate hybrid 
drugs and describes the parent organic drug and the reasons for incorporating the nitrate 
group. 
 
Figure 16. New nitrate hybrids and the goals for their development. 
 
Most of the biological effects of organic nitrates are attributed to their ability to 
release NO•. In general, organic nitrates are able to release NO• after reaction with 
enzymatic systems (e.g., cytochrome P450, xanthine oxidoreductase, glutathione-S-
transferase, and aldehyde dehydrogenase 2), ferrous-heme proteins (deoxyhemoglobin 
and deoxymyoglobin), or thiols [193,197,211]. Glutathione is an exception because its 
reaction with organic nitrates must be catalyzed by glutathione-S-transferase [193].  
The mechanism of NO• release through organic nitrates in physiological medium 
requires reduction reactions involving three electrons [212]. In reductions catalyzed by 
enzymatic systems and ferrous-heme proteins, the first step produces hydrated nitrate 
ester, which decomposes into nitrite ester releasing water. Hydrolysis of nitrite ester 
yields the respective alcohol and nitrous acid (HNO2). In the final step, HNO2 can be 
reduced producing NO• and H2O (Scheme 6A) [212]. In the case of enzymatic reduction 






group. This reaction yields an alcohol and an unstable intermediate thionitrate. This 
latter can further react (nonenzymic) with another thiol molecule producing HNO2 and 
disulfides [213], or decompose into NO• and sulfenyl product (Scheme 6B) [214]. 
 
 
Scheme 6. Mechanism of nitrate organic reduction by enzymatic systems (without thiol 
participation) and ferrous-heme proteins (A) or enzymatic reduction involving thiols 
(B), references [212-214]. 
2.4.2. Secondary amines-based diazeniumdiolates (NONOates) 
The diazeniumdiolates or NONOates compounds have a -O-N=N-O- (NONO) 
moiety connected to a primary or secondary amine. This type of molecule, in special the 
secondary amines, is considered standard NO• donors and is thus used in several 
experimental models. DEA NONOate, DETA NONOate, PROLI NONOate, SPER 
NONOate, and MAHMA NONOate are some examples of these donors (Figure 17) 
[215,216]. A series of studies have shown the ability of NONOates derivatives to 
release NO•, where these molecules were investigated for biological activities such as 










Diazeniumdiolate compounds are unstable under physiological conditions and 
can decompose directly generating up to 2 equivalents of NO• per NONO moiety. 
However, the rate of NO• release is dependent on the temperature, pH and structure of 
the parent compound [220,221]. In general, the decomposition of NONOates is acid-
dependent, such a decomposition mechanism can follow two different pathways 
potentially leading to the same final products as depicted in Scheme 7 [222]. 
 
 
Scheme 7. Mechanism of diazeniumdiolates decomposition, reference [222]. 
 
In order to fine-tune the release of NO• by these NONOates, several new pro-
drugs containing this functional group have also been developed in analogy to what was 
previously shown for DEA and PROLI NONOate. For example V-PYRRO/NO (1-
[(ethenyloxy)-NNO-azoxy]-pyrrolidine), a pro-drug with hepatoprotective properties 
against a variety of toxins, and JS-K (O2-(2,4-dinitrophenyl) 1-[(4-
ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate), a promising anticancer pro-
drug (Figure 18) [223]. Basically, all these proposal compounds are activated through 
the diazeniumdiolate moiety with the production of NO• under physiological conditions. 
Until now, NONOates are not yet approved for clinical use [224]. Up to our knowledge 
only a single study using NONOate derivative MK‐8150 (Figure 18) in hypertension 
treatment (clinical trials Phase I) exist [225]. However, the control of the NO• release as 
well as its targeted delivery through structural modulation, make NONOates potential 







Figure 18. Structure of some promising NONOates derivatives. 
 
2.4.3. S-Nitrosothiols (RSNOs) 
S-nitrosothiols (RS-NO) are considered one of the most common NO• releasers. 
Some well-known S-nitrosothiols derivatives are S-nitroso-glutathione (GSNO), S-
nitroso-cysteine (SNO-Cys), S-nitroso-N-acetylpenicillamine (SNAP), and 1-nitroso-
thiogalactose tetraacetate (SNAG) [193], which are illustrated in Figure 19.  
 
 
Figure 19. Structure of some S-Nitrosothiols (RSNOs).  
 
S-Nitrosothiols accomplish several functions in the body such as vasodilation, 
wound healing, anti-infectious action, and analgesic action against inflammatory pain 
[226]. In general, the properties of S-nitrosothiols are directly associated with their 
decomposition and the release of NO•. This process can be induced by certain metal 






[232]. The mechanisms for all of these induced-decomposition processes are depicted in 
Scheme 8 [228,229,233]. 
 
Scheme 8. Mechanism of RSNOs decomposition induced by Cu+ ions (A), enzymes 
(CuZn-SOD) (B), other metal ions (Hg2+ and Ag+) (C), heat and light (D), references 
[227-233]. 
 
Currently, no S-nitrosothiols are available to clinical use, but there are a large 
number of clinical studies mainly to the GSNO, demonstrating their advantageous 
features, especially in the cardiovascular disorders [234,235]. In addition, its potential 
use in the treatment of asthma has also been evaluated (in clinical trials Phase I, 
ClinicalTrials.gov Identifier: NCT03926741) [236]. 
2.4.4. Furoxans 
Furoxans are molecules containing an 1,2,5-oxadiazole-2-oxides heterocycle as 
part of their structures. Currently furoxans have no clinical application, however, these 
molecules have many pharmacological activities including anti-inflammatory [237], 
antituberculosis, antimalarial [238,239], antiplatelet, antithrombotic [240], and 
anticancer [241], which have drew the attention of the scientific community. 
Additionally, many of the new reported furoxans have been designed by modifying 
known drug structures, enabling the potentiation of pharmacological action and 








Figure 20. Structure of some promising furoxan hybrid-based agents. 
 
In general, these molecules release NO• in physiological medium through 
reaction with thiols [219,245,246]. The mechanistic proposal for this process is based 
on the nucleophilic attack of thiolate ions to the 4 or 3 positions of the furoxan ring, 
followed by the opening of a heterocyclic ring with formation of a nitroso intermediate. 
The latter can decompose releasing HNO, which, in turn, may react either with 
molecular oxygen, or other oxidative species yielding NO•. The formation of 
nitrosothiol is also a possible pathway to explain NO• formation (Scheme 9) [247]. 
Interestingly, despite the supposed generation of HNO in this class of molecules, the 
literature ignore that the observed pharmacological actions of these derivatives may also 
be related to HNO. A detailed analysis of the mechanism of the NO• or HNO release by 







Scheme 9. Mechanism of furoxan-based molecules in releasing NO• by reaction with 
thiol, reference [247]. 
 
Besides that, other authors indicated that the decomposition of certain furoxan-
based molecules can also occur through simultaneous nucleophilic attack in both 3 and 
4 positions [248]. This proposal indicates decomposition of these molecules to release 
NO• is tightly dependent on their structure-reactivity. Beyond the reaction with thiol, 
photoisomerization has been suggested as a way to induce NO• release [249,250]. 
2.4.5. Sydnonimines 
The sydnonimines are a class of direct NO• donors, which have in their structure 
the mesoionic heterocyclic functional group oxadiazole, as shown in Figure 21. These 
compounds have also shown many pharmacological activities such as antihypertension 
[251], anti-ischemic [252], prevention of reperfusion damage [253], and others [254], 
associated to the release of NO• under physiological conditions. Molsidomine is the 
most well studied compound of this class. It is currently used as antianginal pro-drug in 
several countries in Europe [245,255]. Sydnocarb® is another example of sydnomine 
used clinically, however it is only used in Russia as a psychostimulant [256]. In order to 
improve the action of sydnonimines pro-drugs, new sydnonimine derivatives has been 
developed, especially through the hybridization of the sydnonimine moiety with 
chemical carriers (Figure 21). Cai, Nortcliffe and collaborators [257,258] developed 
new sydnonimines linked to carbohydrates and amino acids through carbamate-linked, 






are highly interesting considering the importance of providing local and temporal dose 
of NO• to achieve greater efficacy and minimal side effects. 
 
 
Figure 21. Structures of some sydnonimine-based compounds. 
 
In general, for these sydnonimine-based compounds, the release of NO• depends 
on the pH, and their reactivities are associated to their chemical structures. Besides that, 
enzymatic reactions (e.g., esterase or glycosidases) [254,257] or reactions with thiols 
[258,259] can increase the rate of the NO• release in vivo. In physiological medium, O2 
plays a key role in the release of NO•, after an enzymatic conversion of oxadiazole 
compound to the ring-open form intermediate, this lasted is oxidized by O2, enabling the 
production of NO• [260]. As example, mechanism for the release of NO• by 
molsidomine is illustrated in Scheme 10. 
 
 








2.5. Nitroxyl (HNO) donors 
 
Despite relatively recent reports on the biochemical, pharmacological and 
physiological properties of HNO, this molecule is extremely unstable, dimerizing easily 
into N2O (8×106 M−1 s−1, pH 7.4, 22 °C). This process hinders the direct use of HNO 
and still raises debates about possible routes for the biosynthesis. Thus, the use of HNO 
donors has been essential for a better understanding of its biological role and for the 
appropriate use of this molecule. In addition, in analogy with NO• donors, different 
HNO releasing molecules have been developed and studied in order to generate new 
therapeutic agents, given the pharmacological potential of HNO. Differently from the 
NO• donor class, there are no HNO donors currently in clinical use. 
2.5.1. Angeli's salt and primary amine diazeniumdiolate-based donors 
Sodium trioxodinitrate or Angeli’s salt (AS, Na2N2O3), is an inorganic salt 
synthesized by Angelo Angeli more than 120 years ago (Scheme 11A) [68]. This 
inorganic compound is currently one of the most commonly used HNO donor, 
especially in pharmacological studies [77]. AS releases HNO through spontaneous 
decomposition from pH 4 to 8 [261]. Among the in vivo pharmacological effects 
observed for AS, one can mention: anti-inflammatory [262], vasodilator [263] and 
anticancer [65,264]. Nevertheless, under physiological conditions, AS has a short half-
life time (t1/2 = 2.3 min) requiring relatively high concentrations to achieve 
physiological responses, which has limited its therapeutic applications [217]. Thus, new 
HNO donors have been developed and biologically investigated. O2-alkylated primary 
amine-based diazeniumdiolates are a class of HNO donors structurally similar to AS, 
but with a longer half-life time under physiological conditions [265] and, in addition, 
with a possibility to undergo an enzymatic activation (esterase or β-galactosidase -








Scheme 11. Angeli’s salt (A), AcOM-IPA/NO (B), and Gal-IPA/NO (C) 
decomposition, references [261,265,266]. 
 
Primary amine-based donors generally have short HNO release rates, besides the 
ability to release NO• based on pH, making them chemically similar to AS 
[217,261,267]. However, through O2-alkylation of the diazeniumdiolate group, the rate 
of decomposition can be fine tuned, which can also be achieved by other strategies (e.g., 
enzymatic activation). Keefer and collaborators [265], developed an O2-alkylated 
primary amine-based diazeniumdiolates pro-drug called AcOM-IPA/NO. This molecule 
showed capacity to release HNO spontaneously under physiological conditions, like 
AS, but with a release rate (t1/2 = 41 min) significantly longer than AS (Scheme 11B). 
Furthermore, AcOM-IPA/NO mostly releases HNO without traces of NO•, which makes 






Regarding to O2-alkylated primary amine-based diazeniumdiolates enzyme-activated, 
Holland and co-workers [266] synthesized a hybrid of α-D-galactose and IPA/NO 
(sodium 1-(isopropylamino)diazen-1-ium-1,2-diolate), named Gal-IPA/NO, which 
releases HNO with half-life time of 140 min upon catalysis with β-galactosidase 
(Scheme 11C). This result showed, besides the slow HNO release rate, that such 
modification generates a promising tool that can allow modulation of the HNO 
releasing. 
2.5.2. Hydroxylamine-based donors 
N-Hydroxybenzenesulfonamid or Piloty’s acid (PA) (Figure 22) is a well-known 
HNO donor like AS. In spite of being an old compound, whose synthesis was reported 
in 1896, PA has not been much used in biological studies involving HNO. This is likely 
due to a decomposition process that, in basic solutions (pH 8), occurs with a relatively 
long half-life time of 561 min [268]. PA has a hydroxylamine group linked to a sulfonyl 
group, which if deprotonated can produce an anionic intermediate that decomposes 
releasing HNO (Scheme 12). In order to improve its application in a physiological 
environment, Toscano and collaborators [269] modified the structure of PA by 
introducing a bromine group at position 2 of the benzene ring, resulting in a derivative 
called 2-bromo-Piloty's acid with efficient HNO releasing action in physiological 
medium (pH 7.4 at 24 °C). Thus, several derivatives have been synthesized, including 
CXL-1020, which is in Phase I/II of clinical studies (Figure 22) [268,270,271]. Other 
structural modification approaches have also been explored. Nakagawa and co-workers 
[272], in order to develop new PA derivatives capable of releasing HNO via light 
stimulation, modified the hydroxamic group of the 2-nitro-Piloty's acid by incorporating 
a photolabile protecting group (7-diethylaminocoumarin-4-yl)methyl. They obtained a 
Piloty’s acid derivative (N-((7-(diethylamino)-2-oxo-2H-chromen-4-yl)methoxy)-2-
nitrobenzenesulfonamide) that upon light irradiation (from 400-430 nm) promoted the 
release of the precursor PA in an anionic form, which then decomposes releasing HNO. 
Other classes of molecules containing hydroxylamine group have been explored as 
potential HNO donors in physiological environments. Toscano and collaborators [273-
275] developed new compounds such as (hydroxylamino)barbituric acid (HABA) and 
(hydroxylamino)pyrazolone (HAPY), which under physiological conditions exhibit 







Figure 22. Examples of some hydroxylamine-based donors. 
 
 
Scheme 12. General mechanism of HNO release, reference [268]. 
 
2.5.3. Nitroso-based donors 
Nitroso compounds constitute a class of HNO donors through reactions with 
nucleophiles in aqueous medium [276-278]. Unlike derivatives of AS and PA, it has 
been shown that nitroso compounds, under physiological conditions, behave mainly as 
HNO donors. However, these species are extremely reactive, being in most cases 
produced in situ as intermediates via oxidative, photochemical and thermal reactions 
[279,280]. King and collaborators [276,277] synthesized a series of nitroso acyloxy 
compounds (the most known of them is 1-nitrosocyclohexyl acetate (NCA)) (Scheme 
13), which under physiological conditions releases HNO after hydrolysis. In addition to 
them, they also prepared nitroso acyl derivatives 9,10-dimethylanthracene cycloadducts, 
which upon a thermal retro-Diels-Alder decomposition (40 ºC) releases acyl nitroso 
compounds being a source of HNO [278] (Scheme 13). These latter derivatives can also 
donate HNO through photoinduced retro-Diels-Alder reaction, as demonstrated by 






pro-drugs have encouraged biological studies with promising cardiovascular properties 
[283-285]. 
 
Scheme 13. Mechanism of the decomposition of nitroso derivatives in HNO, promoted 
by nucleophilic attack (OH-) or thermal/photoinduction retro-Diels-Alder reaction, 
references [276-278]. 
 
2.5.4. Hydroxamic acid-based donors 
The first report on hydroxamic acids was dated back to 1869, when H. Lossen 
synthesized the oxalohydroxamic acid molecules [280], and until today these 
compounds continue to be studied with new synthetic approaches and possible 
applications in organic and inorganic chemistry [286-290], as well as in pharmacology 
[286,287,291,292]. These hydroxamic acid-base donors are illustrated by the following 
drugs: vorinostat (SAHA, approved by FDA in 2006 to treat the cutaneous T-cell 
lymphoma) [293], belinostat (PXD101, approved by FDA in 2014 to treat the relapsed 
or refractory peripheral T-cell lymphoma) [294], panobinostat (LBH-589, approved by 
FDA in 2015 to treat multiple myeloma) [295], and hydroxyurea used in the treatment of 







Figure 23. Hydroxamic acid donors. 
 
Hydroxamic acids are within the class of nitrosocarbonyl precursor. In fact, 
hydroxamic acids have been reported as HNO donors through oxidation of the -NH-OH 
group to an acyl nitroso intermediate, which reacts with nucleophiles to release HNO 
[279,297]. The oxidative activation of hydroxamic acids has been studied in a 
physiological context aiming to explain the possible mechanisms of pharmacological 
action of these molecules [298,299]. Goldstein and collaborators have shown that 
SAHA can be oxidized under hypoxic conditions by MbFeIII/H2O2 system in 
physiological medium, causing enhanced radiological response of tumors by multiple 
mechanisms, supposedly attributed to the production of HNO and NO• [298]. 
2.6. NO•/HNO metal-based donors  
Several metal-based compounds have been developed showing potential 
pharmacological action [17,300]. Despite that and the knowledge of the important 
biological roles played by metallo-proteins [47,54,301,302], supporting the therapeutic 
potential of metal complexes, there are still not many metallo-drugs in clinical use, 
particularly if compared to organic-based drugs [17,300]. Related to the clinical use of 
NO• donor metallo-compounds, there is only one case, sodium nitroprusside (SNP, 
Na2[Fe(CN)5NO]). First prepared in 1849 by Playfair [24], SNP, a cyanoferrate 
complex, has been used in cardiac surgery with hypertensive crisis conditions and other 






related to its administration, due to the rapid release of NO• and cyanide. This latter can 
be managed by the co-administration of sodium thiosulfate and hydroxocobalamin [24]. 
Recently, a material containing SNP anchored in silica-based nanoparticles was 
prepared, where vasorelaxation activity similar to that of isolated SNP was noticed 
along with a significant reduction in cytotoxicity, proving an alternative for the safer 
and broader use of SNP in medicine [303]. 
In addition to strategies based on nanomaterials, several NO• metal donors have 
been developed in order to provide more efficient cardiovascular activities with lower 
undesired side effect to the patient. Oxacom®, a dinitrosyl iron complex (DNIC) 
containing glutathione as a ligand (Figures 6 and 24), is undergoing clinical trials in 
Phases I/II. This compound represents an exciting example of a new hypotensive drug 
with no adverse effects reported to date [26,304].  
Polypyridine ruthenium-nitrosyl complexes (Figure 24) have been considered as 
another large class of NO• donors widely studied by several laboratories. Many of these 
compounds have also shown moderate antihypertensive activities (e.g., EC50 from 200 
to 690 nM) compared to SNP [305-307]. These activities suggest that they may have 
opportunities to be used as models for antihypertensive drugs. Metal-compounds 




Figure 24. Structures and in vitro vasodilation action of nitrosyl iron and ruthenium 






2.6.1. Photorelease of NO• by nitrosyl complexes 
Phototherapy has emerged as an alternative way to minimize the toxicity of 
many treatments thanks to the possibility of performing more efficient temporal and 
local dosing of the drug [310]. Several metal complexes have been investigated as NO• 
releasing phototherapeutic agents [305,306,308,309]. Metal complexes are versatile in 
terms of design and reactivity modulation, which have raised interest in their use as 
model photosensitizers [19,311-313]. The incidence of irradiation (UV-Vis) in a 
metallo-nitrosyl compound induces formations of an excited state, in which π* anti-
bonding orbitals of the nitrosyl ligand are electronically populate, leading to a decrease 
in the bond order between the metallic center and NO•, promoting the release of the 
ligand [305,306,309].  
The [Ru(bpy)2(SO3)NO](PF6) complex is an interesting example on the 
modulation of reactivity based on the substitution of ancillary monodentate ligand. 
Once sulfite, bound through S atom, is used as ligand, there was a significant change in 
the overall electronic density of NO• moiety if compared to that of a complex with an 
N-based ligand instead (e.g., isonicotinamide). This can dramatically alter the acid-base 
equilibrium of nitrosyl/nitrite found for these systems (Scheme 14). Depending on the 
equilibrium constant for this process we can have in physiological pH mainly nitrite or 
nitrosyl bound species, which can modulate NO• release and reactivity. NO• 
photorelease may occur more efficiently if the nitrosyl bound is the main species. 
 
[M(L)x(NO)]n (aq) + 2 OH−  [M(L)x(NO2)](n-2) (aq) + H2O (aq) 
Scheme 14. Generic acid-base nitrosyl/nitrite equilibrium for polypyridine ruthenium-
nitrosyl complexes, reference [314]. 
 
By replacing isonicotinamide (isn) ligand for sulfite ion (SO32–) in the 
[Ru(bpy)2(L)NO]n+ system, there is a remarkable increased in the pH values for the 
conversion of nitrosyl into nitrite ligand, from 1.45 to 10.32 (Figure 25) [314]. This 
major change upon binding sulfite allowed the nitrosyl species to become the main 
species under physiological conditions and might be a reason for many promising 
biological properties found for this compound. Photorelease (463 nm) of NO• from the 
[Ru(bpy)2(SO3)NO]+ complex was validated using the selective NO• trap cPTIO (2-(4-






contrast, in the presence of thiols (e.g., glutathione), the [Ru(bpy)2(SO3)NO]+ complex 
released HNO. Other polypyridine ruthenium compounds have also showed a pH of 
nitrosyl/nitrite (1:1) conversion close to or higher than the physiological pH (6.4-8.0) 
(Figure 25). Interestingly, all these metallo-nitrosyl derivatives show indeed an ancillary 
ligand bound to ruthenium through sulfur atom, indicating that such ligands can 
positively influence the acid-base nitrosyl/nitrite equilibrium. Those results showed the 
use of sulfur-based ligands as a relevant strategy in the development of new therapeutic 
platforms for NO•/HNO release [152,306,314,315]. 
 
 
Figure 25. Structures of some metallo-nitrosyl compounds and pH of nitrosyl/nitrite 
conversion (isn = isonicotinamide, tu = thiourea and tbz = thiobenzamide). 
 
Recently, two interesting new strategies involving photoactivation of metal 
complexes were published. The first one was based on the indirect route for NO• 
photorelease. Cardoso and co-workers developed a new Ru(II) nitrosylsulphito complex 
(trans-[Ru(NH3)4(isn)(N(O)SO3)]+) (Figure 26), where upon photoactivation (355-410 
nm) there is a release of ONSO3- species, which further decomposes into NO• and SO3•- 
[316]. It is interesting to note that there are only a few metallic systems with N-bonded 
nitrosylsulphite (N(O)SO3) ligand isolated and characterized, indicating this strategy 








Figure 26. Structures of nitrosyl FeII [Fe(NO)(TMSPS2)(TMSPS2H)] and ruthenium(II) 
nitrosylsulphito trans-[Ru(NH3)4(isn)(N(O)SO3)](PF6) (isn = isonicotinamide) complex. 
 
Another exciting case is based on the photorelease of HNO. Lee and 
collaborators [317] developed an nitrosyl iron complex based on the 2,2′-dimercapto-
3,3′-bis(trimethylsilyl)diphenyl)phenylphosphine (TMSPS2H2) ligand. This compound 
upon light irradiation (> 400 nm) showed formation of NO• that was reduced to HNO by 
a thiol group (-SH) already present in the structure (Figure 26). This photorelease of 
HNO features as a rare case via an iron complex nitrosyl, considering that in many cases 
NO• is found as NO+ and requires two-electrons for HNO production. 
One key issue for nitrosyl complexes as a photoreleaser species is the 
wavelength capable to promote this stimulus, which, unfortunately, in most of the cases 
requires highly energetic light. Despite that, any suitable phototherapy requires stable 
compounds with efficient activation using light from 650 to 900 nm, called therapeutic 
window, where light has maximum penetration in the skin with minimum issue on other 
biomolecules [318]. Several authors have developed strategies for the delivery of NO• to 
biological targets, mainly aiming at application within the therapeutic window, systems 
such as Roussin’s Red Salt ester, Ru(salen)(Cl)NO, Cr(cyclam)(ONO)2+, 
[Mn(PaPy2Q)(NO)]+, in addition to nano-structured materials, are part of these 
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Taking into account that NO•/HNO can exhibit a large spectrum of interesting 
therapeutic actions and metal complexes can be useful in medicinal chemistry, the 
objective of this thesis is the development of new design strategies involving the 
synthesis and physicochemical and biological studies of metal complexes able to carry 
and delivery the biological active agent, NO•/HNO. 
The first chapter aims to i) study the reactivity of the nitrosyl complex trans-
[Fe(cyclam)(NO)Cl]Cl2, ii) investigate the stability of this complex under physiological 
conditions (pH 7.4 at 37º C) in order to assess the influence of any possible spontaneous 
decomposition, as well as the identification of possible products generated, iii) ascertain 
the influence of light (365 nm) on the possible release of NO•, and iv) verify the 
biological potential of the trans-[Fe(cyclam)(NO)Cl]Cl2 as an antiangiogenic agent with 
potential anticancer property. Besides that, another important objective is to investigate 
the vasodilation profile of the nitrosyl complex. All results from this work are already 
published and presented in chapter 1 [1].  
In order to advance in the search for new NO•/HNO donor platforms for 
therapeutic purposes, we explored the ability of aromatic hydroxamic acid derivatives to 
release NO•/HNO after oxidative reaction steps. This platform could be of particular 
interest due to the possible mechanism of activation of this type of molecule, in addition 
to NO•/HNO release (metabolite active of the anti-TB drug delamanid and vasodilatator 
agent), an aroyl radical intermediate or an aromatic carboxylic acid might also be 
formed, which can be seen, respectively, as the corresponding active metabolites of 
isoniazid and pyrazinamide, two major antitubercular drugs. Thus, the second part of 
this thesis describes two chapters. The aim of the first one (chapter 2) is the 
investigation of the intermolecular oxidative activation mechanism of the isonicotino-, 
nicotino-, and pyrazino- hydroxamic acids, respective analogues of isoniazid (anti-TB), 
nicotinamide (vitamin B3), and pyrazinamide (anti-TB), by reaction with potassium 
ferricyanide (K3[FeIII(CN)6]) in pH physiological conditions. This work could assist in 
the design of new drugs. This study has also been published in a scientific peer-
reviewed journal and presented in chapter 2 [2]. Then, the third project (chapter 3) is 
relative to the synthesis of new FeII complexes formulated with isonicotino-, nicotino- 
and pyrazino- hydroxamic acid ligands bound to the [-Fe(CN)5]n- moiety, as well as the 






and structural characterization of the species formed. This synthetic approach is applied 
aiming at development of new antituberculosis and cardiovascular agents. This latest 
study was equally published in a peer-reviewed journal and is presented in chapter 3 [3]. 
 
OBJECTIF 
Compte tenu du fait que le NO•/HNO peut présenter un grand spectre d’actions 
thérapeutiques intéressantes et que les complexes métalliques peuvent être un outil 
intéressant en chimie inorganique médicinale, l’objectif de cette thèse est le 
développement de nouvelles stratégies de conception de médicaments impliquant la 
synthèse et l’étude physicochimique et biologique de complexes métalliques capables 
de porter et de délivrer l’agent actif biologique, NO•/HNO. 
Le premier chapitre vise à i) étudier la réactivité du complexe nitrosyl trans-
[Fe(cyclam)(NO)Cl]Cl2, ii) étudier la stabilité de ce complexe dans des conditions 
physiologiques (pH 7,4 à 37 ºC) afin d’évaluer l’influence de toute décomposition 
spontanée possible, ainsi que l’identification des produits possibles générés, iii) 
déterminer l’influence de la lumière (365 nm) sur la libération possible de NO• , et iv) 
vérifier le potentiel biologique du trans-[Fe(cyclam)(NO)Cl]Cl2 en tant qu'agent 
antiangiogénique avec une propriété anticancéreuse potentielle. De plus, l’investigation 
du profil vasodilatateur du complexe nitrosyle est également un des objectifs de cette 
thèse. Les résultats de ces travaux ont déjà été publiés et sont présentés au chapitre 1 
[1]. 
Afin d’avancer dans la recherche de nouveaux châssis moléculaires capables de 
relarguer NO•/HNO et d’avoir des intérêts thérapeutiques, nous explorons l’habilité des 
dérivés aromatiques azotés de l’acide hydroxamique à libérer NO•/HNO après une étape 
de réaction oxydative. Cette forme de châssis moléculaire pourrait avoir un intérêt tout 
particulier parce qu’en fonction du mécanisme d’activation de ce type de molécule, 
outre la libération de NO•/HNO (métabolite actif du délamanide -médicament anti-TB- 
et agent vasodilatateur), un intermédiaire de type radical aroyle ou un acide 
carboxylique aromatique pourrait également être formé, ce qui pourrait être considéré, 
respectivement, comme le métabolite actif de l’isoniazide ou du pyrazinamide, deux 
pro-drogues antituberculeuses majeurs. Ainsi, la deuxième partie de cette thèse est 
divisée en deux projets. Le but du premier (chapitre 2) est l’étude d’un mécanisme 
intermoléculaire de l’activation oxydative des acides hydroxamiques dérivés des acides 






TB), du nicotinamide (vitamine B3) et du pyrazinamide (antituberculeux), par le 
ferricyanure de potassium (K3[FeII(CN)6]) dans des conditions physiologiques de pH. 
Ceci afin d’aider à la conception de nouveaux médicaments. Cette étude a également été 
publiée dans une revue scientifique et est ici présentée dans le chapitre 2 [2]. Ensuite, le 
troisième projet (chapitre 3) est relatif à la synthèse de nouveaux complexes de FeII 
associant les ligands d’acide hydroxamique isonicotinique, nicotinique et pyrazinique 
au fragment [-Fe(CN)5]n-, ainsi qu’à l’étude d’un mécanisme intramoléculaire 
d’activation oxydative de ces complexes (oxydation via H2O2) suivi d’une 
caractérisation structurale des espèces formées. Cette approche de synthèse a été 
appliquée dans le but de développer de nouveaux agents antituberculaires et 
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4. PART 1 - NITROSYL IRON COMPLEX: CYCLAM AS THERAPEUTIC 
PLATFORM 
The increase number of cases of cardiovascular diseases and cancer has led the 
scientific community to seek new treatment strategies that are more efficient and less 
harmful to patients. The part 1 of this manuscript presents the chemical and biological 
studies of a known nitrosyl FeII complex, which has never been further investigated 
from a pharmacological perspective. In the context of this thesis a special emphasis on 
the release of NO•/HNO and on potential antiangiogenic and cardiovascular action was 
placed. 
4.1. Introduction 
Among the drugs used to treat cardiovascular diseases, the SNP is the only metal 
complex available [1]. As we mentioned in the introduction of this thesis, in addition to 
the release of CN-, another factor that limits the widespread use of this drug, is its 
powerful vasodilating action, due to fast release of NO• in the body [1]. In order to 
obtain more moderate NO• donor agents, with lower toxicity compared to SNP, several 
other metal complexes have been explored, for example, the DNIC 2,2’-bipyridine- 
Fe(NO)2 [2], SNP analogs (Kn[M(CN)5NO] (M = V, Cr, Mn and Co with n = 3, or M = 
Mo with n = 4)) [3], and polypyridine ruthenium derivatives such as 
[Ru(bpy)2(ImN)NO](PF6)3 (bpy = 2,2’-bipyridine, ImN = imidazol)  and 
[Ru(phen)2(tu)NO](PF6)3 (phen = phenanthroline, tu = thiourea) [4,5]. 
In addition to the development of new nitrosyl complexes with therapeutic 
potential related to the NO• release, the discussion about the ability of these complexes 
to release HNO has also emerged, since the latter shows also biological relevance. 
Sousa and collaborators [6], motivated to identify the possible production of HNO by 
[Ru(bpy)2(SO3)NO]+, have studied the reaction of this ionic complex with glutathione 
(GSH). This study have shown, through the use of a selective trap to distinguish 
NO/HNO and cellular angiogenesis assays, the potential ability of this complex to 
release HNO under physiological conditions. Thus, HNO production in a physiological 
context has also been an important part of the reactivity studies involving nitrosyl 
complexes.  
Holanda and his collaborators developed in 2007 a new nitrosyl iron(II) complex 
using 1,4,8,11-tetraazacyclotetradecane (Cyclam) as ligand, called trans-
[Fe(cyclam)(NO)Cl]Cl2 [7]. This complex has been studied from a chemical point of 




view, being indicated as a promising photoreleaser of NO•. However, such results 
lacked data showing NO• can be directly produced from the complex. Additionally, no 
results proving HNO release as well as relevant biological tests were available. Thus, 
the trans-[Fe(cyclam)(NO)Cl]Cl2 complex is an interesting system to be explored 
mainly from a biological point of view. 
In view of that, the following article presents details of the reactivity study of the 
well-known nitrosyl complex, trans-[Fe(cyclam)(NO)Cl]Cl2, with emphasis on 
examining the differential release capacity of NO• and HNO, either through 
photochemical stimulation or reaction with GSH. By using a selective probe cPTIO (2-
(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide potassium) for UV-
Vis and EPR techniques, or through other experimental (Griess reagent) and theoretical 
studies (density functional theory (DFT) and time-dependent DFT (TD-DFT)), we were 
able to confirm the NO• production from the complex via light stimulus (365 nm). On 
the other hand, the reaction of trans-[Fe(cyclam)(NO)Cl]Cl2 complex with GSH 
indicated the HNO production, as well as the formation of an intermediate adduct 
between the nitrosyl complex and GSH (trans-[Fe(cyclam)(Cl)N(O)SG]+) [6]. The 
hypothesis that this complex can release HNO in the presence of thiols has been 
reinforced by a cell angiogenesis assay based on the HIF-1α degradation. Additionally, 
the vasorelaxation capacity of the metal complex ion was assessed, in comparison to the 
SNP, and a more moderate vasodilation activity was noticed. These results, in addition 
to the evidences of its low cytotoxicity [8], made the trans-[Fe(cyclam)(NO)Cl]Cl2 
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Chapter 1 - Nitrosyl trans-[Fe(cyclam)(NO)Cl]Cl2 complex - new approach in 
anticancer and antihypertensive treatments 
4.2. Article 1: Journal of Inorganic Biochemistry, 2020, 210, 111133 - Résumé 
de l’article en français 
 
Les complexes métalliques libérant oxyde nitrique (NO•) et/ou nitroxyle (HNO), 
ont fait l'objet d’études dans une perspective thérapeutique. L'exemple le plus connu est 
le complexe de fer appelé nitroprussiate de sodium (SNP, Na2[Fe(CN)5NO]). Ce 
puissant agent capable de libérer NO• est utilisé dans les cas cliniques d'hypertension 
artérielle. Cependant, son administration prolongée peut provoquer plusieurs effets 
secondaires dus à une libération trop rapide de NO• et de l’ion cyanure. Ces limitations 
ont conduit à la recherche de nouveaux agents alternatifs à base de métaux, en espérant 
avoir une libération plus lente de NO• et des effets secondaires moindres. De nombreux 
laboratoires se sont concentrés sur la synthèse et la caractérisation de complexes 
nitrosylés libérant du NO• en réponse à des stimuli lumineux ou après une réduction 
chimique. 
Dans le cadre de cette thèse, nous avons étudié dans un premier temps la 
réactivité chimique et la stabilité du complexe de fer, trans-[Fe(cyclam)(NO)Cl]2+ 
(cyclam = 1,4,8,11- tétraazacyclotétradécane) (1) (Figure 27). L'étude de stabilité 
thermique du composé 1 dans des conditions physiologiques (pH 7,4, 37 ºC), a été 
réalisée en utilisant des techniques spectroscopiques : infrarouge, (N≡O+ at 1894 cm-1), 
et UV-Vis, ( = 235 nm (transitions de transfert de charge de type intra-ligand (TCIL) 
et métal-ligand (TCML)) et 360 nm (transition de type transfert de charge ligand-
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ligand)), et chronoampérométriques (électrode NO• sélective). Ces études ont révélé que 
le complexe nitrosyle se décompose en solution, au moyen d'un processus 
d'oxydoréduction intramoléculaire spontané dans lequel le ligand NO+ est réduit par 
oxydation du centre métallique, provoquant sa libération sous forme de NO0 et la 
production du complex trans-[Fe(cyclam)(H2O)2]3+ complex. 
 
 
Figure 27. Structure des complexes trans-[Fe(cyclam)(NO)Cl]Cl2 (1) et trans-
[Fe(cyclam)Cl2]Cl (3). 
 
La capacité de la lumière à induire la libération de NO• ou de HNO à travers le 
complexe 1 a également été évaluée. À l'instar de l'étude précédente, ces expériences 
ont également été menées dans des conditions aqueuses tamponées (pH 7,4, 37 ºC) et 
suivies à l'aide de techniques spectroscopiques (UV-Vis et résonance paramagnétique 
électronique (RPE)). L'utilisation du piège sélectif cPTIO (2-(4-carboxyphényl)-4,4,5,5-
tétraméthylimidazoline-1-oxyl-3-oxyde de potassium) a permis l'identification et la 
distinction des espèces NO•/HNO, car les réponses spectroscopiques générées sont 
différentes. L'irradiation (365 nm) du composé 1 en présence de cPTIO, a conduit à la 
production de l'espèce cPTI (Schème 15), montrant une réaction directe du cPTIO et du 
NO• [1]. La photo-libération de NO• par le complexe 1 a également été renforcée par le 
test de Griess et des études théoriques (théorie fonctionnelle de la densité (DFT) et DFT 
en fonction du temps (TD-DFT)). 
 
Schème 15. Produits de réaction du cPTIO avec NO• ou HNO. 
 




La réaction du complexe nitrosylé avec le glutathion (GSH) a été suivie par 
l’infrarouge, UV-Vis, Stopped-Flow et RPE. Les résultats ont indiqué que la présence 
de GSH provoque des changements significatifs dans le profil spectroscopique du 
complexe. Dans l'infrarouge, la bande caractéristique de l'étirement de la liaison N=O 
du  groupe NO+ (1894 cm-1) a été complètement supprimée après 5 minutes de réaction, 
indiquant que le ligand nitrosyle est directement affecté dans le processus. Cette même 
réaction a également été suivie par RPE en utilisant la sonde cPTIO, où la disparition du 
signal caractéristique de la forme cPTIO était presque complète après 15 minutes de 
réaction, indiquant que le produit cPTIO-H (Schème 15) non radicalaire était généré. Ce 
dernier, à son tour, est une preuve solide de la réaction du précurseur cPTIO avec HNO 
[1]. Ainsi, ce résultat corrobore l'hypothèse que l'un des principaux composés produits 
lors de la réduction du complexe trans-[Fe(cyclam)(NO)Cl]2+ par le GSH est HNO. 
Afin d'étudier le mécanisme d'activation réductrice du complexe nitrosyle par le GSH, 
l’utilisation des techniques « Stopped-Flow » et d'UV-Vis ont également été mises à 
profit. Il a été possible d'observer que le GSH provoque des changements significatifs 
dans le spectre électronique du complexe nitrosylé. Au cours de la réaction, une bande 
d'absorption maximale à 541 nm a été observée. Dans la littérature il a été rapporté que 
la réaction du SNP avec H2S, est responsable de la formation du complexe intermédiaire 
[Fe(CN)5N(O)SH]3- ; cette espèce étant responsable de l'apparition d'une bande 
d'absorption électronique avec un maximum à 535 nm à pH 7,4 [2]. Un comportement 
similaire a été observé pour la réaction de la cystéine avec d'autres complexes nitrosylés 
[3,4]. Ainsi, l'apparition de la bande à 541 nm dans la réaction étudiée dans le cadre de 
cette thèse, est une forte indication de la formation d'intermédiaires réactifs entre le 
complexe de fer trans-[Fe(cyclam)(NO)Cl]2+ et le GSH. Cet intermédiaire est appelé 
trans-[Fe(cyclam)(Cl)N(O)SG]+. Au fur et à mesure que la réaction progresse, la bande 
de 541 nm finit par diminuer presque totalement. Comme l’expérience suivie par RPE 
indiquait la formation de HNO, nous avons proposé que la désintégration de la bande à 
541 nm est liée à une seconde réduction par une autre molécule de GSH, conduisant à la 
production de HNO, ainsi qu'à la dégradation de l'adduit.  
Dans les cellules cancéreuses, la production de facteurs pro-angiogéniques est 
induite dans des conditions d'hypoxie (provoquée par un métabolisme accéléré 
anormal). L'adaptation à différents niveaux d'oxygène dans la cellule est médiée par une 
famille de régulateurs transcriptionnels appelés facteurs inductibles par l'hypoxie (HIF) 
[5]. Sous normoxie, l'activité transcriptionnelle de HIF est spécifiquement supprimée 




par la dégradation de sa sous-unité α dépendante de l'oxygène (HIF-α). Des conditions 
de faible teneur en oxygène induisent la stabilisation de HIF-1α, favorisant 
l'angiogenèse cellulaire [6]. Ainsi, la protéine HIF-1α a été considérée comme une cible 
prometteuse pour la thérapie anticancéreuse [5]. 
NO• et HNO joue un rôle clé dans la régulation de HIF-1α dans les cellules 
tumorales. Alors que NO• a été indiqué comme agent stabilisant pour HIF-1α dans des 
conditions normoxiques, HNO s'est avéré agir dans le sens inverse, bloquant la 
stabilisation de HIF-1α, à la fois dans des conditions induites par l'hypoxie ou par NO•, 
ce dernier dans des conditions normales d'air [7,8]. Basé sur ces informations, la 
capacité antiangiogénique du complexe trans-[Fe(cyclam)(NO)Cl]2+ a été évaluée en 
utilisant le test de stabilité HIF-1α. Cette expérience, réalisée en collaboration avec 
l’équipe du Pr. David A. Wink où « National Cancer Institute, Cancer and Inflammation 
Program, Frederick – USA », a montré une diminution significative de l'accumulation 
de HIF-1α causée par le composé étudié. Parallèlement, le complexe 1 a également 
démontré une action antiangiogénique potentielle, via le test de formation du tube 
endothélial. Le test de formation du tube endothélial des cellules HUVEC (cellules 
endothéliales humaines de veine ombilicale) a démontré qu'en présence du composé 1, 
le nombre de vaisseaux était significativement réduit par rapport au composé précurseur 
sans NO+ (composé 3, trans-[Fe(cyclam)Cl2]+, Figure 27). Cette partie du travail a 
également été réalisée avec la collaboration du Pr. David A. Wink. 
 Les propriétés vasodilatatrices du composé 1 ont également été explorées, celui 
a présenté une CI50 = 910 nM (valeur correspondant à la concentration minimale 
nécessaire du composé pour provoquer une vasodilatation à 50%), tandis que celle de 
molécule de référence SNP est de 24 nM. Cette partie du travail a été réalisée avec la 
collaboration du Pr. Nilberto R. F. do Nascimento. Cette activité modérée, attribuée à 
libération de NO• ou HNO, ajoutée à la faible cytotoxicité du complexe (mesurée à 
travers les lignées cellulaires cancéreuses B16-F10 et HUH-7) [9], fait du composé 1 
une plateforme thérapeutique prometteuse pour des molécules à propriétés 
antihypertensive avec des avantages par rapport au SNP. En effet, l’activité du 
complexe 1 peut être indicative d'une libération plus contrôlée de NO•, évitant les 
problèmes d'hypotension causés par la libération trop rapide de NO• associée au SNP. 
De plus, ce complexe n’est pas concerné par le relargage des ions cyanures toxiques. En 
résumé, ce composé prometteur mérite des études biologiques complémentaires afin de 
découvrir tout son potentiel thérapeutique, car il représente l'un des premiers composés 
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4.4. Supporting information 
4.4.1. DFT studies (Results and discussion) 
The structural and electronic properties of trans-[Fe(cyclam)(NO)Cl]2+ complex 
(1) were investigated using density functional theory (DFT) and time-dependent DFT 
(TD-DFT). Electronic transitions contributions were subsequently determined, which 
were used to guide interpretation of UV-Vis electronic absorption spectrum and 
photochemical processes. The optimized geometry of 1 obtained by DFT was compared 
with experimental data (Fig. S1 and Table S1) [1]. 
 
Fig. S1 DFT optimized structure of the complex trans-[Fe(cyclam)(Cl)(NO)]2+. 
 
 
Table S1. Bond lengths (Å) and angles (°) of the trans-[Fe(cyclam)(NO)Cl]Cl2: 
experimental and optimized. 
 Experimental Optimized Deviation (±) 
Bond lengths (Å)    
Fe–N(1) 1.682(3) 1.648 0.017 
Fe–N(2) 2.012(3) 2.057 0.023 
Fe–N(3) 2.009(3) 2.058 0.025 
Fe–N(4) 1.999(3) 2.029 0.015 
Fe–N(5) 2.006(3) 2.029 0.012 
Fe–Cl(1) 2.248(1) 2.305 0.029 
O(1)–N(1) 1.091(4) 1.135 0.022 
N(2)–C(1) 1.482(5) 1.495 0.007 
N(2)–C(10) 1.487(5) 1.495 0.004 
N(3)–C(3) 1.484(5) 1.495 0.006 
N(3)–C(4) 1.487(5) 1.495 0.004 
N(4)–C(6) 1.485(5) 1.491 0.003 
N(4)–C(5) 1.491(5) 1.492 0.001 
N(5)–C(9) 1.476(5) 1.492 0.008 




Table S1. Continuation    
 Experimental Optimized Deviation (±) 
Bond lengths (Å)    
N(5)–C(8) 1.484(5) 1.491 0.004 
C(1)–C(2) 1.516(6) 1.527 0.006 
C(2)–C(3) 1.522(6) 1.527 0.003 
C(4)–C(5) 1.493(6) 1.519 0.013 
C(6)–C(7) 1.519(6) 1.528 0.009 
C(7)–C(8) 1.510(6) 1.528 0.009 
C(9)–C(10) 1.498(5) 1.519 0.011 
Bond Angle (°)    
N(1)–Fe–Cl(1) 178.63(11) 178.44 0.10 
N(1)–Fe–N(2) 91.53(13) 92.45 0.46 
N(1)–Fe–N(5) 91.40(14) 93.42 1.01 
N(2)–Fe–Cl(1) 88.44(9) 88.62 0.09 
N(3)–Fe–Cl(1) 87.94(10) 88.60 0.33 
N(3)–Fe–N(2) 95.36(13) 95.08 0.14 
N(4)–Fe–Cl(1) 86.50(10) 85.61 0.45 
N(4)–Fe–N(2) 174.80(12) 174.19 0.31 
N(4)–Fe–N(3) 85.61(13) 85.45 0.08 
N(4)–Fe–N(5) 93.41(13) 93.38 0.02 
N(5)–Fe–N(3) 175.13(13) 174.08 0.53 
N(5)–Fe–N(2) 85.20(12) 85.50 0.15 
N(5)–Fe–Cl(1) 87.24(9) 85.52 0.86 
O(1)–N(1)–Fe 177.4(3) 179.3 0.95 
C(1)–N(2)–Fe 118.9(3) 117.6 0.65 
C(10)–N(2)–Fe 107.6(2) 107.2 0.20 
C(1)–N(2)–C(10) 112.5(3) 112.6 0.05 
C(3)–N(3)–Fe 119.0(3) 117.7 0.65 
C(4)–N(3)–Fe 107.7(2) 107.1 0.30 
N(1)–Fe–N(3) 93.43(14) 92.44 0.50 
N(1)–Fe–N(4) 93.51(13) 93.31 0.10 
C(3)–N(3)–C(4) 112.7(3) 112.7 0 
C(5)–N(4)–Fe 107.8(2) 107.8 0.0 
C(6)–N(4)–Fe 117.4(2) 117.8 0.20 
C(6)–N(4)–C(5) 112.5(3) 113.6 0.55 
C(8)–N(5)–Fe 117.2(2) 117.9 0.35 
C(9)–N(5)–Fe 107.9(2) 107.7 0.10 
C(9)–N(5)–C(8) 112.9(3) 113.5 0.30 
N(2)–C(1)–C(2) 112.0(3) 112.4 0.20 
C(1)–C(2)–C(3) 113.8(3) 114.5 0.35 
N(3)–C(3)–C(2) 112.8(3) 112.7 0.05 
N(3)–C(4)–C(5) 108.0(3) 108.6 0.30 
N(4)–C(5)–C(4) 108.0(3) 108.2 0.10 
N(4)–C(6)–C(7) 111.3(3) 112.4 0.55 
C(8)–C(7)–C(6) 115.0(3) 115.4 0.20 
N(5)–C(8)–C(7) 112.6(3) 112.6 0 
N(5)–C(9)–C(10) 107.7(3) 108.2 0.25 
N(2)–C(10)–C(9) 107.7(3) 108.8 0.55 




The computed geometrical parameters of such complex are in excellent 
agreement with crystallographic data obtained by single crystal X-ray diffraction. 
Interestingly, a Fe-N-O angle of 179.3° calculated by DFT was very close to 177.4° 
found by X-ray data. This value indicated nitrosyl ligand primarily exhibits major NO+ 
character as previously reported [2]. Additionally, a plane containing O-N-Fe-Cl is not 
perfectly perpendicular to the one containing the nitrogen atoms of the cyclam ligand. 
This distortion occurs due to interactions of the hydrogens of cyclam with axial ligands 
[1]. 
A comparison of experimental and theoretical electronic spectra of 1 is shown in 
supporting Fig. S2, where satisfactory agreement was observed. These calculations 
provided support of assigned electronic transitions based on the character of the 
molecular orbitals involved in this process (see Tables S2 and Fig. S3-S4). 
 
 
Fig. S2 Experimental (▬), theoretical (---) electronic spectra of the trans-
[Fe(cyclam)(NO)Cl]2+ complex ion in water and vertical electronic transitions 











Table S2. Selected electronic transitions of the trans-[Fe(cyclam)(NO)Cl]2+ obtained by 
TD-DFT and experimentally measured in water.  
 
LLCT = ligand-to-ligand-charge-transfer transition; ILCT = intraligand-charge-transfer 
transition; ligand-metal charge transfer (LMCT). 
 
 
Fig. S3 Molecular orbitals involved in the main electronic transitions of trans-
[Fe(cyclam)(Cl)(NO)]2+. 
 





Fig. S4 Percent contributions of selected molecular orbitals of  
trans-[Fe(cyclam)(Cl)(NO)]2+. 
 
Interestingly, the very low-intensity band at 435 nm resulted mainly from 
isoenergetic transitions originating from the highest occupied molecular orbitals 
(HOMO and HOMO-1) centered mainly on Cl– ligand to the lowest unoccupied 
molecular orbitals (LUMO and LUMO+2) associated primarily with the NO• moiety 
(π*(NO)) (see Fig. S2 and S3). Considering the participation of these relevant MO, this 
absorption band can be assigned mainly as a ligand-to-ligand charge transfer (LLCT). 
The most intense band at 237 nm is associated with the transitions (HOMO-2 → 
LUMO+3 and HOMO-4 → LUMO+3). HOMO-2 and HOMO-4 are centered on the 
cyclam ligand while LUMO+3 is centered on σ-antibonding p(cyclam)-d(Fe) MO, 
which characterizes this transition as an intraligant charge transfer (ILCT). The latter 
has further contribution of the transition from HOMO-10 also centered on cyclam to 
LUMO-2 delocalized over the entire complex ion (σ-antibonding d(Ru)-p(all ligands) 
MO), this transition presents an mixture of ILCT and LLCT.  
We did not have observed any metal-to-ligand charge transfer (MLCT) 
transitions, which are expected to nitrosyl FeII complexes. This can be explained by the 
very strong π-acceptor bonding of NO+, which may stabilize significantly the iron-based 









4.4.2. Thermal stability 
 
Fig. S5 Electronic spectra of aqueous solution of Griess reagent (50 mM) and trans-
[Fe(cyclam)Cl2]2+ (2 mM) after 24 hours in water at 37 ºC, under aerobic conditions. 
 
4.4.3. Photorelease of NO• 
 
 
Fig. S6 Probing the photorelease of NO•/HNO. Spectroscopic changes of a mixture of 
cPTIO (100 μM), complex trans-[Fe(cyclam)(NO)Cl]2+ (200 μM) in 0.1 M phosphate 
buffer pH 7.4 solution, containing DTPA (100 μM), during light irradiation at 365 nm 
for 20 min, at room temperature (ca. 25 oC) and aerobic conditions. Inset: kinetic curves 
at 560 nm (first order equation fit, kobs = 379.3 x 10-3 min-1, R2 = 0.9967). 
 
 





Fig. S7 Electronic spectra of cPTIO (▬), cPTI (▬) (resulted of cPTIO in reaction with 
NO•, from a NO• saturated solution), cPTIO-H (▬) (resulted of cPTIO in reaction with 
HNO by using Angeli’s salt (200 μM)), trans-[Fe(cyclam)(NO)Cl]2+ (▬) (200 μM) 
after 30 min of light irradiation at 365 nm and cPTIO (▬) after 30 min of light 
irradiation at 365 nm. All electronic spectra were obtained in 0.1 M phosphate buffer 
pH 7.4 solution at 37 ºC, under aerobic conditions. The concentration of cPTIO used in 
all assays was 100 μM. 





Fig. S8 EPR monitoring of the reaction of trans-[Fe(cyclam)(NO)Cl]2+ (400 µM) with 
light (365 nm) using cPTIO (200 µM) as probe, in 0.1 M phosphate buffer pH 7.4 
solution at 25 ºC. A. Reaction in the presence of light (365 nm) without complex. B. 
Reaction with complex in absence of light. C. Reaction of trans-[Fe(cyclam)Cl2]+ (400 
µM) with cPTIO (200 µM) in absence of light, 0.1 M phosphate buffer pH 7.4 solution 














Fig. S9 – Electronic spectra of aqueous solution of Griess reagent (50 mM) and trans-
[Fe(cyclam)(NO)Cl]2+ (2 mM) before irradiation (gray), with 15 min of irradiation (λirrd 
= 365 nm) (black) and 15 min without irradiation (dotted) at room temperature (ca. 25 
oC), under aerobic conditions. Inset: Solution before and after irradiation. 
 
4.4.4. Reaction with glutathione 
 
Fig. S10 Investigation of the reaction of trans-[Fe(cyclam)(NO)(Cl)]2+ (10 mM) with 
glutathione (GSH, 100 mM) in 0.1 M phosphate buffer pH 7.4 solution monitored by 
FTIR-ATR at 25 ºC, under aerobic conditions. Phosphate buffer (▬), GSH (▬), 
complex trans-[Fe(cyclam)(NO)(Cl)]2+ (▬) and mixture containing the complex and 



















Fig. S11 EPR monitoring of the reaction of GSH (4 mM), cPTIO (200 µM), containing 
DTPA (400 µM) at 25 ºC, under aerobic conditions. All spectra were recorded during 




Fig. S12 Cell viability curves (%) vs. concentration (μM) of the complex trans-
[Fe(cyclam)(NO)Cl]2+ to a cell line (A) B16-F10 (mouse melanoma, IC50 = 202.7 μM. 
R2 = 0.9994) and (B) HUH-7 (human hepatocarcinoma, IC50 = 142.9 μM. R2 = 0.9965). 
 
Abbreviations 
ATR  Attenuated total reflectance 
cPTIO 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-
oxide potassium salt 
Cyclam  1,4,8,11-tetraazacyclotetradecane 
DFT  Density functional theory 
DTPA  Diethylenetriaminepentaacetic acid 
EPR  Electron paramagnetic resonance 
GSH    Glutathione 




HNO   Nitroxyl 
HOMO  Highest occupied molecular orbital 
IC   Cell viability 
ILCT  Intraligand-charge-transfer transition 
LLCT  Ligand-to-ligand charge-transfer 
LMCT  Ligand-metal charge transfer 
LUMO  Lowest unoccupied molecular orbital 
Mb-Fe3+  met-Myoglobin 
MLCT  Metal-to-ligand charge-transfer 
MO  Molecular orbital 
NO•   Nitric oxide 
TD-DFT  Time-dependent DFT 
Reference  
1. Holanda, A. K. M.; Silva, F. O. N.; Carvalho, I. M. M.; Batista, A. A.; Ellena, J.; 
Castellano, E. E.; Moreira, Í. S.; Lopes, L. G. F., « Crystal structure, 
electrochemical and photochemical studies of the trans-[Fe(cyclam)(NO)Cl]Cl2 
complex (cyclam=1,4,8,11-tetraazacyclotetradecane) », Polyhedron, 26, 2007, 
pp. 4653-4658. 
 
2. Dziȩgielewski, J. O.; Machura, B., « The x-ray crystal structure of 
[Re(NO)(Ph)Br3(PPh3)] complex », Polyhedron, 15, 1996, pp. 3713–3716. 
 
4.5. Unpublished results associated with the article 
Besides the results presented in article 1, some other studies were performed 
aiming at HNO detection from the trans-[Fe(cyclam)(NO)Cl]2+ in thermal- and photo-
decomposition conditions by using metmyoglobin (Mb-FeIII) as a probe. The stability of 
the iron complexes (trans-[Fe(cyclam)(NO)Cl]2+ and trans-[Fe(cyclam)Cl2]+), in the 
presence of the chelating pentetic acid (DTPA), were also carried out. Finally, the 
photostability of the nitrosyl complex trans-[Fe(cyclam)(NO)Cl]Cl2, in the solid state, 









4.5.1. Experimental section 
Thermal- and photo- stability of the trans-[Fe(cyclam)(NO)Cl]2+ in the presence of 
metmyoglobin (Mb-FeIII) 
The thermal stability of the trans-[Fe(cyclam)(NO)Cl]2+ complex, in the 
presence of metmyoglobin (Mb-FeIII), was monitored by UV–Vis spectroscopy for ca. 
24 h at 37 ºC, using 134 μM of the nitrosyl complex and 6.7 μM of the Mb-FeIII 
dissolved in 0.1 M phosphate buffer pH 7.4 solution, under anaerobic conditions. The 
solutions were prepared in an argon atmosphere with the aid of an inert gas glove box. 
This study was also performed with Angeli’s salt (27 μM) and Mb-FeIII (6.7 μM) for 
comparative purposes. The experiment with Angeli’s salt was monitored for ca. 1 h at 
37 ºC. 
The study of NO/HNO photorelease was carried out using light irradiation at 
365 nm and Mb-FeIII as NO/HNO probe. The solution containing 4.6 μM of Mb-FeIII 
and 100.0 μM of the nitrosyl complex was prepared in anaerobic phosphate buffer (0.1 
M, pH 7.4), and monitored for 1.5 h at 37 ºC by absorption spectroscopy in UV-Vis 
region. This experiment was also prepared in an argon atmosphere with the aid of an 
inert gas glove box. 
 
Thermal stability in the presence of pentetic acid (DTPA) 
The stability of the nitrosyl complex in the presence of pentetic acid (DTPA), 
was studied by UV–Vis spectroscopy using a solution composed of trans-
[Fe(cyclam)(NO)Cl]2+ (2 mL at 50 μM) and of DTPA (2 mL at 75 μM), in 0.1 M 
phosphate buffer (pH 7.4). This study was also performed using a solution of trans-
[Fe(cyclam)Cl2]+ complex (2 mL at 100 μM) and DTPA (2 mL at 150 μM), under the 
same conditions. The solutions of these complexes were prepared and monitored for ca. 
4 h at 37 ºC under aerobic conditions. 
 
Photodecomposition in solid state 
The photostability of the nitrosyl complex, in solid state, was studied by FTIR 
using trans-[Fe(cyclam)(NO)Cl]Cl2 salt, dispersed in KBr pellet, and irradiation at 365 
nm. The study was monitored based upon the presence of the band at 1888 cm−1, 
assigned to the v(NO+), measured over a period of 6 h under aerobic conditions. 
 
 




4.5.2. Synthetic procedures 
Precursor trans-[Fe(cyclam)Cl2](PF6) complex 
A solution of cis-[Fe(cyclam)Cl2]Cl (0.100 g, 0.214 mmol), in methanol/water 
(50%) was heated (80 ºC) and mixed for 30 min then a change of color from yellow to 
green was observed. A saturated solution of NH4PF6 in methanol was added dropwise. 
The green solid formed was filtered, washed with ice-cold methanol, and dried by 
vacuum. 
Yield = 40% (0.040 g), green solid. IR symmetric stretching (νs), symmetric bending 
(δs) and twisting (τ) (cm-1): 3255 – 3208 (νs N-H), 2980 - 2925 (νs C-H), 1483 – 1430 
(δs CH2), 1331 – 1280 (τ CH2), 1122 – 1020 (νs C-N), 835 and 561 (νs P-F). UV-Vis 
(H2O) λmax/nm (ɛ/M-1cm-1) = 238 (7635), 300, (2019), 355 (1096). Cyclic voltammetry 
in CF3COOH/CF3COONa solution 0.1 M (pH 3.2), V = 0.1 V s-1: E1/2 = 0.291 V vs 
NHE. 
 
Nitrosyl trans-[Fe(cyclam)(NO)Cl]Cl2 complex 
To a solution of cis-[Fe(cyclam)Cl2]Cl (0.100 g, 0.214 mmol), in degassed water 
(10 mL), it was bubbled NO gas for 60 min. The solution was concentrated by vacuum 
and, then, added dropwise to a mixture of ethanol/diethyl ether (70 mL, 1:1). The 
resulting yellow precipitate was kept overnight (16 h) at -20 ºC before it was collected 
by filtration, washed with ethanol/diethyl ether (1:1) ice-cold solution, and dried in a 
vacuum desiccator. CAUTION: since the complex is moderately light sensitive, it must 
be stored in a vacuum desiccator protected from light to extend their lifetime. 
Yield = 80% (0.080 g), yellow white solid. IR symmetric stretching (νs), symmetric 
bending (δs) and twisting (τ) (cm-1): 3092 (νs N-H), 3012 – 2857 (νs C-H), 1888 (νs NO), 
1452 (δs CH2), 1380 – 1290 (τ CH2), 1100 – 1044 (νs C-N), 835 and 885 (τ N-H), 812 (τ 
CH2). UV-Vis (H2O) λmax/nm (ɛ/M-1cm-1) = 232 (14025), 438, (66). Cyclic 
voltammetry in CF3COOH/CF3COONa solution 0.1 M (pH 3.2), V = 0.1 V s-1: E1/2 = 
0.292 and 0.595 V vs NHE, Epa = 0.905 V and Epc = -0.375 V vs NHE. 
4.5.3. Results and discussion 
Thermal- and photo- stability of the trans-[Fe(cyclam)(NO)Cl]Cl2 in the presence of 
metmyoglobin (Mb-FeIII) 
Metmyoglobin (Mb-FeIII) can be used as a probe for nitric oxide (NO) and 
nitroxyl (HNO) detection. While the reaction of Mb-FeIII with HNO directly generates 




the NO-MbFeII adduct, k = 2.7 x 105 M-1 s-1 (Scheme 16) [1], that of NO and Mb-FeIII 
produces the NO-MbFeII adduct via three steps; (i) formation of NO-MbFeIII adduct 
(unstable species), k = 5.3 x 104 M-1 s-1, (ii) reaction between NO-MbFeIII and OH- 
generating nitrite (NO2-) and Mb-FeII, k = 3.2 x 102 M-1 s-1, (iii) and myoglobin (Mb-
FeII) reaction with NO finally producing NO-MbFeII, k = 1.7 x 107 M-1 s-1 (Scheme 16) 
[2,3]. Thus, the thermal- and photo-stability of the ion trans-[Fe(cyclam)(NO)Cl]2+ was 
studied in the presence of Mb-FeIII aiming at the discrimination of NO and HNO. 
 
 
Scheme 16. Production of the NO-MbFeII adduct through reacting with NO• or HNO 
[1-3]. 
 
First of all, a control experiment using Mb-FeIII and Angeli’s salt, a well 
established direct HNO donor, was performed under physiological conditions (degassed 
phosphate buffer 0.1 M, pH 7.4, at 37 ºC), to obtain the UV-Vis spectral profile of the 
NO-MbFeII adduct (Figure 28). All anaerobic experiments were prepared in an inert gas 
glove box. Before the spectrophotometer analysis, the cuvettes containing the samples 
were efficiently sealed to prevent the entry of atmospheric air. The main differences 
observed in the initial and final UV-Vis spectra of the heme-protein were the 
displacement of the Soret band, from 408 to 420 nm, and Q bands, from 506 and 634 
nm, to 548 and 580 nm, respectively. These modifications are indicative of the Mb-FeIII 
conversion to the NO-MbFeII form [1]. 
 





Figure 28. Spectral variation in the UV-Vis region for a mixture containing Mb-FeIII 
(6.7 μM) and Angeli’s salt (27 μM), in anaerobic phosphate buffer (0.1 M, pH 7.4, at 
37 ºC). Solution before (grey) and after 1 h (black) of reaction. A = Full spectra (Soret 
band) and B = Spectra zoom between 450 and 700 nm (Q bands). 
 
The study of the trans-[Fe(cyclam)(NO)Cl]2+ complex in the presence of Mb-
FeIII, under the same conditions of the control experiment (anaerobic phosphate buffer 
solution, 0.1 M, pH 7.4, at 37 ºC), was monitored by UV-Vis for 24 h (Figure 29). The 
results did not indicate significant changes in the Mb-FeIII spectrum over the time (24 
h). Since the reaction of Mb-FeIII with NO is about fivefold slower than that with HNO, 
these results suggest a potential NO release, via thermal decomposition of the nitrosyl 




Figure 29. Spectral variation in the UV-Vis region for a mixture containing Mb-FeIII 
(6.7 μM) and trans-[Fe(cyclam)(NO)Cl]2+ complex (134.0 μM), in anaerobic phosphate 
buffer (0.1 M, pH 7.4, at 37 ºC). Solution before (gray) and after 24 h (black) of 
reaction. A = Full spectra (Soret band) and B = Spectra zoom between 450 and 700 nm 
(Q bands). 






















































In photodecomposition study, a mixture containing the nitrosyl complex and 
Mb-FeIII, in anaerobic solution of phosphate buffer (0.1 M pH 7.4 at 37 °C), was 
monitored before and after 1.5 h of irradiation (365 nm), by absorption spectroscopy in 
the UV-Vis region (Figure 30). No evidences of the NO-Mb-FeII adduct was observed 
over the time (1.5 h). Since the reaction of the oxidized protein with HNO is 
substantially faster, this result suggests that HNO was not produced in this experiment. 
 
 
Figure 30. Spectral variation in the UV-Vis region for an anaerobic solution of Mb-FeIII 
(4.6 μM) and trans-[Fe(cyclam)(NO)Cl]2+ (100.0 μM), in phosphate buffer 0.1 M, pH 
7.4, at 37 ºC. Mixture before (gray) and after 1.5 h (black) of irradiation (365 nm). A = 
Full spectra (Soret band) and B = Spectra zoom between 450 and 700 nm (Q bands). 
 
trans-[Fe(cyclam)(NO)Cl]Cl2 stability in the presence of pentetic acid (DTPA) 
Aiming to inhibit potential interferences of free iron ions in solution, some 
experiments were performed in the presence of chelating agents, pentetic acid (DTPA) 
or deferoxamine. For that, control experiments to examine the potential influence of the 
use of DTPA in the assays were performed. In this context, the stabilities of the trans-
[Fe(cyclam)(NO)Cl]2+ and trans-[Fe(cyclam)Cl2]+ complexes, alone and in the presence 
of DTPA, were monitored for 4 h via electronic absorption spectroscopy, in UV-Vis 
region, in phosphate buffer solutions (0.1 M, pH 7.4 at 37 °C). In the study involving 
the trans-[Fe(cyclam)(NO)Cl]2+ and DTPA, it was observed a decrease of the band at 
235 nm (Figure 31A) assigned to intraligand-charge-transfer transition (ILCT) of the 
cyclam ligand and ligand-metal charge transfer (LMCT) from the cyclam ligand to FeII 
metal center. The mixture of the trans-[Fe(cyclam)Cl2]+ and DTPA showed a 
hyperchromic and hypsochromic effect of the band at 320 nm related to the iron 
complex (Figure 31B). Similar results were obtained in the thermal stability 



























experiments of the trans-[Fe(cyclam)(NO)Cl]2+ and trans-[Fe(cyclam)Cl2]+ (see the 
chapter 1 - Thermal stability and NO release section), indicating that, in fact, the 
spectral changes observed are related to the spontaneous thermal decomposition of the 
iron complexes in solution, and do not arise from the presence of free iron ions. Since 
the spectral records, in the presence and absence of DTPA, showed similar profiles and 
trends, we conclude that DTPA did not influence the thermal decomposition of the 
complexes nor influence the other experiments. 
 
































































Figure 31. Thermal stability of the iron complexes in the presence of DTPA. A. 
Spectroscopic changes for trans-[Fe(cyclam)(NO)Cl]2+ (50 μM) solution in the presence 
of DTPA (75 μM), inset shows the kinetic curve based on changes at 235 nm. B. 
Spectroscopic changes for trans-[Fe(cyclam)Cl2]+ (100 μM) solution in the presence of 
DTPA (150 μM), inset shows the kinetic curve at 320 nm. The spectra were monitored 
by electronic spectroscopy for ca. 4 h in 0.1 M phosphate buffer (pH 7.4) solution at 
37 ºC, under aerobic conditions. Final spectrum in black. 
 
Photostability study of the trans-[Fe(cyclam)(NO)Cl]Cl2 in solid state 
To verify the stability of the trans-[Fe(cyclam)(NO)Cl]Cl2, in solid state, when 
subjected to irradiation (365 nm), the nitrosyl complex, dispersed in KBr pellet, was 
irradiated at different times and then the respective spectra in the infrared region were 
recorded (Figure 32). It was observed that over the irradiation time, the stretch 
corresponding to the ligand NO+ (1888 cm-1) disappears, indicating that also in a solid 
state, the irradiation at 365 nm can induce the decomposition of the nitrosyl complex. 
 





Figure 32. Irradiation of the trans-[Fe(cyclam)(NO)Cl]Cl2 at 365 nm (6 h), in KBr 
pellet, monitoring by FTIR. 
 
4.6. Conclusion 
The results shown in this section provide important information about the 
reactivity of the nitrosyl complex. The thermal stability and photoirradiation studies, 
involving Mb-FeIII and trans-[Fe(cyclam)(NO)Cl]2+ complex, indicated that the HNO 
was not detected in both experiments, corroborating with the experiments reported in 
the publication. The presence of the DTPA chelator was not able to induce significant 
changes in the standard spectra of the trans-[Fe(cyclam)(NO)Cl]2+ and trans-
[Fe(cyclam)Cl2]+ complexes, indicating that the presence of DTPA did not influence the 
experimental responses obtained. In addition, it was shown that the nitrosyl complex 
trans-[Fe(cyclam)(NO)Cl]Cl2, in solid state, can be photodecomposed by irradiation at 
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5. PART 2 – PENTACYANOFERRATE COMPLEXES: HYDROXAMIC ACID 
AS THERAPEUTIC PLATFORMS 
Hydroxamic acids display several chemical and biological properties [1-4], 
many of which attributed to their ability to release NO•/HNO under oxidative 
conditions. The pharmacological effects aligned with the HNO and NO• metabolites are 
diverse, the releasing moiety may also display physiological roles, which illustrates the 
potential use of these agents in the development of new drugs [4-6]. In this part of the 
thesis, we focused on the oxidative study of these organic molecules. From a 
fundamental perspective, the chapter 2 describes the oxidative mechanism involving 
three azine hydroxamic acid derivatives, while in the chapter 3 we explore the 
antituberculosis and cardiovascular properties of new FeII hydroxamic acid complexes 
under oxidative conditions. HNO release is one of the key points of these two studies. 
5.1. Introduction 
The reaction between diethyl oxalate and hydroxylamine, producing the 
compound oxalohydroxamic acid (Scheme 17), carried out by H. Lossen in 1869, marks 
the beginning of hydroxamic acid chemistry [1,7]. From this milestone, a series of 
studies have begun involving new synthetic approaches and possible applications in 
organic and inorganic chemistry, and biochemistry as bioactive molecules [2,3]. 
 
 
Scheme 17. Oxalohydroxamic acid synthesis by Lossen [1,7]. 
 
It was mentioned earlier that hydroxamic acids are able to release NO•/HNO 
under oxidative conditions and many of their chemical and biological properties are 
attributed to this ability [2]. 
In the introduction of this thesis, we report that isoniazid (INH), pyrazinamide 
(PZA) and delamanid are all pro-drugs used in antituberculosis treatments [8]. The 
pharmacological action of these drugs is dependent on an activation step mediated by 
enzymes present in Mtb. INH is activated through an oxidative process mediated by the 
mycobacterial catalase-peroxidase enzyme, KatG, generating the isonicotinoyl radical 




intermediate that reacts with NAD(H) yielding an INH-NADH adduct, the ultimate 
active metabolite against Mtb (Scheme 18) [9]. On the other hand, the PZA activation 
occurs via a hydrolysis process mediated by the pyrazinamidase enzyme, PncA, 
yielding pyrazinoic acid as the active metabolite (Scheme 18) [8]. Delamanid is also 
proposed as a pro-drug that requires enzymatic activation. It has been suggested that its 
main active metabolite against Mtb is HNO, this latter resulting from a reductive 
decomposition of the nitroimidazole group by a mycobacterial nitroreductase enzyme 
(Ddn) (Scheme 18) [9]. 
 
Scheme 18. Enzymatic activation of INH, PZA and delamanid [8,9]. 
 
Nevertheless, the emergence of multidrug-resistant strains of Mtb has limited the 
use of drugs such as INH and PZA in TB therapy. In most cases, the resistance 
mechanism is associated with mutations in the gene that encodes for the enzymes 
responsible for activating drugs, as a result, mycobacteria can no longer oxidize the 
drugs [8]. Multidrug-resistant tuberculosis (MDR-TB) has opened up opportunities to 
develop new strategies to control TB. Delamanid is an example of a new pro-drug 
developed for use in MDR-TB cases. However, the possible strategies are not limited to 
organic compounds only. Motivated by a potential therapeutic approach using metal 
complexes, Sousa and collaborators [9], developed a strategy based on the 
pentacyanoferrate(II) complex of INH, called IQG607. In summary, IQG607, when 
oxidized to FeIII by H2O2/O2-, produces isonicotinoyl radical, a key tool in the anti-TB 




action of INH (Figure 33). During this oxidation process, isonicotinic acid and 
isonicotinamide are also formed as final metabolites. Furthermore, this complex has 
shown an efficient inhibition of the InhA enzyme in vitro, even in the absence of KatG, 
accompanied by a very low MIC (0.2 μg/mL) against Mtb [9]. This approach could be 
very important, especially in cases of acquired resistance to INH, since this process 
would overcome the enzymatic activation of INH promoted by KatG. Thus, the use of 
the pentacyanoferrate(II) moiety as an alternative to enable drug activation has 
stimulated its use with other molecules of biological interest such as hydroxamic acids. 
 
 
Figure 33. Proposal of the redox metal-mediated activation of IQG607 in Mtb, 
extracted from the reference [9]. 
 
In light of what was discussed, the development of new therapeutic platforms 
capable of releasing HNO, through chemical activation mediated by metal-complexes, 
is a promising strategy. This part of the thesis presents the development and biological 
study of three new pentacyanoferrate (II) complexes containing pyrazino-, isonicotino-, 
and nicotino- hydroxamic acids as the sixth ligand. 
Prior to the synthesis of FeII complexes, we have judged necessary to study the 
ability of ligands alone to release NO•/HNO in oxidative conditions to better appreciate 
the interest to complex the hydroxamic acids (NO•/HNO donors) to a inorganic moiety 
[-Fe(CN)5]. Thus, the first article presents a study of three hydroxamic acid derivatives 
with oxidizing agents such as hexacyanoferrate(III) complex and H2O2. In this study, 




when hexacyanoferrate(III) complex was used as oxidizing agent, it was possible to 
identify HNO as one of the final products of these reactions and N,O-
di(di)azinoylhydroxylamine as intermediate. In the presence of H2O2 alone, hydroxamic 
acids are not oxidized. The aim of this article is to highlight the ability of hydroxamic 
acids to act as HNO donors, and to provide more clarity as to its mechanism. 
The second article aims at the synthesis of pentacyanoferrate(II)-type complexes 
with the pyrazino- and isonicotino-hydroxamic acids as ligands, which are 
pyrazinamide’s and isoniazid’s analogs, respectively. The study of their oxidation 
mechanism and their potential to release HNO and another active metabolite (pyrazinoic 
acid or isonicotinoyl radical) was conducted. Finally, the antimycobacterial activity 
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Mechanistic insights into the in vitro metal-promoted oxidation of (di)azine 
hydroxamic acids: evidence of HNO release and N,O-di(di)azinoyl 
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Chapter 2 - Mechanistic study of oxidative activation of aryl hydroxamic acids 
5.2. Article 2: New Journal of Chemistry, 2020, 44, 11965-11973 - Résumé de 
l’article en français: 
 
Le nitroxyle (HNO) est un acide inorganique faible (pKa = 11,4) et instable [1] 
qui présente plusieurs activités biologiques importantes qui sont pourtant encore très 
mal comprises. L'une des principales propriétés pharmacologiques de HNO est son 
action bénéfique sur le système cardiovasculaire [2]. HNO présente aussi une activité 
antiangiogénique, en opposition à son cousin NO• qui lui favorise l'angiogenèse. Cette 
dernière propriété citée de HNO ouvre des opportunités intéressantes pour la thérapie 
contre le cancer [3]. Étant donné que HNO ne peut pas être directement utilisé in vivo 
en raison de sa forte instabilité en milieu aqueux (dimérisation et déshydratation 
donnant du protoxyde d'azote, N2O, schème 19) [4] et une forte réactivité vis-à-vis des 
biomolécules nucléophiles (principalement avec des composés soufrés) [5], toutes les 
études concernant les propriétés biologiques de HNO ou son emploi comme agent 
thérapeutique nécessitent des composés donneurs de HNO. 
 
Schème 19. Réactions de HNO en milieu aqueux ou biologique. 
 
Le HNO a été décrit comme l'un des principaux produits de l'oxydation de 
l'acide hydroxamique médiée par divers agents oxydants (NaIO4, metaloenzymas, 
Na3[FeII(CN)5NH3]/oxydante, K3[FeIII(CN)6], ˙OH, ˙N3, etc.). Toutefois, le mécanisme 




exact de cette réaction d’oxydation dans des conditions physiologiques de pH ainsi que 
la caractérisation directe ou indirecte des éventuels intermédiaires générés, restent 
encore à être élucidés et font ainsi objet d'étude. Compte tenu du fort potentiel des 
acides hydroxamiques à générer de HNO, l'élucidation de leur mécanisme d'oxydation 
dans des conditions physiologiques de pH est cruciale pour assister à la conception de 
nouvelles molécules donneuses de HNO plus performantes. Dans le premier chapitre de 
cette deuxième partie (chapitre 2), nous avons examiné l'oxydation intermoléculaire 
directe des dérivés: acide hydroxamique isonicotinique (1), nicotinique (2) et 
pyrazinique (3), médiée par le ferricyanure de potassium (K3[FeIII(CN)6]) à pH = 7.4, 
ainsi qu’élucidé les structures des intermédiaires et des produits finaux formés (Schème 
20). 
 
Schème 20. Réaction d'activation oxydative de l'acide hydroxamique isonicotinique (1), 
nicotinique (2) et pyrazinique (3), par l'ion [FeIII(CN)6]3- à pH = 7.4. 
 
L'oxydation des acides hydroxamiques 1-3 (1 éq.) par [Fe(CN)6]3- (2,5 éq.) 
réalisée dans une solution tampon phosphate (D2O, pH = 7,4) a été initialement suivie 
par RMN 1H. Cette étude a révélé qu’après 1 h de réaction, il existe une conversion 
partielle du produit de départ (50%, 56% et 38% pour 1, 2 et 3, respectivement). 
L’analyse spectrale de RMN 1H montre, en plus des signaux relatifs au produit de 
départ restante, l’apparition d’un nouveau composé, possédant des signaux aromatiques 
dupliqués. Ce nouveau composé, au fil du temps, a tendance à disparaître en faveur de 
la formation d’un composé final présentant des signaux à 7,61–8,70 et 7,91 ppm pour 1, 
8,42 et 8,68 ppm pour 2 et 8,70–9,04 et 9,15 ppm pour 3, qui ont pu être reconnus 
comme étant caractéristiques des acides carboxyliques correspondants sous forme 
déprotonée (carboxylate). Cette proposition a été confirmée par comparaison avec les 
données de RMN 1H obtenues à partir d’échantillons authentiques de sels d’acides 
carboxyliques. Ces résultats confirment ainsi que l'acide carboxylique est le produit 
final de l'oxydation - métabolite potentiel - de l'acide hydroxamique. Après 312 h de 




réaction, les spectres RMN 1H indiquent essentiellement des pics correspondant à la 
structure du carboxylate. Sur la base de ces résultats, nous postulons que l'oxydation des 
acides hydroxamiques dans de telles conditions se produit d'abord en produisant un 
radical nitroxyde instable (oxydation monoélectronique de l'acide hydroxamique), qui 
est converti, après dimérisation, en HNO et une N,O-di(di)azinoylhydroxylamine, ce qui 
explique la duplication de signaux aromatiques observés en RMN 1H (Schème 21). 
L'intermédiaire diacylhydroxylamine pourrait en effet être hydrolysé pour produire les 
acides carboxyliques correspondants et l'acide hydroxamique de départ qui subirait de 
nouveau une étape d’oxydation. 
 
Schème 21. Hypothèses mécanistiques pour la libération de HNO via oxydation des 
acides hydroxamiques. 
 
La possibilité d'une oxydation supplémentaire du radical nitroxyde (oxydation à 
2 électrons) conduisant à la formation d'un intermédiaire nitrosocarbonylé devrait être 
aussi considérée puisque ce dernier pourrait réagir facilement avec H2O se décomposant 
en acide carboxylique correspondant et HNO (Schème 21) [6].  Cependant, les spectres 
RMN 1H montrent qu'après 1 h de réaction la conversion de l’acide hydroxamique de 
départ conduit uniquement or très majoritairement à l'intermédiaire N,O-
di(di)azinoylhydroxylamine correspondant ; le produit acide carboxylique 
correspondant, qui pourrait être formé à partir d’un éventuel intermédiaire 
nitrosocarbonylé avec de l’eau, n'étant pas détecté en début de réaction. Ensemble, ces 
résultats suggèrent que l’intermédiaire nitrosocarbonylé n'est pas impliqué dans la 
formation de HNO et d'acide carboxylique. 
Pour tenter de caractériser l'intermédiaire proposé, les réactions d'oxydation des 
acides hydroxamiques 1-3 ont été répétées sur une échelle préparative (acide 
hydroxamique (0,72 mmol) et K3[FeIII(CN)6] (2,5 éq.)) et arrêtées après 24 h. Le 
nouveau produit a été isolé puis caractérisé par des techniques de RMN (1H et 13C) et 




SM (basse et haute résolution (HR)). Pour le dérivé 1, l'analyse RMN 1H a montré un 
produit présentant quatre doublets à 8,91 (d, 1H), 8,81 (d, 1H), 7,99 (d, 1H) et 7,79 (d, 
1H) ppm. Par RMN 13C, on constate la présence de deux signaux à 167,7 et 166,0 ppm 
compatible avec le carbone quaternaire de deux groupes carbonylés différents, quatre 
signaux à 149,7, 147,8, 123,4 et 122,7 ppm dus à des CH aromatiques et deux pics à 
146,0 et 137,5 ppm désignés comme étant les Cq des noyaux aromatiques. L’ensemble 
des données corrèle très bien avec la structure N,O-diisonicotinoylhydroxylamine 
(Schéme 21, composé 4) proposée pour l’intermédiaire. L'analyse SM (DCI-CH4) n'a 
pas permis l'identification du pic ion moléculaire de cet intermédiaire (composé 4). Par 
contre, la détection des pics à m/z = 199, attribués à l'amide 13 [M+] (Schéme 21), m/z = 
124, attribué à l'acide 7a [M+ + 1] (Schème 22), et principalement à m/z = 123 qui a été 
attribué à l'amide 10 [M+ + 1] (Schème 22) sont des forts indices d’être des fragments de 
l’intermédiaire di(di)azinoylhydroxylamine proposé. En effet, l’amide m/z = 123 
pourrait être issu d’une étape de decarboxylation (perte de CO2) de 4. Par SMHR (mode 
positif ESI), un petit pic à m/z = 244,0726 a pu finalement être détecté et la masse 
exacte correspond bien à celle de la formule brute de 4 plus une unité [M+ + 1]. 
 
 
Schème 22. Voies de fragmentation par SM des intermédiaires proposés, N,O-di(di) 
azinoylhydroxylamines, issus de l'oxydation des acides (di)azine hydroxamiques. 
 




La RMN 1H de la même réaction d’oxydation mais utilisant le composé 2 
comme substrat a montré 8 signaux attribuables aux hydrogènes aromatiques (9,18, 
9,00, 8,86, 8,68, 8,39, 8,18, 7,62, 7,49 ppm) du composé 5 (Schème 22). Par contre, le 
spectre de masse (DCI-CH4) du produit issu de la réaction d’oxydation de 2 a montré, 
des pics à m/z = 215 (composé 14 [M + CH4+•]) et à m/z = 200 (composé 14, [M + H+]), 
caractéristique d’une fragmentation de 5 (Schème 22). De plus, l’analyse de masse de 
haute résolution (mode positif ESI) a permis de détecter d'un pic à m/z = 244,0726 
correspondant au ion moléculaire [M + H+] du composé 5. 
Contrairement aux études présentées pour les molécules 1 et 2, le spectre RMN 
1H de l'oxydation de 3 était plus spéculatif en raison de chevauchements de signaux, ne 
contribuant pas de façon significative à supporter la structure supposée pour 
l’intermédiaire 6. Par contre, dans le cas de l'oxydation de 3 (K3[FeIII(CN)6] + H2O2) [7] 
étudiée par SM haute résolution (mode positif ESI), il a été possible de détecter un pic 
de l'ion moléculaire à m/z = 246,0619 ([M + H+]) cohérent avec la structure proposée 
pour le composé 6 (schéma 21). L’ensemble de ces caractérisations supporte N,O-
di(di)azinoylhydroxylamine comme étant l’intermédiaire formé lors de l’étape 
d’oxydation des acides hydroxamiques in milieu aqueux et à pH physiologique. 
Outre les résultats de mise en évidence de l'intermédiaire N,O-
di(di)azinoylhydroxylamine, nous avons aussi démontré qu’en présence de méthylamine 
cet intermédiaire est capable d’agir comme un agent acylant conduisant la formation de 
dérivés de type N-méthylamide. 
Enfin, les résultats des études spectroscopiques (UV-Vis et EPR), en utilisant le 
piège cPTIO, du suivi de la réaction d’oxydation des acides hydroxamiques par l’ion 
FeIII, supportent fortement la proposition de formation de HNO. En effet, les réactions 
des acides hydroxamiques avec l’ion [FeIII(CN)6]3−, en présence de cPTIO, ont conduit à 
une diminution du quintuplet caractéristique du cPTIO présent dans le spectre de RPE et 
à une diminution de sa bande à 541 nm (UV-Vis). Les modifications observées lors de 
ces expériences, peuvent être corrélées à une réaction du cPTIO avec HNO [8]. Toutes 
ces approches expérimentales corroborent à une nouvelle perspective sur le mécanisme 
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5.4. Support information 
5.4.1. Experimental section 
General Protocol for the 1H NMR following of the K3[Fe
III(CN)6] mediated oxidation of 
(di)azine hydroxamic acids 1, 2 and 3 
The isonicotinohydroxamic acid (1 eq.) was added in phosphate buffer solution 
(0.1 M, pH 7.4) (3 mL). After solubilization of the substrate, K3[Fe(CN)6] (2.5 eq.) was 
added to the hydroxamic acid solution. The mixture was stirred at room temperature and 
analyzed by 1H NMR spectroscopy for 322 h. 
 
General protocol for the synthesis of N,O-diaroylhydroxylamines 4, 5 and 6 
The hydroxamic acid (1 eq.) was added in phosphate buffer (0.1 M, pH 7.4) (3 
mL). After solubilization of the substrate, K3[Fe(CN)6] (2.5 eq.) was added to 
hydroxamic acid solution. The mixture was stirred at room temperature for 24 h. The 
mixture was extracted with EtOAc. The organic phase was concentrated under reduced 
pressure, and the solid residue was dried under vacuum before characterization. 
 
N,O-diisonicotinoylhydroxylamine (4) 
From isonicotinohydroxamic acid (0.100 g, 0.734 mmol) and K3[Fe(CN)6] (0.604 g, 
1.835 mmol). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.91(d, J = 4.4 Hz, 2H), 8.81 
(d, J = 4.4 Hz, 2H), 7.98 (d, J = 4.4 Hz, 2H) and 7.79 (d, J = 4.4 Hz, 2H) (400 MHz, 
D2O) δ (ppm): 8.80 (tt, J = 4.6, 1.6 Hz, 4H), 8.22 (dt, J = 5.2, 1.6 Hz, 2H), 8.13 (dt, J = 
4.6, 1.6 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ (ppm): 167.7 (C=O), 166.0 (C=O), 
149.7 (CH x 2), 147.8 (CH x 2), 146.0 (C), 137.5 (C), 123.4 (CH x 2), 122.7 (CH x 2). 
IR Symmetric stretching (νs), Antisymmetric stretching (νas), Symmetric bending (s) 
and Twisting () (cm-1): 3465-3297 (νs N-H), (νs C-H), 1719 (νs C=O/ bonding to O), 
1592 (νs C=O/ bonding to N) 1560 - 1499 (νs C=N, nsC=C), 1420 (s N-H), 1269 (s C-
H), 1059 - 1015 (νas C=N), 854 ( C-H). HRMS (ESI): m/z calcd. for C12H9N3O3: 
244.0722 found: 244.0726. 
 
N,O-dinicotinoylhydroxylamine (5) 
From nicotinohydroxamic acid (0.100 g, 0.734 mmol) and K3[Fe(CN)6] (0.604 g, 1.84 
mmol). 1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.17 (dd, J = 2.2, 0.9 Hz, 1H), 9.00 
(dd, J = 2.3, 0.9 Hz, 1H), 8.86 (dd, J = 4.8, 1.7 Hz, 1H), 8.68 (dd, J = 4.8, 1.7 Hz, 1H), 
8.39 (dt, J = 8.0, 2.0 Hz, 1H), 8.18 (dt, J = 7.9, 2.0 Hz, 1H), 7.62 (ddd, J = 8.0, 4.9, 0.9 








From pyrazinohydroxamic acid (0.100 g, 0.719 mmol) and K3[Fe(CN)6] (0.592 g, 1.797 
mmol). MS (DCI/CH4): m/z = 230 [M9 + C2H5+], 217 [M9 + CH3+], 202 [M9 + H+] and 
m/z = 124 [M14 + H+].  
 
General protocol for the synthesis of N-methylisonicotinamide, N-methylnicotinamide, 
and N-methylpyrazinamide 16, 17 and 18 
The hydroxamic acid (1 eq.) and NH2CH3 40% in water (10 eq.) was added to a 
phosphate buffer solution (0.1 M, pH 7.4) (3 mL). After solubilization of the substrate, 
K3[Fe(CN)6] (2.5 eq.) was added to hydroxamic acid solution. The mixture was stirred 
at room temperature for 2 h. The solvent was removed by evaporation under reduced 
pressure. The crude material was purified by silica gel flash column chromatography 
using a mixture of MeOH/DCM (0-100 / 10-90) as eluent. 
 
N-methylisonicotinamide (16) 
From isonicotinohydroxamic acid (0.10 g, 0.734 mmol), NH2CH3 40% in water (0.228 
g, 7.35 mmol) and K3[Fe(CN)6] (0.604 g, 1.84 mmol). Yield = 79% (0.078 g), white 
solid. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.78 – 8.65 (m, J = 4.44, 3H (In this 
case, the N-H part, there is in the same zone of the C-H of the ring), 7.73 (d, J = 4.44, 
2H), 2.80 (d, J = 4.6 Hz, 3H). 13C NMR (101 MHz, D2O) δ (ppm): 164.99 (C=O), 
150.22 (CH x 2), 141.36 (C), 121.10 (CH x 2), 26.25 (CH3). IR Symmetric stretching 
(νs), antisymmetric stretching (νas), symmetric bending (δs) and twisting () (cm-1): 
3348-3304 (νs N-H), 3000-2852 (νs C-H), 1644 (νs C=O), 1543 - 1494 (νs C=N, νs C=C), 
1407 (δs N-H), 1311 (s C-H), 1065 (νas C=N), 838 ( C-H). UV-Vis (H2O) λmax/nm 
(ε/M-1cm-1) = 266 (2706), 232 (4032), 221 (4535), 213 (5750). HRMS (DCI/CH4): m/z 
calcd. for [(C7H8N2O) + H+] 137.0715, found: 137.0712. Elemental Anal. calcd. for 
C7H8N2O·0.15H2O: C, 60.55; H, 6.03; N, 20.17. Found: C, 60.95; H, 6.13; N, 19.73. 









From nicotinohydroxamic acid (0.10 g, 0.734 mmol), NH2CH3 40% in water (0.228 g, 
7.35 mmol) and K3[Fe(CN)6] (0.604 g, 1.84 mmol). Yield = 68 % (0.067 g), white 
solid. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.98 (d, J = 2.3 Hz, 1H), 8.69 (dd, J = 
4.9, 1.6 Hz, 1H), 8.62 (s, 1H), 8.16 (dt, J = 8.0, 2.0 Hz, 1H), 7.49 (dd, J = 8.0, 4.8 Hz, 
1H), 2.80 (d, J = 4.6 Hz, 3H). 13C NMR (101 MHz, D2O) δ (ppm): 165.18 (C=O), 
151.73 (CH), 148.25 (CH), 134.80 (CH), 129.96 (C), 123.47 (CH), 26.20 (CH3). IR 
Symmetric stretching (ns), antisymmetric stretching (nas), symmetric bending (s) and 
twisting () (cm-1): 3331 (ns N-H), 3091 - 2854 (ns C-H), 1644 (ns C=O), 1549 - 1484 
(ns C=N, ns C=C), 1412 (s N-H), 1315 (s C-H), 1029 (nas C=N), 829 ( C-H). UV-Vis 
(H2O) max/nm (/M-1cm-1) = 263 (3286), 212 (6723). HRMS (DCI/CH4): m/z calcd. for 
[(C7H8N2O) + H+]: 137.0670, found: 137.0706. Elemental Anal. calcd. for 
C7H8N2O·0.2H2O: C, 60.16; H, 6.06; N, 20.04. Found: C, 60.07; H, 5.87; N, 19.67. 
TLC Retention Factor (MeOH/DCM 10%) = 0.47. M.p = 108 ºC. 
 
N-methylpyrazinamide (18) 
From pyrazinohydroxamic acid (0.10 g, 0.729 mmol) NH2CH3 40% in water (0.226 g, 
7.29 mmol) and K3[Fe(CN)6] (0.600 g, 1.82 mmol). Yield = 69% (0.068 g), white solid. 
1H NMR (400 MHz, DMSO-d6)  (ppm): 9.17 (d, J = 1.4 Hz, 1H), 8.89 (s, 1H), 8.85 (d, 
J = 2.5 Hz, 1H), 8.71 (dd, J = 2.4, 1.6 Hz, 1H), 2.83 (d, J = 4.8 Hz, 3H). 13C NMR (101 
MHz, D2O)  (ppm): 163.29 (C=O), 147.37 (CH), 144.87 (C), 143.35 (CH), 143.32 
(CH), 25.98 (CH3). IR Symmetric stretching (ns), antisymmetric stretching (nas), 
symmetric bending (s) and twisting () (cm-1): 3358 (ns N-H), 2929 (ns C-H), 1669 (ns 
C=O), 1583 - 1542 (ns C=N, ns C=C), 1404 (s N-H), 1294 (s C-H), 1054 - 1024 (nas 
C=N), 868 ( C-H). UV-Vis (H2O) λmax/nm (ε/M-1cm-1) = 310 (657), 270 (7045), 209 
(8544). HRMS (DCI/CH4): m/z calcd. for [(C6H7N3O) + H+]: 138.0667, found: 
137.0662. TLC Retention Factor (MeOH/DCM 10%) = 0.58. M.p = 110 ºC. 
 
General protocol for the synthesis of sodium isonicotinoate, nicotinoate and 
pyrazinoate molecules 
To a mixture of the suitable carboxylic acid (1 eq.) in water (8 mL) was added a 
solution of NaOH (0.85 eq.) in water (2 mL). The solution was stirred at room 
temperature for 30 min. The solvent was removed by evaporation under reduced 
pressure at 50 ºC. The solid obtained was characterized. 




Sodium Isonicotinoate (7b) 
From isonicotinic acid (0.12 g, 0.975 mmol) and NaOH (0.033 g, 0.817 mmol). Yield = 
99.0% (0.140 g), white solid. 1H NMR (400 MHz, D2O) δ (ppm): 8.64 (d, J = 2H), 7.78 
(d, J = 2H). 13C NMR (101 MHz, D2O) δ (ppm): 173.28 (C=O), 148.42 (CH x 2), 
147.47 (C), 124.19 (CH x 2), 49.50 (reference: CH3OD). IR Symmetric stretching (νs), 
Antisymmetric stretching (νas), Symmetric bending (δs) and Twisting (τ) (cm-1): 1576 
(νs C=O), 1528 - 1408 (νs C=N, C=C), 1300 (δs C-H), 1012 (νas C=N), 760 (τ C-H). 
UV-Vis (H2O) λmax/nm (ε/M-1cm-1) = 268 (2343), 211 (6575). Elemental Anal. calcd. 
for NaC6H4O2·0.1H2O: C, 49.06; H, 2.88; N, 9.54. Found: C, 49.10; H, 2.52; N, 9.45. 
Retention Factor (MeOH/DCM 50%) = 0.6. 
 
Sodium Nicotinoate (8b) 
From nicotinic acid (0.12 g, 0.975 mmol) and NaOH (0.033 g, 0.817 mmol). Yield = 
99.5 % (0.14 g), white solid. 1H NMR (300 MHz, D2O) δ (ppm): 8.95 (dd, J = 2.2, 0.9, 
1H), 8.62 (dd, J = 5.1, 1.7, 1H), 8.34 (ddd, J = 8.0, 2.2, 1.7, 1H), 7.59 (ddd, J = 8.0, 5.1, 
0.9, 1H). 13C NMR (101 MHz, D2O) δ (ppm): 172.98 (C=O), 149.74 (CH), 148.51 
(CH), 139.65 (CH), 133.54 (C), 125.04 (CH), 49.50 (reference: CH3OD). IR Symmetric 
stretching (ns), Antisymmetric stretching (nas), Symmetric bending (s) and Twisting () 
(cm-1): 1610 (νs C=O), 1562 - 1403 (ns C=N, ns C=C), 1322 (s C-H), 1029 (nas C=N), 
752 ( C-H). UV-Vis (H2O) λmax/nm (ε/M-1cm-1) = 272 (2137), 265 (2819), 260 (2549), 
212 (7350). Elemental Anal. calcd. for NaC6H4O2·0.4H2O: C, 47.32; H, 3.18; N, 9.20. 
Found: C, 47.35; H, 2.96; N, 9.48. TLC Retention Factor (MeOH/DCM 50%) = 0.6. 
 
Sodium pyrazinoate (9b) 
From pyrazine-2-carboxylic acid (0.12 g, 0.970 mmol) and NaOH (0.033 g, 0.817 
mmol). Yield = 87.5 % (0.124 g), white solid. 1H NMR (400 MHz, D2O) δ (ppm): 9.09 
(d, J = 1.1 Hz, 1H), 8.70 (m, 2H). 13C NMR (101 MHz, D2O) δ (ppm): 170.87 (C=O), 
148.54 (C), 146.46 (CH), 145.13 (CH), 144.79 (CH), 49.50 (reference: CH3OD). IR 
Symmetric stretching (ns), Antisymmetric stretching (nas), Symmetric bending (s) and 
Twisting () (cm-1) (cm-1): 1620 (ns C=O), 1572 - 1428 (ns C=N, ns C=C), 1384 (s C-
H), 1012 (nas C=N), 844 ( C-H). UV-Vis (H2O) λmax/nm (ε/M-1cm-1) = 313 (639.4), 
271 (7074), 204 (7345). Elemental Anal. calcd. for NaC6H4O2: C, 41.11; H, 2.07; N, 
19.18. Found: C, 41.33; H, 1.65; N, 19.06. TLC Retention Factor (MeOH/DCM 50%) 
= 0.5.  




































Figure S2. Mass spectra of a) isonicotionohydroxamic acid, b) nicotinohydroxamic acid 




































Figure S4a. EPR spectra of the controls: a) cPTIO (200 µM), b) cPTIO (200 µM) and 
[Fe(CN)6]3- (15 mM), c) cPTIO (200 µM) and [Fe(CN)6]4- (15mM), d) cPTIO (200 µM) 
and isonicotinohydroxamic acid (5 mM), e) cPTIO (200 µM) and nicotinohydroxamic 
acid (5 mM), and f) cPTIO (200 µM) and pyrazinohydroxamic acid (5 mM) 5.5 hours in 
phosphate buffer 40 mM, pH 7.4 at room temperature. 




Figure S4b: EPR signal intensity of the reaction of isonicotinohydroxamic acid, 
nicotinohydroxamic acid and pyrazinohydroxamic acid (5 mM) with [Fe(CN)6]3- 
(15 mM) in the presence of cPTIO (200 µM) at 0 and 5.5 h in phosphate buffer 40 mM 
(pH 7.4) and at room temperature. 
 
 
Figure S5. UV-Vis absorption monitoring at 0-24 h of the evolution of a mixture of 









5.5. Unpublished results associated with the article 
The oxidative reaction of the hydroxamic acids synthesized in this work was 
also studied in the presence of PBN (N-tert-butyl-α-phenylnitrone) spin trap, aiming at 
the detection of the aroyl radical as a potential intermediate. Furthermore, the Diels-
Alder reaction was also investigated as a strategy to demonstrate the possible formation 
of a nitroso intermediate during oxidation of the isonicotino-hydroxamic acid ligand.  
An attempt to synthesize a new pentacyanoferrate(II) complex based on the 
hybridization of isoniazid (INH) and pyrazinamide was also made. The results obtained 
from these experiments are presented and discussed briefly below. 
5.5.1. Experimental section 
Attempts to detect the aroyl radical 
The experiments were monitored by EPR technique. All samples used were 
prepared in 40 mM phosphate buffer pH 7.4, at 0 °C, by mixing appropriate amounts of 
studied compound and PBN dissolved in phosphate buffer solution. The reactions were 
initiated by the addition of the oxidant (H2O2 or [Mn(H2P2O7)3]3-). The first spectrum 
was recorded ca. 2 min after initiating the reaction. In the control experiments were used 
solutions containing INH (1 mL at 5 mM) or IQG-607 (1 mL at 5 mM), the oxidizing 
agent (1 mL at 2.5 mM of [Mn(H2P2O7)3]3- for the INH oxidation, and 1 mL at 5 mM or 
15 mM of the H2O2 for the IQG-607 oxidation), and PBN (1 mL at 20 mM). 
 
Attempt to trap the acyl nitroso intermediate via Diels-Alder reaction 
The oxidative activation reaction of the isonicotino-hydroxamic acid ligand, in 
the presence of cyclohexa-1,3-diene, was performed using a THF:H2O (2:1, 6 mL) 
solution containing the isonicotino-hydroxamic acid ligand (0.05 g, 36.2 mmol) and 
cyclohexa-1,3-diene (48.9 μL, 54.3 mmol, 97%). K3[Fe(CN)6]·3H2O (0.333 g, 90.5 
mmol) was added in the previous solution and the mixture was stirred for 96 h at room 
temperature [3]. The organic phase was extracted with ethyl acetate (3 x 6 mL), 
combined, dried over MgSO4 (anhydrous) and concentrated under vacuum. The crude 









5.5.2. Synthetic procedures 
Oxidant agent [Mn(H2P2O7)3]
3- 
The [Mn(H2P2O7)3]3- was prepared following the literature procedure with some 
adaptations [4]. Pyrophosphoric acid (1.75 mL, 5 M) was added dropwise in a 
pyrophosphate sodium solution (25 mL, 200 mM). The pH was measured at 4.4. Then, 
MnIII(OAc)3∙2H2O (0.027 g, 0.1 mmol) was added in the latter solution. The mixture 
was stirred overnight (16 h). After the time reaction, the concentration of the product 
[Mn(H2P2O7)3]3- was determined based on literature data:  6200 M-1cm-1 at 260 nm or 
104 M-1cm-1 at 480 nm, the valor obtained for this synthesis was 3.7 mM. The final 
product is stable for several months at 4 ºC. 
 
Ligand N’-(pyridine-4-carbonyl) pyrazine-2-carbohydrazide 
A suspension of pyrazinoic acid (0.104 g, 0.838 mmol) in thionyl chloride (1.2 
mL, 16.6 mmol) was refluxed at 75 ºC for 2.5 h. The color of solution changed from 
white to strong violet color. The excess of the thionyl chloride was then removed under 
vacuum. The crude was resuspended in dichloromethane (2 mL) and cooled to 0 ºC. 
INH (0.114 g, 0.838 mmol) and triethylamine (0.28 mL, 1.68 mmol) was added in the 
pyrazinoic acid solution. The reaction was stirred overnight (16 h) at r.t, and the residue 
was concentrated under vacuum (Scheme 23). The crude was purified by flash 
chromatography (eluent: dichloromethane/methanol: 100/0 to 94/6). The white solid 
was washed several times (4x) with dichloromethane. 
 
Scheme 23. Synthesis of N’-(pyridine-4-carbonyl) pyrazine-2-carbohydrazide. 
 
Yield = 39% (0.080 g), white solid. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 10.98 (s, 
1H), 10.93 (s, 1H), 9.22 (d, J = 1.4 Hz, 1H), 8.95 (d, J = 2.5 Hz, 1H), 8.81 (m, 3H), 7.83 
(d, J = 4.0 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ (ppm): 164.45 (C), 162.76 (C), 
150.95 (CH x 2), 148.59 (CH), 144.52 (C), 144.23 (CH), 144.14 (CH), 139.85 (C), 
121.79 (CH x 2). IR Symmetric stretching (νs), Antisymmetric stretching (νas), 




Symmetric bending (δs) and Twisting (τ) (cm-1): 3304-3244 (νs N-H), 1708-1660 (νs 
C=O), 1546-1468 (νs C=N, νs C=C), 1402 (δs N-H), 1282 (δs C-H), 1024-994 (νas C=N), 
850 (τ C-H). UV-Vis (H2O) λmax/nm (ɛ/M-1cm-1) = 214 (15930), 274, (12480), 324 
(914), 379 (188). MS (DCI/NH3): m/z calcd. for C11H9N5O2: 243.2, found: 244.0 (M + 
H)+. Elemental Anal. calcd. For C11H9N5O2: C, 54.32; H, 3.73; N, 28.79. Found: C, 
53.92; H, 3.34; N, 28.44. TLC Retention Factor (MeOH/DCM 10%) = 0.41. M.p. = 
215 °C. 
 
Complex Na6[Fe2(CN)10(N’-(pyridine-4-carbonyl) pyrazine-2-carbohydrazide)] 
To a solution of Na3[FeII(CN)5(NH3)]·3H2O (0.100 g, 0.31 mmol, 2 equiv.) in 
degassed water (2 mL), it was slowly added a solution of the ligand N’-(pyridine-4-
carbonyl) pyrazine-2-carbohydrazide (0.038 g, 0.155 mmol, 1 equiv.) in degassed water 
(1 mL). The mixture was stirred at room temperature, under argon atmosphere and 
protected from light for 3 h. Then 100 mL of a cold solution of ethanol containing an 
excess of sodium iodide (30 equiv.) was added dropwise. The resulting suspension was 
kept overnight (16 h) at -20 °C before the precipitate was filtered, washed with cold 
ethanol, and dried in a vacuum desiccator.  
5.5.3. Results and discussion 
Attempts to detect aroyl radical 
In order to check whether an aroyl radical is formed as intermediate during the 
hydroxamic acids oxidation, reactions using [Mn(H2P2O7)3]3- or H2O2 as oxidizing 
agents and PBN (N-tert-butyl-α-phenylnitrone), a well-known trap for carbon-centered 
radicals [1,2], in phosphate buffer (40 mM, pH 7.4) were performed. 
The INH and IQG-607 were used as positive controls. Oxidation of INH by 
[Mn(H2P2O7)3]3- in the presence of PBN led to the formation of an EPR signal mainly 
consisting of a six-line spectrum with hyperfine splitting constants of aN = 15.5 - 15.8 G 
and aH = 3.2 - 3.6 G for a g-value of 2.006 attributed to the trapping, by PBN, of the 
isonicotinoyl radical (Figure 34A). Oxidation of IQG-607 by H2O2 resulted in a six-line 
spectrum with hyperfine splitting constants of aN = 15.5 - 15.6 G and aH = 4.5 - 4.6 G 
for a g-value of 2.006, ascribed to the acyl radical of the IQG-607 trapped by PBN, 
(Figure 34B), as described by Sousa and his collaborators [1,2]. 





Figure 34. EPR signals for PBN-spin trap experiments controls. A. Mixture of INH 
(5 mM), [Mn(H2P2O7)3]3- (2.5 mM), and PBN (20 mM) in phosphate buffer (40 mM, 
pH 7.4). B. Mixture of IQG-607 (5 mM), H2O2 (5 mM) and PBN (20 mM) in phosphate 
buffer (40 mM, pH 7.4). 
 
After the control experiments, the next step was then to study the chemical 
activation of isonicotino-, nicotino-, and pyrazino-hydroxamic acids free ligands and 
complexed with FeII(CN)5 moiety in the presence of [Mn(H2P2O7)3]3- and PBN, in 
phosphate buffer (40 mM, pH 7.4). The resulting EPR spectra did not show any 
detectable signal (Figure 35A). In order to study the influence of the coordination to the 
pentacyanoferrate(II) moiety in the process of the oxidative activation, the same 
experiment was performed using the isonicotino-, nicotino-, and pyrazino-hydroxamic 
acids FeII complexes (Figure 35B), no signal was detectable, as well. 
 
Figure 35. EPR signals for PBN-spin trap experiments. A. Mixture of ligand (5 mM), 
[Mn(H2P2O7)3]3- (2.5 mM) and PBN (20 mM) in phosphate buffer (40 mM, pH 7.4). B. 
Mixture of complex (5 mM), [Mn(H2P2O7)3]3- (2.5 mM) and PBN (20 mM) in 
phosphate buffer (40 mM, pH 7.4). The vertical scale was kept identical for all spectra. 




Then, similarly to the previous tests, the chemical activation of the isonicotino- 
and pyrazino-hydroxamic acid complexes was mediated by H2O2 and monitored by 
EPR in the presence of PBN, in phosphate buffer (40 mM, pH 7.4). Under these 
conditions, using two different proportions of complex:H2O2 (1:1 and 1:3), no signal 
was observed for the both complexes (Figure 36). In view of these results, experiments 
with the nicotino-hydroxamic acid pentacyanoferrate complex were not carried out. 
Altogether these results indicate that the aroyl radical is not an intermediate of the 
oxidation mechanism of the hydroxamic acid derivatives studied, corroborating the 
mechanistic proposition of this chapter. 
 
 
Figure 36. EPR signals for PBN-spin trap experiments. A. Mixture of isonicotino 
hydroxamic acid complex (5 mM), H2O2 (5 (black) or 15 (green) mM) and PBN 
(20 mM) in phosphate buffer (40 mM, pH 7.4). B. Mixture of pyrazino hydroxamic acid 
complex (5 mM), H2O2 (5 (black) or 15 (green) mM) and PBN (20 mM) in phosphate 
buffer (40 mM, pH 7.4). The vertical scale was kept identical for all spectra. 
 
Attempts to trap the potential acyl nitroso intermediate by Diels-Alder reaction 
As mentioned in article 2 (section 5.3), nitroso compound is one of the main 
intermediates proposed for hydroxamic acids oxidation. The Diels-Alder reactions, in 
organic solvent media, have been used as an approach for the detection of nitroso 
intermediate [3]. In this work, we tried to use this strategy in THF aqueous conditions 
(THF:H2O (2:1)). For this, the oxidation of the hydroxamic acid by [Fe(CN)6]3- 
(oxidizing agent) was performed in the presence of cyclohexa-1,3-diene, aiming at 
production of the (2-oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl)(pyridin-4-yl)methanone, 
which could be an evidence for the nitroso intermediate formation (Scheme 24). 
 
 





Scheme 24. Detection of the isonicotino nitroso intermediate by Diels-Alder reaction. 
 
Nevertheless, the product of the reaction between the potential intermediate acyl 
nitroso and cyclohexa-1,3-diene was not observed. The 1H NMR analysis of the crude, 
obtained at the end of the reaction, showed a higher percentage of the starting ligand 
and a small fraction of several other peaks non identifiable. 
 
Complex Na6[Fe2(CN)10(N’-(pyridine-4-carbonyl) pyrazine-2-carbohydrazide)] 
Bearing in mind the idea of synthesizing new hybrid-type antituberculosis pro-
drugs capable of exhibiting both isoniazid- (through isonicotinoyl radical potential 
formation) and pyrazinamide-like actions (through pyrazinoic acid potential formation), 
the synthesis of the binuclear complex Na6[FeII2(CN)10(N'-(pyridine-4-carbonyl) 
pyrazine-2-carbohydrazide)] was investigated. 
First, the ligand was prepared from a mixture of pyrazinoic acid and thionyl 
chloride (20 equiv.) at reflux (75 ºC), followed by, after solvent evaporation, addition of 
isoniazid and triethylamine in dichloromethane. More details are presented in the 
experimental part. The attempt to obtain the corresponding pentacyanoferrate complex 
was produced by reacting the ligand N’-(pyridine-4-carbonyl) pyrazine-2-
carbohydrazide with the precursor Na3[FeII(CN)5(NH3)], following procedures already 
described for similar compounds [2]. Nevertheless, the desired compound was not 
obtained. By the 1H-NMR technique, we observed that the product obtained 
corresponds to a mixture of pyridine-4-carboxylate and pyrazine-2-carboxylate 
compounds coordinated to Fe(CN)5 moiety ([FeII(CN)5(pyridine-4-carboxylate)]4- in 
D2O, δ (ppm): 9.03 (d, J = 5.9, 2H), 7.46 (d, J = 5.9, 2H), and [FeII(CN)5(pyrazine-2-
carboxylate)]4- in D2O, δ (ppm): 9.54 (s, 1H), 9.16 (d, J = 3.3 Hz, 1H), 8.28 (dd, J = 2.9, 
1.5 Hz, 1H)), suggesting that the binuclear compound is very unstable and is rapidly 
oxidized and cleavage. 





The oxidative activation of the hydroxamic acid compounds in the presence of 
PBN, did not show evidences for the aroyl radical formation, corroborating the 
activation mechanism proposed in this chapter i.e. passing through the N,O-
di(di)azinoylhydroxylamine intermediate. The reaction of isonicotino-hydroxamic acid 
ligand, [Fe(CN)6]3- and cyclohexa-1,3-diene in THF aqueous conditions did not lead to 
the Diels Alder adduct. Two explanations are possible: i) the nitroso compound is 
probably not the intermediate of oxidative reaction of hydroxamic acids or ii) the Diels 
Alder reaction does not work well under these THF-aqueous conditions. Finally, the 
experimental results linked to synthesis of Na6[Fe2(CN)10(N'-(pyridine-4-carbonyl) 
pyrazine-2-carbohydrazide)] showed that the desired product was not obtained. On the 
other hand, a mixture of the pentacyanoferrate(II) complexes, coordinated with the 
pyridine-4-carboxylate and pyrazine-2-carboxylate ligands were produced. The 
formation of such products may be related to the instability of the binuclear complex 





1.  Laborde, J.; Deraeve, C.; Vieira, F. G. M.; Sournia-Saquet, A.; Rechignat, L.; 
Villela, A. D.; Abbadi, B. L.; Macchi, F. S.; Pissinate, K.; Bizarro, C. V.; 
Machado, P.; Basso, L. A.; Pratviel, G.; Lopes, L. G. F.; Sousa, E. H. S.; 
Bernardes-Genisson, V., « Synthesis and mechanistic investigation of iron(II) 
complexes of isoniazid and derivatives as a redox-mediated activation strategy 
for anti-tuberculosis therapy », Journal of Inorganic Biochemistry, 179, 2018, 
pp. 71-81. 
 
2.  Sousa, E. H. S.; Vieira, F. G. M.; Butler, J. S.; Basso, L. A.; Santiago, D. S.; 
Diógenes, I. C. N.; Lopes, L. G. F.; Sadler, P. J., « [Fe(CN)5(isoniazid)]3-: an 
iron isoniazid complex with redox behavior implicated in tuberculosis therapy », 
Journal of Inorganic Biochemistry, 140, 2014, pp. 236-244. 
 
3.  Frazier, C. P.; Bugarin, A.; Engelking, J. R.; Alaniz, J. R., « Copper-Catalyzed 
Aerobic Oxidation of N-Substituted Hydroxylamines: Efficient and Practical 
Access to Nitroso Compounds », Organic Letters, 14, 14, 2012, pp. 3620-3623. 
 
4.  Nguyen, M.; Claparols, C.; Bernadou, J.; Meunier, B., « A Fast and Efficient 
Metal-Mediated Oxidation of Isoniazid and Identification of Isoniazid-NAD(H) 
Adducts », ChemBioChem, 2, 12, 2001, pp. 877-883. 
 





Chapter 3 - New pro-drugs study of FeII hydroxamic acids complexes based: a new 
approach in antihypertensive and antituberculosis treatments 
5.7. Article 3: Journal of Biological Inorganic Chemistry, 2020, 25, 887-901 - 
Résumé de l’article en français 
 
La tuberculose (TB), maladie due à l'infection par Mycobacterium tuberculosis 
(Mtb), reste aujourd'hui un problème majeur de santé publique mondial causant plus 
d'un million de décès par an [1]. Bien que la guérison de la tuberculose puisse être 
obtenue par un régime thérapeutique impliquant les médicaments de première ligne 
(isoniazide (INH), la rifampicine, l'éthambutol et le pyrazinamide (PYZ)) (Figure 37), 
ce traitement de première intention devient inefficace face à des souches de Mtb 
résistantes à des multiples médicaments. Le PYZ est un promédicament qui est activé 
par la pyrazinamidase (PncA), une enzyme du Mtb [2]. Cette activation passe par la 
conversion du PYZ en l’acide carboxylique correspondant (acide pyrazinoïque), ce 
dernier reconnu comme étant l'agent toxique pour Mtb. Cependant, l'émergence de cas 
de souches résistantes à ce médicament a également limité son utilisation [3]. 
  
Figure 37. Structure des promédicaments antituberculeux rifampicine, isoniazide 
(INH), pyrazinamide (PZY), éthambutol et délamanide. 
Pentacyanoferrate(II) complex of pyridine-4- and pyrazine-2-hydroxamic acid 
as source of HNO: investigation of anti-tubercular and vasodilation activities 
Edinilton Muniz Carvalho, Tercio de Freitas Paulo, Alix Sournia Saquet, Bruno 
Lopes Abbadi, Fernanda Souza Macchi, Cristiano Valim Bizarro, Rafael de Morais 
Campos, Talles Luann Abrantes Ferreira, Nilberto Robson Falcão do Nascimento, 
Luiz Gonzaga França Lopes, Remi Chauvin, Eduardo Henrique Silva Sousa, Vania 
Bernardes-Génisson. 
Journal of Biological Inorganic Chemistry, 2020, 25, 887-901. 




Afin de surmonter les problèmes de résistances bactériennes dans le traitement 
de la TB, quelques nouveaux médicaments ont été développés. L'un de ces nouveaux 
médicaments est le délamanide (Figure 37), utilisé en troisième intention et approuvé 
pour le traitement de la tuberculose résistante [4]. Fort intéressant, il y a peu de cas de 
résistance rapportés pour ce médicament et son action est dirigée contre des souches de 
Mtb dormantes et réplicantes [5]. Le délamanide est en fait un promédicament 
nécessitant d’une étape d'activation enzymatique pour générer son métabolite actif, le 
HNO (nitroxyle). Une possible action émanant de NO• (oxyde nitrique) ne peut à ce jour 
être complètement exclue [3]. 
Outre la tuberculose, les maladies cardiovasculaires représentent également un 
défi dans le domaine de la santé et la situation d'urgence appelle au développement de 
nouveaux agents thérapeutiques, y compris ceux capables de libérer NO• et HNO. Dans 
la lignée des médicaments donneurs de NO•, nous pouvons mettre en évidence le 
nitroprussiate de sodium (SNP) comme le seul donneur de NO•, à base de métal 
approuvé cliniquement pour les procédures cardiovasculaires d'urgence à l’hôpital [6]. 
En revanche, il n'existe actuellement aucun agent donneur de HNO cliniquement 
disponible. 
Les acides hydroxamiques ont été classiquement signalés comme des espèces 
libérant des NO•/HNO après une réaction d'oxydation [7]. Dans cette même ligne 
d'activation oxydative, il a été décrit récemment dans la littérature, comme déjà cité 
précédemment, un système biomimétique, alternatif capable d’activer le promédicament 
antituberculeux INH tout en se franchissant de l’activation enzymatique par KatG à 
l’intérieur du Mtb. Ce système est basé sur la réactivité redox d'un complexe de FeII de 
l’INH ([FeII(CN)5(INH)]3-) qui en présence d'agents oxydants tels que H2O2 [8,9], 
génère le radical isonicotinoyle, espèce réactive de l’INH. L’activité antituberculeuse 
(in vitro MICMtb ~ 3,5 μM) [10], la stabilité chimique et l’absence de toxicité (indice de 
sélectivité SI> 4000, DL50> 2000 mg/kg) [11] du complexe [FeII(CN)5(INH)]3-, nous a 
motivé à étendre cette approche d'activation aux acides (di)azine hydroxamiques qui 
vont en fait servir de plateforme pour le développement de nouveaux complexes de fer 
capables de libérer HNO. 
Cet article présente la synthèse et la caractérisation de deux complexes de 
pentacyanoferrate(II) avec l'acide hydroxamique pyrazinique (3) (analogue du PYZ) et 
l'acide hydroxamique isonicotinique (6) (analogue de l’INH) (Figure 38). Ces 
complexes ont été capables, par l’action d'un agent oxydant (H2O2), de générer du HNO 




et l’acide carboxylique correspondant : l'acide pyrazinique et isonicotinique, 
respectivement. Les oxydations du complexe 3 et 6 par H2O2 ont été suivies par RPE (à 
l'aide du piège sélectif cPTIO), UV-Vis et RMN 1H, ceci dans le but d'étudier le 
mécanisme de la réaction d’oxydation. 
 
Figure 38. Complexes de type pentacyanoferrate(II) synthétisés. 
 
Dans un premier temps, les ligands 2 et 5 ont été synthétisés à partir du 
pyrazine-2-carboxylate de méthyle et de l'isonicotinate de méthyle, respectivement, 
avec un excès d'hydroxylamine dans du méthanol. Après obtention des ligands, les 
complexes 3 et 6 ont été préparés en faisant réagir les acides hydroxamiques 
correspondants avec le complexe précurseur Na3[FeII(CN)5(NH3)] en milieu aqueux. 
Puis, les complexes ont été caractérisés par des techniques spectroscopiques telles que 
RMN (1H, 13C et 15N), infrarouge (IR), Raman et UV-Vis, analyse élémentaire et 
électrochimique (voltamétrie cyclique). 
Les spectres RMN 1H des composés 3 et 6 montrent que les protons aromatiques 
des positions vicinales au fragment N-Fe(CN)53- (pour 3 : H3 s, 9,46 et H5 d, 9,18 ppm, 
pour 6 : H3 et H5 d, 9,05 ppm) sont déplacés vers un champ faible par rapport au ligand 
libre 2 (H3 s, 9,11 et H5 d, 8,80 ppm) et 5 (H3 e H5 d, 8,70 ppm) respectivement 
(Figure 38). En revanche, les protons aromatiques distaux H6 de 3 et H6 et H2 de 6, 
sont déplacés vers un champ haut (pour 3 : 8,27 ppm ; pour  6 : 7,39 ppm) par rapport 
aux protons correspondants des ligands libre 2 (8,68 ppm) et 5 (7,67 ppm). Ce 
comportement a également été observé pour les noyaux 13CH aromatiques 
correspondants lors de l’analyse par RMN 13C. De plus, les résultats de la corrélation 
HMQC 1H-15N de 3 ont montré sans ambigüité que la coordination de 2 se produit 
sélectivement en position N4 du cycle pyrazine. Les signaux 15N1 et 15N4 de 2 à 319,30 
et 323,36 ppm sont respectivement décalés vers un champ haut à 308,56 et 301,11 ppm, 
respectivement dans le cas du complexe. Le déplacement le plus prononcé subi par N4 
suggère fortement que la coordination de l’entité Fe(CN)5 se produit à ce niveau. Les 




spectres d’infrarouges (IR) et Raman de 3 et 6, à l'état solide, ont montré des bandes 
dans la région de 2050–2100 cm-1 caractéristiques des fréquences ν (C≡N) des systèmes 
Fe-C≡N [12]. Les comparaisons des spectres expérimentaux et théoriques (DFT) d’IR et 
Raman ont montré que les structures de 3 et 6 sont en accord avec celles représentées 
dans la Figure 38, c’est-à-dire avec l’espèce tétraanionique du complexe. Par ailleurs, 
les données de l'analyse élémentaire soutiennent aussi les formes tétraanioniques pour 
les composés 3 et 6. Considérant que la valeur de pKa de 3 et 6 est voisine de 8,5 
(déterminée par une méthode titrimétrique utilisant 0,025 M HCl), la forme 
tétraanonique des complexes est tout à fait cohérente, puisque la préparation de ces 
espèces a été faite en milieu basique (pH >> 9). 
Les données de voltamétrie cyclique obtenues pour 2, 3, 5, et 6 dans le tampon 
phosphate (0,1 M, pH 7,4) permettent de montrer que les ligands libres subissent deux 
processus d'oxydation (pour le composé 2 : 0,68 et 1,12 V vs NHE, pour le composé 5 : 
0,767 et 1,207 V vs NHE), tandis que les complexes, sont sujets à un processus 
réversible d'oxydation et de réduction, attribué à la paire redox FeII/III, et à un processus 
d'oxydation, relatif à l’oxydation du ligand coordonné (pour le complexe 3 : i) paire 
redox FeII/III = intervalle 0,50-0,90 V vs NHE, ii) oxydation de la partie organique du 
ligand coordonné = 1,091 V vs NHE ; pour le complexe 6 : i) paire redox FeII/III = 
intervalle 0,40-0,70 V vs NHE, ii) oxydation de la partie organique du ligand coordonné 
= 1,099 V vs NHE). Il convient de noter que l'oxydation de la partie organique des 
ligands coordonnés peut être initiée par un processus intramoléculaire impliquant le 
centre FeIII, bien qu'une réaction intermoléculaire ne puisse être strictement exclue. 
Enfin, les spectres électroniques des complexes 3 et 6 en solution aqueuse (pH = 
6,8), ont montré trois bandes principales avec des absorptions maximales à 216, 270 et 
486 nm, pour le composé 3 et à 233, 266 et 439 nm pour le composé 6. En général, les 
deux premières bandes sont attribuées à des transitions de type transfert de charge 
ligand-ligand (TCLL), tandis que la dernière est indiquée comme étant une transition de 
type transfert de charge métal-ligand (TCML). Les calculs TD-DFT ont validé le 
caractère de ces transitions. 
Après l'obtention du composé 3, celui-ci a été soumis à plusieurs expériences 
afin d'évaluer et de valider une éventuelle activation chimique médiée par H2O2. Les 
métabolites actifs potentiellement formés au cours de cette oxydation ont également été 
étudiés. L’ensemble de l’étude a également été réalisée avec le composé 6 à des fins de 
comparaison. 




La réaction d'oxydation du composé 3 suivie par spectroscopie de l’UV-Vis 
pendant 2 h, après l'ajout de H2O2, a montré que la bande avec un maximum 
d’absorption à 489 nm et caractéristique de la transition TCML entre le centre 
métallique FeII et le ligand 2 diminue progressivement. En effet, une fois que le centre 
métallique est oxydé en FeIII, il n'y a plus d'électrons disponibles pour que cette 
transition TCML se produise, ce qui entraîne la disparition de cette bande. Cette 
expérience a indiqué que dans l'intervalle de temps étudié (2 h) l'agent H2O2 a agi 
efficacement dans l'oxydation du centre métallique de fer. 
La réaction d’oxydation par H2O2 (2,5 équivalents) a également été suivie par 
spectroscopie de RMN 1H. L’analyse spectral du milieu réactionnel après 52 h de 
réaction a révèle que 3 est presque totalement converti en acide pyrazinoique libre et 
que une toute petite fraction de l'acide pyrazinoique coordonné à Fe(CN)5 en reste. 
La réaction entre le complexe 3 (5 mM) et H2O2 (200 mM) a également été 
étudiée en présence de cPTIO par RPE. Au cours de la réaction, il a été observé que les 
signaux caractéristiques du cPTIO (quintuplet) diminuent, indiquant ainsi qu’une 
réaction potentielle entre cPTIO et le HNO généré in situ a eu lieu [13]. Puisque l’acide 
hydroxamique non complexé au fer est inerte à H2O2 (pas de libération de HNO) nous 
suggérons que l’oxydation des complexes par H2O2, conduisant à la libération de HNO, 
passe par un transfert intramoléculaire d'électrons du ligand acide hydroxamique vers le 
FeIII, ce dernier issu de l’oxydation du FeII par l’H2O2. D’autre part, vu qu’aucun radical 
aroyle n’a pu être détecté par RPE au cours de la réaction, nous proposons en 
conséquence un mécanisme réactionnel passant par l’intermédiaire nitrosocarbonylé, via 
lequel la formation des métabolites finaux, HNO et l’acide pyrazinoique, pourrait être 
expliquée. Le complexe 6 a montré le même profil d'activation chimique médiée par 
H2O2, et a conduit aux mêmes types de métabolites finaux : HNO et l'acide 
isonicotinoique. 
L'étude de l'activité inhibitrice de 3 et 6 ainsi que des ligands libres 
correspondants vis-à-vis de la croissance des souches H37Rv de Mtb, réalisée en 
collaboration avec Pr. Cristiano V. Bizarro et Pr. Luiz A. Basso où « Pontifícia 
Universidade Católica Do Rio Grande Do Sul (PUCRS), Porto Alegre, Brasil », a révélé 
qu'aucun des composés n'est actif (MIC > 10 μg/mL). Cependant, bien que ces 
complexes ne présentent pas d'activité anti-Mtb contre les souches non résistantes et en 
croissance active, l'activité putative de 3 et 6 contre les souches de Mtb intracellulaires 




(à l’intérieur des macrophages) ou encore contre Mtb dans un état de dormance, mérite 
d’être examinée. 
La capacité de libération de NO•/HNO du composé 3 a également été évaluée 
par des tests de vasodilatation en collaboration avec l’équipe du Pr. Nilberto R. F. do 
Nascimento. Les ligands 2 et 5, ainsi que le SNP et le complexe 6 ont également été 
testés à des fins de comparaison. Alors que les ligands libres 2 et 5 présentaient une 
valeur d’CE50 (concentration efficace médiane) significativement plus élevée pour 
l'activité de vasodilatation (19 μM) en comparaison à SNP (CE50 = 13 nM), le complexe 
3 avait une valeur CE50 de 250 nM, étant ainsi 19 fois moins puissant que SNP. Le 
complexe 6 présente une CE50 inférieure (64 nM) à celle du composé 3 et est seulement 
cinq fois moins puissant que le SNP. De plus, les complexes 3 et 6 ont tous les deux 
montré une efficacité (effet de relaxation maximum) tout à fait comparable à celle du 
SNP. 
En conclusion, les résultats obtenus dans ce chapitre indiquent le rôle clé de la 
partie métallique des complexes 3 et 6 dans la vasodilatation exercée par ces systèmes. 
Bien que les complexes 3 et 6 soient moins puissants que le SNP, cela peut être un 
avantage, car le SNP, libérant du NO• trop rapidement, peut provoquer d'importantes 
chutes de tension artérielle, nécessitant un contrôle minutieux par titrage. Sans parler 
encore du danger de la libération des ions cyanures par le SNP, que dans le cas des 
nouveaux complexes de type pentacyanoferrate(II) est assez réduit. Ces résultats 
montrent que ces complexes sont extrêmement prometteurs du point de vue 
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5.9. Supporting information 
5.9.1. Synthetic procedures 
Sodium pyrazine-2-carboxylate (8) 
To a suspension of pyrazinoic acid (0.12 g, 0.970 mmol) in water (8 mL) was added a 
solution of NaOH (0.033 g, 0.817 mmol) in water (2 mL). The final solution was stirred 
at room temperature for 30 min. The solvent was removed under vaccum at 50 °C. The 
solid was collected and recrystallized (solubilized in water (1mL) then addition of 
ethanol (50 mL)). The mixture was stirred for 30 min then the solid was collected and 
washed with ice-cold ethanol. 
Yield = 87.5% (0.124 g), white solid. 1H NMR (400 MHz, D2O) δ (ppm): 9.02 (s, 1H), 
8.63-8.61 (s, 2H). 13C NMR (101 MHz, D2O) δ (ppm): 170.37 (C=O), 148.04 (Cq), 
145.96 (CH), 144.63 (CH), 144.29 (CH). IR symmetric stretching (ns), antisymmetric 
stretching (nas), symmetric bending (δs) and twisting (τ) (cm-1): 1612 - 1572 (ns C=O), 
1420 - 1380 (ns C=N, ns C=C), 1308 (δs C-H), 1156 - 1020 (nas C=N), 852 (τ C-H). UV-




To a solution of Na3[FeII(CN)5(NH3)]·3H2O (0.100 g, 0.307 mmol, 1 eq.) in water (3 
mL) was slowly added a solution of the ligand sodium pyrazine-2-carboxylate (0.054 g, 
0.368 mmol) in water (2 mL). The mixture was stirred at room temperature, under argon 
atmosphere and protected from light for 3 h. Then a cold solution of ethanol (150 mL) 
containing an excess of sodium iodide (30 eq.) was added dropwise. The resulting 
precipitate was stand overnight at -20 ºC before to be collected by filtration, washed 
with cold ethanol and dried in a vacuum desiccator. CAUTION: since these complexes 
are light- and oxygen-sensitive, they must be stored in a vacuum desiccator in the dark. 
Yield = 64% (0.064 g), red solid. 1H NMR (400 MHz, D2O) δ (ppm): 9.54 (s, 1H), 9.16 
(d, J = 3.3 Hz, 1H), 8.28 (dd, J = 2.9, 1.5 Hz, 1H). 13C NMR (101 MHz, D2O) δ (ppm): 
178.81 (CNeq), 173.95 (CNax), 171.02 (C=O), 154.05 (CH), 153.17 (CH), 147,09 (Cq), 
142.44 (CH). IR symmetric stretching (ns), antisymmetric stretching (nas), symmetric 
bending (δs), antisymmetric bending (δas) and wagging (π) (cm-1): 3532 - 3268 (ns C-H), 
2052 (ns C≡N), 1638 (ns C=O), 1578 - 1470 (ns C=C, ns C=N), 1410 - 1169 (δs C-H), 
1032 (τ C-H). 864 (δas C-H), 792 and 743 (π C-H), 653 (ns C=N). UV-Vis (H2O) 




max/nm (ɛ/M-1cm-1) = 203 (22700), 268 (6228), 478 nm (3638). Electrochemistry in 
0,1M Phosphate buffer pH 7.4: E1/2 0.581 V/NHE. 
5.9.2. Tables and Figures 
 
Table S1. Selected experimental and calculated wavenumber values obtained from IR 









Key transition Character 
3 
 496 0.0955 HOMO-1 →LUMO MLCT 
360 385 0.0113 HOMO-1 →LUMO+1 MLCT 
270 273 0.0147 HOMO-6→LUMO IL+LLCT 
216 218 0.0504 HOMO-17→LUMO IL+LLCT 
6 
439 493 0.1334 HOMO-1→LUMO MLCT 
266 284 0.0243 HOMO-3→LUMO MLCT+LLCT 































Table S2. Selected electronic transitions for complex 3 and 6. 














3 6 3 6 
Infrared Raman 
Exp. DFT Exp. DFT Exp. DFT Exp. DFT 
   508 503 507   β(FeC≡N) 
571  572 587 574 549 575 508 β(NH)OP 
654 617 697 663 653 617   Ring 
749 745   746 745   Ring 
856 828 849 828   701 722 β(CH)OP 
    1033 996 1023 975 Ring 
  1035 1034 1074 1023 1066  Ring+v(NO) 
  1169 1135 1155 1140   β(CH) 
1029 1050       Ring 
1176 1161      1135 Ring 
    1292 1344 1227 1191 ν(C–NH)+β(CH) 
1352 1360 1316 1339 1358 1388 1314 1338 β(NH)+β(CH) 
1574 1525 1415 1485     β(CH)+ν(C=O)+β(NH) 
 1539 1652 1560 1583 1542   ν(CC)ring+ν(C=O)+β(NH) 
      1610 1560 ν(CC)ring 
2053 2048 2047 2046 2071 2050 2070 2047 ν(C≡N) 
2094 2057 2093 2065 2097 2071 2093 2065 ν(C≡N) 



















Figure S1. (A) and (B) 1H NMR spectra of 2 and 3, respectively, in D2O, 400 MHz. (C) 
and (D) 13C NMR spectra of 2 and 3, respectively, in D2O, 101 MHz (13C reference = 
MeOD). (E) and (F) 2D 1H-15N HMQC NMR spectrum of 2 and 3, respectively, in D2O, 
50.7 MHz. 
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Figure S2 - Cyclic voltammograms of glassy carbon electrode in solution of compound 
[FeII(CN)5(PyzCONHO)]3- (A) and [FeII(CN)5(PyCONHO)]3- (B), using vitreous carbon 
electrode as work, platinum electrode as auxiliary electrode and saturated calomel 
electrode (SCE) as reference, in phosphate buffer 0.1M pH 7.4 as electrolyte. Scan 
speed of 200 mV s-1. Potential values were plotted from SCE to NHE for comparative 




Figure S3. UV-Visible absorption spectra of the free ligand 2 (103 µM, blue) and 
complex 3 (45 µM, red) in water solution, at pH = 6.8. 
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Figure S4. Calculated UV-Visible absorption spectra and calculated singlet−singlet 












Scheme S1. (A) Reactions of cPTIO with HNO and NO• and (B) Trapping reaction of 
the isonicotinoyl radical by PBN. 
 
5.10. Unpublished results associated with the article 
This study allowed the development of the compound Na4[FeII(CN)5(pyridine-3-
hydroxamic acid)] (13), as well as its characterization and the study of its oxidative 
activation as done for complexes 3 and 6. Despite not being included in the previous 
article, this complex presented chemical and biological results similar to compounds 3 
and 6. The results regarding this complex are presented and discussed briefly below. 
5.10.1. Synthetic procedures 
Pyridine-3-hydroxamic acid (10) 
The synthesis of pyridine-3-hydroxamic acid followed the same protocol 
mentioned in the article for the preparation of hydroxamic acids ligands. 
Yield = 82 % (0.40 g), white solid. 1H NMR (300 MHz, DMSO-d6) δ (ppm): 11.39 (s, 
1H), 9.21 (s, 1H), 8.90 (dd, J = 2.3, 0.9 Hz, 1H), 8.70 (dd, J = 4.8, 1.7 Hz, 1H), 8.10 
(ddd, J = 7.9, 2.3, 1.7 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ (ppm): 163.04 
(C=O), 152.30 (CH), 148.34 (CH), 135.13 (CH), 128.95 (Cq), 124.02 (CH). IR 
symmetric stretching (νs), antisymmetric stretching (νas), symmetric bending (δs) and 
twisting (τ) (cm-1): 3197 (νs N-H), 3100 (νs O-H), 1643 (νs C=O), 1588 – 1499 (νs C=N, 
νs C=C), 1300 (δs C-H), 1192 - 1024 (νas C=N), 808 (τ C-H). UV-Vis (H2O) λmax/nm 




(ε/M-1cm-1) = 208 (7459), 261 (3544).  HRMS (DCI/CH4): for {(C5H5N3O2) + H+} 
calcd.: 139.0508 found: 139.0514. Anal. Calcd. for C6H6N2O2: C, 52.17; H, 4.38; N, 
20.28. Found: C, 52.09; H, 3.96; N, 20.12. Retention Factor 
(methanol/dichloromethane 10%) = 0.31. M.T = 164 °C Electrochemistry (0,1 M 
Phosphate buffer pH 7.4) Epa = 0.641, 0.963 and 1.104 V vs NHE. 
 
Pyridine-4-carboxylate (11) and pyridine-3-carboxylate (12) sodium salt 
The synthesis protocol of pyridine-4-carboxylate (11) and pyridine-3-
carboxylate (12) sodium salt was the same employed for the sodium pyrazine-3-
carboxylate (described in the supplementary material of the article). 
 
Pyridine-4-carboxylate sodium salt (11) 
Yield = 99.0 % (0.140 g), white solid. 1H NMR (400 MHz, D2O) δ (ppm): 8.66 (d, J = 
4.8, 1H), 7.85 (d, J = 4.9, 1H). 13C NMR (101 MHz, D2O) δ (ppm): 173.28 (C=O), 
148.42 (CH), 147.47 (Cq), 124.19 (CH), 49.50 (MeOD). IR symmetric stretching (νs), 
antisymmetric stretching (νas), symmetric bending (δs) and twisting (τ) (cm-1): 1588 
(C=O), 1540 - 1396 (νs C=N, νs C=C), 1300 (δs C-H), 1216 - 1024 (νas C=N), 844 (τ C-
H). UV-Vis (H2O) λmax/nm (ε/M-1cm-1) = 211 (6575), 268 (2343). Anal. Calcd. for 
NaC6H4O2·0.1H2O: C, 49.06; H, 2.88; N, 9.54. Found: C, 49.10; H, 2.52; N, 9.45. 
 
Pyridine-3-carboxylate sodium salt (12) 
Yield = 99 % (0.14 g), white solid. 1H NMR (300 MHz, D2O) δ (ppm): 8.95 (dd, J = 
2.2, 0.9 Hz, 1H), 8.61 (dd, J = 5.0, 1.7 Hz, 1H), 8.25 (ddd, J = 7.9, 2.2, 1.7 Hz, 1H), 
7.52 (ddd, J = 7.9, 5.0, 0.9 Hz, 1H). 13C NMR (101 MHz, D2O) δ (ppm): 172.98 (C=O), 
149.74 (CH), 148.51 (CH), 139.65 (CH), 133.54 (Cq), 125.04 (CH). IR symmetric 
stretching (νs), antisymmetric stretching (νas), symmetric bending (δs) and twisting (τ) 
(cm-1): 1616 (νs C=O), 1557 - 1403 (νs C=N, νs C=C), 1301 (δs C-H), 1200 - 1029 (νas 
C=N), 837 (τ C-H). UV-Vis (H2O) λmax/nm (ε/M-1cm-1) = 212 (7350), 260 (2549), 265 
(2819), 272 (2137). Anal. Calcd. for NaC6H4O2: C, 49.67; H, 2.78; N, 9.65. Found: C, 










The synthesis protocol of Na4[FeII(CN)5(pyridine-3-hydroxamic acid)] (13), 
Na4[FeII(CN)5(pyridine-4-carboxylate)] (14), and Na4[FeII(CN)5(pyridine-3-
carboxylate)] (15) was the same employed for the complex 3 (see article). 
 
Na4[Fe
II(CN)5(pyridine-3-hydroxamic acid)] (13) 
Yield = 92 % (0.202 g), yellow solid. 1H NMR (400 MHz, D2O) δ (ppm): 9.19 (d, J = 
2.0 Hz, 1H), 9.08 (dd, J = 5.7, 1.4 Hz, 1H), 7.95 (dt, J = 7.9, 1.8 Hz, 1H), 7.30 (dd, J = 
7.9, 5.6 Hz, 1H). 13C NMR (101 MHz, D2O) δ (ppm): 180.64 (CNeq), 175.84 (CNax), 
165.30 (Cq), 159.35 (CH), 154.67 (CH), 135.10 (CH), 128.83 (Cq), 123.91 (CH). IR 
symmetric stretching (νs), symmetric bending (δs), antisymmetric bending (δas) and 
twisting (τ) (cm-1): 3452 (νs N-H), 3312 - 3102 (νs O-H), 2056 (νs C≡N), 1638 - 1572 (νs 
C=C, νs C=N, νs C=O), 1319 (δs C-H), 1022 (τ C-H), 912 (δas C-H). UV-Vis (H2O) 
λmax/nm (ε/M-1cm-1) = 215 (18870), 261 (5254), 394 (2608). Anal. Calcd. for 
C11H5FeN7O2Na4·3.6H2O: C, 27.53; H, 2.56; N, 20.43. Found: C, 27.23; H, 2.92; N, 
20.17. Electrochemistry in 0,1 M Phosphate buffer pH 7.4: Epa = 0.623 and 0.891 V vs 




Yield = 42 % (0.042 g), yellow solid. 1H NMR (400 MHz, D2O) δ (ppm): 9.03 (d, J = 
5.9, 2H), 7.46 (d, J = 5.9, 2H). 13C NMR (101 MHz, D2O) δ (ppm): 180.71 (CNeq), 
176.45 (CNax), 170.66 (Cq), 157.50 (CH), 143.89 (Cq), 122.42 (CH), 49.50 (MeOD). 
IR symmetric stretching (νs), symmetric bending (δs), antisymmetric bending (δas) and 
twisting (τ) (cm-1): 2044 (νs C≡N), 1636 – 1540 (νs C=C, νs C=N, νs C=O), 1384 (δs C-
H), 1036 (τ C-H), 928 (δas C-H). UV-Vis (H2O) λmax/nm (ε/M-1cm-1) = 262 (2509), 416 
(1934). Anal. Calcd. for C11H4FeN6O2Na4·4.2H2O: C, 27.78; H, 2.63; N, 17.67. Found: 





Yield = 60 % (0.060 g), yellow solid. 1H NMR (400 MHz, D2O) δ (ppm): 9.35 (s, 1H), 
9.02 (d, J = 5.5, 1H), 8.05 (d, J = 7.8, 1H), 7.25 (dd, J = 7.9, 5.6, 1H). 13C NMR (101 
MHz, D2O) δ (ppm): 180.88 (CNeq), 176.60 (CNax), 173.40 (Cq), 158.64 (CH), 157.58 
(CH), 136.62 (CH), 132.05 (Cq), 123.45 (CH), 49.50 (MeOD). IR symmetric stretching 




(νs), symmetric bending (δs), wagging (π) and twisting (τ) (cm-1): 2044 (νs C≡N), 1612 – 
1564 (νs C=C, νs C=N, νs C=O), 1396 (δs C-H), 1192 (τ C-H), 856 (π C–H). UV-Vis 
(H2O) λmax/nm (ε/M-1cm-1) = 214 (21630), 261 (5872), 382 (2911). Anal. Calcd. for 
C11H4FeN6O2Na4·2H2O·0.3NaI: C, 27.47; H, 1.68; N, 17.47. Found: C, 27.44; H, 1.65; 
N, 17.37. Electrochemistry in 0,1 M Phosphate buffer pH 7.4: E1/2 = 0.468 V vs NHE. 
 
5.10.2. Results and discussion 
i. Characterizations 
As with complexes 3 and 6, the characterization results also indicated that 
compound 13 was successfully obtained. The data were very similar to that reported for 
3, so that only the spectra and tables relevant to the characterization of the complex 13 




Figure 39. (A) and (B) 1H NMR spectra of 10 and 13, respectively, in D2O, 400 MHz. 





Figure 40. (A) and (B) 1H NMR spectra of 11 and 14, respectively, in D2O, 400 MHz. 
 
Figure 41. (A) and (B) 1H NMR spectra of 12 and 15, respectively, in D2O, 400 MHz. 
 






Figure 42. (A), (B) and (C) 13C NMR spectra of 13, 14 and 15, respectively, in D2O, 














Table 1. Selected experimental and calculated wavenumber values obtained from IR 
and NR spectra of solid complex 13, and their corresponding vibrational assignments. 
Wavenumber (cm-1) Vibrational 
Assignment Infrared Raman 
Exp. DFT Exp. DFT 
  497 471 β(FeC≡N) 
571 524 577 548 β(NH)op 
692 689 647 629 Ring 
912  714 746 β(CH)op 
  914  Ring 
  1036 1011 Ring + ν(NO) 
  1204 1238 β(CH) 
1022 1042   Ring 
1176 1148   Ring 
  1327 1347 ν(C–NH) + β(CH) 
1319 1348 1337 1375 β(NH) + β(CH) 
1638 1537 1599 1573 ν(CC)ring + ν(C=O) + β(NH) 
  1577 1557 ν(CC)ring  
2056 2055 2094 2069 ν(C≡N) 
2100 2086 2084 2060 ν(C≡N) 
Op = out-of-plane / ν = symmetric stretching / β = symmetric bending. 
 
 
Figure 43. Experimental NR (A) and IR (B) spectra of the complex 13 under 
tetraanionic form, Na4[Fe(CN)5L], L = NicCONHO– (black line), in the solid state, and 
DFT-simulated spectra for [Fe(CN)5L]4− (gray line). 
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Figure 44. Cyclic voltammograms of glassy carbon electrode in solution of 10 (blue) 
and 13 (red), using vitreous carbon electrode as work, platinum electrode as auxiliary 
electrode and saturated calomel electrode (SCE) as reference, in phosphate buffer 0.1 M 
pH 7.4 as electrolyte. Scan speed of 200 mV s-1. Potential values were plotted from SCE 
to NHE for comparative purposes. 
 
UV–Vis absorption spectroscopy 
 
 
Figure 45. UV-Visible absorption spectra of the (A) ligand 5 (217 μM, blue) and 
complex 6H+ (50 μM, red), and (B) ligand 10 (105 μM, blue) and complex 13H+ (47 









Table 2. Selected electronic transitions for complex 13H+. 
λexp (nm) λDFT (nm) Osc. Strength (f) Key transition Character 
394 437 0.0289 HOMO-1→LUMO MLCT 
 375 0.0290 HOMO-1→LUMO+1 MLCT 
261 247 0.0227 HOMO-6→LUMO LLCT 
215 239 0.0547 HOMO-4→LUMO+1 LLCT 
 223 0.0594 HOMO-7→LUMO+1 LLCT 
LLCT = ligand-to-ligand charge transfer/ MLCT = metal-to-ligand charge transfer. 
 
 
Figure 46. Calculated UV-Visible absorption spectra and calculated singlet−singlet 
transition energies of the complex 13H+ taking account in a water solvent field. 
 
 
5.10.3. Chemical oxidation of the FeII complex under physiological pH 
conditions 
The chemical oxidation studies of complexes 6 and 13 via UV-Vis, 1H-NMR, 
and EPR (formation of NO•/HNO), also presented experimental behavior similar to the 
compound 3. The results obtained are reported below. 





Figure 47. UV–Vis monitoring of the reaction of 6H+ (A) and 13H+ (B) (171 µM for 
both complexes) with H2O2 (427.5 µM) in phosphate buffer solution, 40 mM, pH 7.4, 
22 ºC. Reaction at t = 0 min, before addition of H2O2, (blue line), and after 2 h (red line). 




Figure 48. 1H-NMR spectra at 400 MHz: of the complex 6H+ (20 mM) at 0 h (A) and at 
52 h (B) without addition of H2O2, at 52 h after reaction of 6H+ with H2O2 (50 mM) (C), 
and 14 complex (20 mM) (D) and isonicotinic carboxylate (11) (20 mM) (E). Solutions 
in 40 mM phosphate buffer, pH 7.4, at 25 ºC. 





Figure 49. 1H-NMR spectra at 400 MHz: of the complex 13H+ (20 mM) at 0 h (A) and 
at 52 h (B) without addition of H2O2, at 52 h after reaction of 13H+ with H2O2 (50 mM) 
(C), and 15 complex (20 mM) (D) and nicotinic carboxylate (12) (20 mM) (E). 










Figure 50. EPR signal of the cPTIO radical in the presence of H2O2 and the complexes 
(6H+ (A) and 13H+ (D)) (t0 = black line and t10min = red line). Control of the stability of 
the cPTIO EPR signal in the presence of 6H+ (B) and 13H+ (C) (t0 = black line and 
t15min = red line). Control of the stability of the cPTIO EPR signal in the presence of free 
ligands (5 (C) and 10 (F)) and H2O2 (t0 = black line and t15min = red line). All spectra 
were recorded in phosphate buffer solution, 40 mM, pH 7.4. 
 
 
5.10.4. Anti-Mtb and vasodilation activities 
 Complex 13, as well as its ligand 10, did not show anti-Mtb activity against 
H37Rv strains, with MIC values > 100 μg/mL as compounds 2, 3, 5 and 6. However, a 
vasodilating activity was also observed for 13 (Figure 51). The hydroxamic acid 
complex 13 showed a promising vasodilator profile with EC50 = 106 nM, whereas 
ligand 10 showed a benefic action only in high concentration with EC50 = 43 μM. This 
remarkable difference supports the key role of metal center, which enhanced ca. 406-
fold the activity. This metal complex exhibited a more moderate action compared to 
SNP (EC50 = 13 nM), showing an EC50 value 8-fold higher than SNP. In addition, the 
concentration-response curve of the vasodilation experiment shows that 13 have lower 
efficacy than the SNP and the other complexes 3 and 6. 
























Figure 51. Relaxation effects on aortic rings pre-contracted with 0.1 µM phenylephrine: 
10 (red), 13 (blue), and SNP (black). The EC50 and respective 95% confidence interval 
were calculated only for 13 (106 nM, 62-181 nM). 
 
5.10.5. Cytotoxicity 
The cytotoxicity of the complexes (3, 6 and 13) and their respective free ligands 
(2, 5 and 10), was tested by Mrs Sandra Bourgeade-Delmas in Pharmadev laboratory 
(IRD-UPS, Toulouse), whose the director is Pr. Nicolas Fabre, using macrophage cells 
(J774A.1) in accord with the references [1-3]. The CC50 values (concentration equal to 
50% of the cytotoxicity effect) obtained for the six compounds were generally higher 
than 60 µM, being significantly less toxic (1200 -fold) than the doxorubicin control 
(CC50 = 0.05 µM) (Table 3), a chemotherapeutic used in the treatment against solid 
tumors of several cancers [4]. These high CC50 values are indicative of a low cytotoxic 
activity by the hydroxamic acid derivatives studied. 
 
Table 3. CC50 values to cytotoxic of complexes 3, 6, and 13, and ligands 2, 5, and 10, 
measured using macrophage (J774A.1) cells. 
Compound CC50 (µM) 
2 285.10 (± 2,22) 
3 > 106.37 
5 59.80 (± 1,26) 
6 68.26 (± 2,57) 
10 133.79 (± 0,65) 
13 > 104.60 
Doxorubicin 0.05 (± 0,01) 
 




5.10.6. Antiparasitic activity (leishmaniasis and malaria) 
In an opportunistic way, the anti-leishmania and anti-malaria action of the 
complexes (3, 6, and 13) and the corresponding free ligands (2, 5, and 10) were also 
evaluated in collaboration with Pharmadev laboratory (IRD-UPS) in accord with the 
references [1-3]. The set of hydroxamic acids derivatives (ligands and complexes) tested 
showed high IC50 values (> 60 µM) for leishmaniasis, being approximately 860 -fold 
less active than the control amphotericin B (IC50 = 0.07 µM) (Table 4), a second-line 
antileishmanial drug [5]. These results showed that compounds 2-13 have no promising 
action against this type of disease. In contrast, anti-malaria tests exhibited more 
promising results, particularly to the free ligands 2, 5 and 10, which presented IC50 
values of 21.57, 2.53, and 3.98 µM, respectively, being relatively better than their 
respective FeII complexes (Table 4) and in the case of 5, it is only 14 less active than the 
antimalarial drug chloroquine (IC50 = 0.18 µM) [6]. Interestingly, the presence of the [-
Fe(CN)5] moiety was not responsible for beneficial effects, suggesting that biological 
action is not due to HNO as metabolite. 
 





IC50 (µM)* IC50 (µM)* 
2 117.03 21.57 
3 82.33 38.29 
5 85.43 2.53 
6 61.57 4.81 
10 121.70 3.98 
13 66.25 5.23 
Amphotericin B 0.07 - 
Chloroquine - 0.18 
*Concentrations referring to a single measure. 
 
5.11. Conclusion 
The complex 13 has exhibited the same chemical and biological behave as the 
complexes 3 and 6. Although 13 also had no action against Mtb strains, it has proven to 




be an interesting vasodilating agent, which stimulates future studies. In addition, none 
of the complexes has shown high cytotoxicity in trials with macrophages, indicating that 
such compounds may be safe for further in vivo studies. The anti-leishmaniasis tests do 
not encourage us to use such systems for this purpose. Anti-malaria studies have shown 
that ligands 5 and 10 have a significant action against malaria, however the introduction 
of the metal center has not been responsible for improving antimalarial action and 
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6. General conclusion and perspectives 
Metal complexes have proven to be quite versatile tools in the development of 
new therapeutic approaches. As part of this thesis, the association of metal system with 
ligands acting as NO• or HNO donors emerged as a promising alternative in 
cardiovascular and anticancer drug research.  
The first chapter focused on the reactivity of the trans-[Fe(cyclam)(NO)Cl]Cl2 
complex. Although this complex was known to release NO• upon light stimulus, in this 
work we demonstrated that it also exhibits a high potential as direct NO• and HNO 
donor in physiological conditions. This property is associated with the antihypertensive 
and antiangiogenic activities observed for this complex. In this way, the results of 
antiangiogenic activity through the inhibition of HIF-1α suggest this nitrosyl metal 
complex as a strong candidate in anticancer drug design. Moreover, the vasodilation 
studies show that the trans-[Fe(cyclam)(NO)Cl]Cl2 complex allows a milder control of 
the blood pressure (IC50 = 910 nM) than the classical metal pro-drug SNP (IC50 = 24 
nM), the latter being currently used in cases of hypertensive crisis. This can be 
considered as an advantage, the general use of the more potent vasodilator SNP being 
indeed limited by its abrupt capacity in inducing vasodilatation. In addition, the absence 
of cyanide ions in the coordination sphere of the FeII center, which, if released, can be 
very toxic for patients treated by SNP, supports the potential use of the present complex 
in future pre-clinical studies. 
The second part of the thesis has concerned the study of (di)azine hydroxamic 
acid derivatives, with emphasis on the ability of these molecules to release HNO after 
oxidative activation. A study of the oxidation of isonicotino-, nicotino-, and pyrazino-
hydroxamic acids by K3[FeIII(CN)6] in aqueous conditions, revealed that a N,O-
di(di)azinoylhydroxylamine intermediate was formed and no nitrosocarbonyl 
intermediate could be detected (Figure 52). These results contrast with the frequently 
reported hypothesis that a nitrosocarbonyl intermediate is responsible for the release of 
HNO by oxidation of hydroxamic acids. By performing the same oxidative treatment in 
the presence of NH2CH3, we put forwards that the N,O-di(di)azinoylhydroxylamine 
intermediate has an electrophilic character similar to that of a putative nitrosocarbonyl 
intermediate. In addition, the corresponding (di)azine carboxylic acids are the final 
products, thus resulting from the oxidation of hydroxamic acids, not from their 
hydrolysis.  
 





Figure 52. Mechanistic hypotheses for HNO release by oxidation of aryl hydroxamic 
acids. 
 
The third chapter concerns the development of new iron-metal complexes 
derived from the molecules discussed above serving as ligands: the basic idea is the 
design of a hybrid metallic pro-drug through the association of precursors of the active 
metabolites of isoniazid (isonicotinoyl radical) or pyrazinamide (pyrazinoic acid) and 
delamanid (HNO). While in vitro treatment (at pH 7.4, 37 ºC) of the complexes 3, 6, 
and 13 (Figure 53) by the endogenous oxidizing agent H2O2 did not lead to any aroyl 
radical species, it was shown to trigger the formation of HNO and carboxylic acid 
derivatives, thus validating the concept of pyrazinamide-delamanid hybrid complex. 
These complexes failed to inhibit the growth of non-resistant Mtb strains. However, 
knowing that pyrazinamide is active upon non-replicating bacilli and not upon growing 
strains, it should be relevant to test these compounds towards this more appropriate 
model. On the other hand, a promising vasodilating action was found for the three 
complexes studied, with emphasis on the complex 6 (EC50 = 64 nM), which is only 5-
fold less potent than the SNP drug (EC50 = 13 nM). As shown for the trans-
[Fe(cyclam)(NO)Cl]Cl2 complex, hydroxamic acid complexes exhibit a moderate action 
as compared to SNP, and may thus provide a valuable advance in the design of new 
antihypertensive agents, since the rapid release of NO• from SNP can cause hazardous 
sudden drops in blood pressure. Moreover, while the complexes 3 and 6 showed 
efficacy similar to that of SNP, 13 was found slightly less effective. These results 
stimulated the consideration of complex 6 in studies of antihypertensive action in rats. 
Increasing the doses of complex 6 (1, 5, and 10 mg/kg) promoted a decrease in blood 
pressure more efficiently on hypertensive rats (by 45, 62, and 65%, respectively) than 
on normotensive rats (31, 51 and 53%, respectively). Comparison of the vasodilation 
curves of the "free ligands" with those of their complexes clearly show that the 
pentacyanoferrate(II) moiety plays a crucial role in the activation of hydroxamic acids 
leading to HNO release. 






Figure 53. Structure of the pyrazino- (3), isonicotino- (6) and nicotino- (13) 
hydroxamic acids pentacyanoferrate(II) complexes. 
 
In summary, this work unveils significant systems and proposals in the area of 
bioinorganic chemistry. The results reported in this thesis confirm the possible use of 
metallo-compounds as an alternative strategy in the development of new therapeutic 
drugs, with special emphasis on the release of NO• and HNO. As a perspectives, further 
studies on the vasodilation effect of hydroxamic acid complexes may focus on 
mechanistic issues, e.g., using inhibitors of the soluble guanylyl cyclase (e.g., ODQ = 
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one) and NOS (e.g., L-NAME = "L-NG-nitro 
arginine methyl ester"), which are extremely important enzymes involved in the NO•-
mediated vasodilation mechanism. These studies deserve to be undertaken to bring 
more information about the vasorelaxant activity of the FeII complexes 3, 6 and 13. 
 
Conclusion générale et perspectives 
 
Les complexes métalliques se sont avérés être des outils polyvalents dans le 
développement de nouvelles approches thérapeutiques. Dans le cadre de cette thèse, 
l’association d’un système métallique à une molécule donneuse de NO• ou HNO, de 
type acide hydroxamique jouant le rôle de ligand est apparue comme une alternative 
prometteuse dans la recherche de médicaments cardiovasculaires et anticancéreux.  
Le premier chapitre a porté sur l’étude de la réactivité du complexe trans-
[Fe(cyclam)(NO)Cl]Cl2. Bien que la bibliographie indique que ce complexe libère NO• 
par action d’un stimulus lumineux, ce travail de thèse a permis de montrer que ce 
complexe présente un fort potentiel pour le relargage direct de NO• ou HNO dans des 
conditions physiologiques (à pH 7,4, à 37 ºC). Cette propriété permet d’expliquer les 
activités antihypertensives et antiangiogènes ce complexe, mises en évidence au cours 




de cette thèse. Par ailleurs, les résultats de l’activité antiangiogène par inhibition de 
HIF-1α suggèrent que ce complexe de nitrosyle est un candidat pertinent pour être 
étudié comme agent anticancéreux. En outre, les études de vasodilatation ont montré 
que le complexe trans-[Fe(cyclam)(NO)Cl]Cl2 permet un contrôle plus doux de la 
pressions artérielle (IC50 = 910 nM) que la pro-drogue métallique classiquement utilisée 
en cas de crise d'hypertension, le SNP (IC50 = 24 nM). Ceci peut être considéré comme 
un avantage, l'utilisation du SNP, puissant vasodilatateur, étant limitée par sa capacité 
"abrupte" à induire la vasodilatation. De plus, l’absence d'ion cyanure dans la sphère de 
coordination du centre FeII, potentiellement toxique pour le patient dans le cas du SNP, 
est un argument de poids pour envisager ce complexe dans de futures études 
précliniques. 
La deuxième partie de la thèse a porté sur l’étude d'acides (di)azine 
hydroxamiques, en mettant l’accent sur leur capacité à libérer HNO après une activation 
oxydante. Une étude de l’oxydation des acides hydroxamiques isonicotinique, 
nicotinique et pyrazinique par K3[FeIII(CN)6] en milieu aqueux, a révélé non seulement 
la libération de HNO, mais aussi la formation d’intermédiaires de type N,O-
di(di)azinoylhydroxylamine, aucun dérivé nitrosocarbonylé n’ayant été détecté (Figure 
54). Ces résultats sont en contradiction avec l’hypothèse fréquemment rapportée que 
l’intermédiaire nitrosocarbonylé est le précurseur de HNO par oxydation des acides 
hydroxamiques. Par le même traitement oxydant, mais en présence de NH2CH3, nous 
avons pu mettre en avant que l’intermédiaire N,O-di(di)azinoylhydroxylamine présente 
aussi un caractère électrophile, similaire à celui de l’intermédiaire nitrosocarbonylé 
virtuel. En outre, les acides carboxyliques correspondants ont été identifiés comme les 













Figure 54. Hypothèses mécanistiques pour la libération de HNO par oxydation d'acides 
aryl hydroxamiques. 
 
Le troisième chapitre concerne le développement de complexes métalliques à 
ligands acides hydroxamiques, présentés précédemment à l'état libre : l'objectif ultime 
est la conception d’une pro-drogue hybride métallique issue de l’association, sur un 
centre métallique FeII, de précurseurs des métabolites actif de l’isoniazide (radical 
isonicotinoyle) ou du pyrazinamide (acide pyrazinoique) et du délamanide (HNO). 
Tandis que le traitement in vitro (à pH 7,4 à 37 ºC) des complexes 3, 6 et 13 (Figure 55) 
par l’agent oxydant endogène H2O2, n’a pas conduit à de quelconque radicaux aroyle, il 
a en revanche été démontré induire la formation de HNO et de l'acide carboxylique, 
validant ainsi le concept de complexe hybride pyrazinamide-délamanide. Ces composés 
n’ont pas été observé inhiber la croissance de souches actives de Mtb non-résistantes. 
Toutefois, sachant que le pyrazinamide est actif sur les bacilles latents et non sur des 
souches en croissance, il serait pertinent à l’avenir de tester ces complexes sur un 
modèle plus approprié. D’autre part, des activités vasodilatatrices prometteuses ont été 
trouvées pour les trois complexes, en particulier pour le complexe 6 (EC50 = 64 nM), 
seulement 5 fois moins puissant que le SNP (EC50 = 13 nM). Comme dans le cas du 
complexe trans-[Fe(cyclam)(NO)Cl]Cl2, l’activité modérée des complexes d’acides 
hydroxamiques, en comparaison du SNP, peut être considérée comme une avancée dans 
la conception de nouveaux agents antihypertenseurs, la libération trop rapide de NO• par 
le SNP pouvant provoquer de dangereuses baisses brutales de la pression artérielle. Les 
complexes 3 et 6 ont montré une efficacité similaire à celle du SNP, tandis que celle du 
complexe 13 était moindre. Ces résultats ont encouragé l'utilisation du complexe 6 dans 
des études de l’action antihypertensive chez les rats. L'augmentation des doses du 
complexe 6 (1, 5, et 10 mg/kg) a été observée favoriser une diminution de la pression 
artérielle, et ceci plus efficacement chez les rats hypertendus (de 45, 62, et 65%, 
respectivement) que chez les rats normotenseurs (de 31, 51 and 53%, respectivement). 
La comparaison des courbes de vasodilatation des complexes et des "ligands libres" 




montre clairement que le centre pentacyanoferrate(II) joue un rôle crucial dans 
l’activation des acides hydroxamiques conduisant à la libération de HNO. 
 
 
Figure 55. Structure des complexes pentacyanoferrate(II) des acides hydroxamiques 
pyrazinique (3), isonicotinique (6) et nicotinique (13). 
 
En résumé, ce travail a mis au jour de nouveaux systèmes métallo-organiques 
capables de libérer HNO dans des conditions physiologiques, ainsi que des propositions 
plus générales dans le domaine de la chimie bio-inorganique. Les résultats rapportés 
dans cette thèse confirment le potentiel de tels complexes comme nouveaux agents 
thérapeutiques, en particulier comme agents cardiovasculaires. En perspectives, l'étude 
des propriétés vasodilatatrices des complexes d'acide hydroxamique mérite d'être 
complétée du point de vue mécanistique, en utilisant, par exemple, des inhibiteurs de la 
guanylyl cyclase soluble (par exemple le ODQ = 1H- [1,2,4] oxadiazolo [4,3-a] 
quinoxalin-1-one) et de la NOS (par exemple le L-NAME = L-NG-nitro arginine 
méthylester), qui sont des enzymes jouant un rôle clé dans le mécanisme de 
vasodilatation induite par NO•. Ces études sont méritent d'être entreprises en vue d' 
obtenir des informations complémentaires sur l'activité vasorelaxante des complexes 3, 
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Titre : Métallo-médicaments comme donneurs d'oxyde nitrique (NO•) et / ou de nitroxyle (HNO) : développement de nouveaux agents et 
investigation des activités anticancéreuses, antihypertensives et antituberculeuses. 
Résumé : Le cancer, les maladies cardiovasculaires et la tuberculose (TB) sont des défis de santé majeurs pour lesquels diverses stratégies 
médicamenteuses ont été développées, y compris l'utilisation d'agents inorganiques tels que des complexes métalliques et l'oxyde nitrique (NO•) ou 
le nitroxyle (HNO). L'objectif de la thèse porte sur la conception, la synthèse, les études physico-chimiques et l'évaluation biologique de molécules à 
base de métaux capables de libérer NO• et/ou HNO avec des effets pharmacologiques. Deux types de plates-formes organiques sont envisagés 
comme ligands des complexes de fer, conçus comme sources potentielles de NO•/HNO : le ligand spectateur cyclam (1,4,8,11-
tétraazacyclotétradécane) et les ligands réactifs du type azine acide hydroxamique (ArC(O)NHOH). Le premier chapitre traite de la réactivité du 
complexe trans-[Fe(cyclam)(NO)Cl]Cl2, qui se décompose en libérant NO• à pH physiologique, le processus est accéléré par irradiation lumineuse à 
365 nm. En revanche, des expériences in vitro en présence de glutathion ont révélé que le même complexe produit HNO. Des études d'angiogenèse 
ont montré que le complexe est capable d'inhiber le "facteur inductible par hypoxie" (HIF-1α) induit par hypoxie ou ajout d'un donneur de NO• 
(Spermine NONOate) dans les cellules cancéreuses du sein, résultat cohérent avec une libération de HNO. Des tests de vasodilatation, des anneaux 
aortiques de rat précontractés, ont révélé que le complexe présente une CI50 de relaxation de 910 nM, contre 24 nM pour le médicament de référence 
nitroprussiate. Les chapitres suivants traitent de la libération de HNO par oxydation d'acides hydroxamiques aromatiques. Le chapitre 2 se concentre 
sur le mécanisme d'oxydation des acides hydroxamiques isonicotinoïque, nicotinoïque et pyrazinoïque par le ferricyanure de potassium à pH 
physiologique. Il est montré que l'activation oxydante des acides hydroxamiques par des ions FeIII implique la production de l'intermédiaire N,O-
di(di)azinoylhydroxylamine avec libération concomitante de HNO, au lieu de l'espèce hypothétique acyl nitroso. Les acides hydroxamiques ont été 
évalués pour différentes activités biologiques et utilisés comme témoins pour être comparés aux complexes de fer décrits au chapitre 3. Les 
complexes de type Na3FeII(CN)5(ArCONHOH), initialement conçus comme modèles de médicaments hybride d'isoniazide (INH, anti-TB, dont le 
radical isonicotinoyle est le métabolite actif) et du délamanide (anti-TB, dont HNO est le métabolite actif), ont été synthétisés et caractérisés par des 
techniques spectroscopiques, voltammétrie cyclique, et calculs DFT. En utilisant la spectroscopie RPE et RMN 1H, l'oxydation de ces complexes de 
FeII avec H2O2 s'est avérée entraîner la libération de HNO et des acides azinoïques correspondants, via un probable transfert d'électrons 
intramoléculaire. Contrairement à ce qui a été observé pour le complexe Na3[FeII(CN)5(INH)], aucun radical azinoyle n'a été produit à partir des 
complexes d'acide hydroxamiques. Les acides carboxyliques correspondants ont par contre été observés, en particulier l'acide pyrazinoïque, 
métabolite actif du pyrazinamide, un autre promédicament anti-TB: ce résultat est a priori pertinent pour le traitement de la TB résistante au 
pyrazinamide, car l'activation pourrait ainsi se produire sans l'aide de l'enzyme pyrazinamidase de Mycobacterium tuberculosis (Mtb). Les acides 
hydroxamiques libres ou complexés n'ont montré aucune action antibiotique contre une souche de Mtb non résistante en croissance active. 
Cependant, les complexes ont montré une forte activité de vasodilatation dose-dépendante et réversible, proche de celle du nitroprussiate (64-250 nM 
vs 13 nM). Les acides hydroxamiques libres ont été 19 à 76 fois moins actifs que les complexes correspondants. Sur la base d'expériences in vivo, 
Na4[FeII(CN)5(PyCONHO-)] a aussi montré un profil d'activité cardiovasculaire prometteur pour le développement d'un nouveau médicament 
antihypertenseur. 
Mots clés : acides hydroxamiques, antiangiogenèse, complexes de fer, cyclam, mécanismes d'activation oxydante, nitroxyle, oxyde nitrique, 
tuberculose, vasodilatation. 
 
Title: Metallo-drugs as nitric oxide (NO•) and/or nitroxyl (HNO) donors: development of new agents and investigation of anticancer, 
antihypertensive and antituberculosis activities. 
Abstract: Cancer, cardiovascular diseases and tuberculosis (TB) are major therapeutic challenges, for which various drug strategies have been 
developed, including the use of inorganic agents such as metallo-drugs and NO• (nitric oxide)/ HNO (nitroxyl). Within this prospect, the thesis 
objective addresses the design, synthesis, physical-chemical studies and biological evaluation of metal-based drugs capable of releasing NO• and/or 
HNO with pharmacological effects. Two types of organic platforms are thus envisaged as ligands in FeII/III complexes devised as potential sources of 
NO•/HNO: the spectator cyclam ligand (1,4,8,11-tetraazacyclotetradecane) and three reactive azine hydroxamic acid ligands (ArC(O)NHOH). The 
first chapter deals with the chemical reactivity of a trans-[Fe(cyclam)(NO)Cl]Cl2 complex, which is shown to decompose by releasing NO• under 
physiological pH and temperature conditions, the process being significantly accelerated upon light irradiation at 365 nm. In contrast, in vitro 
experiments in the presence of glutathione revealed that the same complex produces HNO. Angiogenesis studies showed that the complex is able to 
significantly inhibit the hypoxia-inducible factor (HIF-1α) induced by hypoxia or addition of a NO• donor (Spermine NONOate) in breast cancer 
cells: this result is consistent with a release of HNO by the nitrosyl complex. On the other hand, vasodilation assays using precontracted rat aortic 
rings revealed that the complex exhibits a relaxation IC50 of 910 nM, vs 24 nM for the reference drug, nitroprusside. The next chapters deal with the 
oxidation-promoted release of HNO from aromatic hydroxamic acids. Chapter 2 focuses on the oxidation mechanism of isonicotinoic, nicotinoic and 
pyrazinoic hydroxamic acids, mediated by potassium ferricyanide (K3[FeIII(CN)6]) in physiological pH conditions. It is shown that oxidative 
activation of aryl hydroxamic acids, mediated by FeIII, involves the production of the N,O-di(di)azinoylhydroxylamine intermediate with 
concomitant release of HNO, instead of the putative acyl nitroso species. The free hydroxamic acids were also evaluated for different biological 
activities and used as controls to be compared with iron complexes described in chapter 3. These pentacyanoferrate(II) complexes, 
Na3FeII(CN)5(ArCONHOH), initially devised as potential hybrid of isoniazid (INH, first-line anti-TB prodrug, for which the isonicotinoyl radical is 
the active metabolite) and delamanid (third-line anti-TB, for which HNO is the active metabolite), were synthesized and characterized by 
spectroscopic techniques, cyclic voltammetry, and DFT calculations. Using EPR and 1H NMR spectroscopy, oxidation of these FeII complexes with 
H2O2 was shown to result in the release of HNO and corresponding azinoic acids, through a likely intramolecular electron transfer. In contrast to 
what was observed from the INH complex (Na3[FeII(CN)5(INH)]), no azinoyl radical species was evidenced to be produced from the corresponding 
hydroxamic acid complexes. Instead, the corresponding carboxylic acids were found to be formed, in particular pyrazinoic acid which is the active 
metabolite of pyrazinamide, another antitubercular pro-drug: this result would be relevant for the treatment of pyrazinamide-resistant tuberculosis, as 
the activation could thus occur without assistance of the pyrazinamidase enzyme of Mycobacterium tuberculosis (Mtb). The free hydroxamic acids 
and corresponding complexes did not show any antibiotic action against an actively growing/non-resistant Mtb strain. However, the complexes 
showed a strong dose-dependent and reversible vasodilation activity, close to that of nitroprusside (64-250 nM vs 13 nM). The free hydroxamic acids 
were found ca. 19- to 76-fold less active than the corresponding complexes. On the basis of in vivo experiments, Na4[FeII(CN)5(PyCONHO-)] also 
showed a promising cardiovascular activity profile for the development of a new antihypertensive agent.  
Key words: antiangiogenesis, cyclam, hydroxamic acids, iron complexes, nitric oxide, nitroxyl, oxidative activation mechanisms, tuberculosis, 
vasodilation.  
 
